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Abstract 
Background 
Recently, ocular genetics have shown the first successes in genetic therapies, and 
treatment of genetic diseases making identification of disease genes of great importance. 
Gene discovery is most successful through the study of genetic founder populations, such 
as that ofNewfoundland and Labrador. 
Objective 
The objective of this thesis was to identify disease genes in three forms of Mendelian 
ocular disease: anterior segment dysgenesis (ASD), achromatopsia (ACHM), and 
microphthalmia-dwarfism (MDW). This was undertaken to find novel genes and 
mutations to further our understanding genetic pathways involved in each condition. 
Results 
Of the 11 families recruited for this study, 8 were solved through identification of 
pathogenic variants. The ASD phenotype was discovered to be caused by a novel 
mutation in FOX£3, seven ACHM families through mutations in CNGA3 and CNGB3, 
one ACHM family was found to actually have a rare disease called Jalili Syndrome 
through a novel mutation in CNNM4, and two MDW families helped determine a putative 
disease locus on 16q2 1. 
Conclusions 
The identification of seven mutations (two novel, five previously described) have solved 
the genetic etiology in eight of eleven families providing insight into the disease 
pathways for these families. This allows for genetic counseling and the possibility for 
genetically based therapies in the future. 
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Chapter 1: General Introduction 
1.1 Aims of this study 
This thesis is an extension of research started by Dr. Jane Green over 30 years 
ago. Dr. Green reviewed the registration records maintained by the Newfoundland and 
Labrador division of the Canadian National Institute for the Blind (CNIB) and through 
the Ocular Genetics Clinic obtained a plethora of family-based information and pedigrees 
with the goal of pursuing genetic studies to determine the molecular etiology of these 
visual conditions. This thesis examines the genetics of three ocular diseases in the 
population of Newfoundland, from the earlier work of Dr. Green, to identify genes and 
mutations involved in the pathogenic mechanisms of these ocular conditions. These 
conditions included (1) Anterior ~egment Qysgenesis (ASD), a malformation of the 
anterior chamber of the eye (iris, cornea, and lens), (2) Achromatopsia, a cone 
photoreceptor defect of the retina, and (3) Microphthalmia-Dwarfism (MDW), a 
syndromic form of microphthalmia (small eyes causing blindness). This introduction 
discusses the anatomy and structure of the eye, important pathways involved in its 
formation and function, and the importance of identifying disease genes in these 
conditions. 
1.2 Anatomy and Physiology 
The eye is a complex organ comprised of many structures which function to 
translate light energy into sight. These structures exist in two important major sections of 
the eye including the anterior segment (cornea, uvea, lens), and the posterior chamber, 
consisting of the sclera and the light sensitive retinal tissue and the retinal pigment 
epithelium (RPE) (Figure 1.1 ). 
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Figure 1.1: Cross-section of the human eye illustrating the location of various ocular 
structures. The anterior chamber of the eye can be seen at the top of the diagram and 
consists of the lens, iris, cornea and various ligaments for eye and lens movement. The 
chamber posterior to the anterior segment is filled with a gelatinous substance known as 
vitreous humour which nourishes the various structures of the eye. The retina, which 
translates light energy to sight, is the inner layer of the posterior segment of the eye. The 
choroid (middle) is a vascular layer which nourishes the retina, and the outer layer is the 
tough fibrous sheath known as the sclera which provides the structure of the eye .The 
Hyaloid canal is a small transparent canal running through the vitreous humour, from the 
lens to the optic nerve, and is used to help focus sight (accommodation). This image was 
obtained from http://en.wikipedia.org/wiki/Eye and has been released into the public 
domain for free use. 
(http://en. wikipedia.org/wiki/File:Schematic _diagram_ of_ the_ human_ eye_ en.svg) 
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1. 2. 1 Anterior Chamber 
The second chapter and first research project of this thesis is concerned with the 
genetics of a malformation of the anterior segment of the eye, ASD. The anterior segment 
(anterior chamber) refers to the three layers at the front of the eye which consist of the 
cornea, the uvea, and the lens. These structures are important in protection and 
nourishment of the eye, as well as focusing light onto the retina, where it is translated into 
sight through a biochemical pathway known as the phototransduction cascade. 
The cornea, a thin transparent, avascular layer, is the outermost structure of the 
eye and is continuous with the sclera, the white fibrous outer sheath of the eye that 
provides its globular structure (Figure 1.1 ). The cornea is the most important structure in 
refraction of light onto the retina, and is the first line of defense against infectious agents, 
foreign objects, and physical injury. u The structure of the cornea is organized into three 
cellular layers (Epithelium, Stroma, and Endothelium) which maintain clarity of the 
cornea, necessary for the passage of light, 3-5 and two membranous layers, Bowman' s 
Membrane and Descemet' s membrane, which maintain the cornea' s three-dimensional 
structure. 6 
The second component of the anterior chamber, the uvea, is a pigmented, vascular 
layer consisting of the iris, and the ciliary body, and is continuous with the choroid 
(which exists in the posterior chamber, an area directly behind the anterior chamber). The 
iris is a pigmented ring of intrinsically controlled (i.e. not voluntary) smooth muscle 
which regulates the amount of light entering the eye.7 During times of high luminescence, 
the iri s constricts using a set of muscles called the circular (or constrictor) muscles to 
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form a smaller ring, making the opening of the pupil smaller, allowing minimal amounts 
of light to enter.8 During times of low light, the iris relaxes using the radial (or dilator) 
muscles, increasing the opening of the pupil, allowing more light into the eye.8 An 
extension of the iris, the ciliary body, is responsible for the production of aqueous 
humour, a clear substance comprised of mucopolysacchrides.7 This fluid is responsible 
for the nourishment of the cornea and lens.2 The flow of this fluid through the anterior 
chamber also maintains the pressure within the eye, called the intraocular pressure (lOP). 
The aqueous humour flows around the anterior chamber, and eventually out through the 
trabecular meshwork, a tissue continuous with the ciliary body which regulates the flow 
of aqueous humour to maintain lOP. Malformations of these structures can cause 
elevated lOP and can lead to damage or death of the optic nerve, a condition known as 
glaucoma. 9 The third component of the uvea, the choroid, located between the sclera and 
retinal tissues, contains blood vessels and capillaries to provide oxygen and nourishment 
to the outer layers of the retina. The boundaries of this layer begin at the uvea, but extend 
to the retinal pigment epithelium (RPE) at the posterior section of the eye (Figure 1. 1 ) . 
Lastly, the lens is important in light focusing and is a biconvex structure located 
at the back of the anterior chamber (Figure 1.1 ). The lens is comprised of a layer of 
cuboidal epithelial cells, and a population of elongated fiber cells. 10 The majority of the 
dry weight of the lens structure is comprised of a number of heat-shock like proteins 
known as crystallins. These proteins create a stable, gelatinous like material which is 
translucent due to the lack of cellular organelles (including nuclei) which allows the 
passage of light. This lack of nuclei in lens fiber cells means that no cell division occurs 
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after formation, making some fiber cells as old as the organism itself. The exception to 
this are epithelial cells of the lens, which retain nuclei and continue to slowly form lens 
fiber cells in the outer most regions of the lens, throughout the lifetime of the organism. 
Mutations in genes involved in the proper formation and function of the anterior 
chamber and its structures can cause various malformations. One such genetic condition, 
ASD, is fm1her discussed in Chapter 2. 
1. 2.2 Retinal Tissues 
The third chapter of this thesis examines a condition (achromatopsia) affecting the 
light sensitive tissue of the eye, referred to as the retina. The retina, the inner layer of the 
posterior segment of the eye (Figure 1.1 ), is responsible for translating the energy of 
incoming photons into vision. This is accomplished through a biochemical process 
known as ' the phototransduction cascade' which involves a number of complex 
enzymatic processes within the retinal photoreceptors (rods and cones), and the RPE. The 
electric signal produced by these processes is then transmitted via the neuronal cells 
(bipolar, horizontal, amacrine, ganglion, and Muller gl ial cells). 
(i) Photoreceptors (Rods and Cones) 
The photoreceptors of the retina are the cells responsible for the biochemistry 
involved in phototransduction and are located in the outer nuclear layer of the retina, 
adjacent to the retinal pigment epithelium (RPE). These highly specialized cells come in 
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two subtypes: rods and cones. Both cells are similar in structure, containing outer and 
inner segments, though they carry out different responses termed ' scotopic' (rod-
mediated) and ' photopic' (cone-mediated) responses. ' ' The rod cells of the retina are by 
and large the most prominent of the photoreceptors (approximately 120 million), by 
about a margin of 20:1 in comparison to their counterpart, the cones. 12 The rod cells are 
extremely sensitive to small amounts of light and are thus specialized for low light vision 
but have low spatial resolution and because of their increased numbers in the periphery of 
the retina provide side (peripheral) vision. 13 The cone cells, however, have high spatial 
resolution, but are comparatively insensitive to incoming light. Thus, the cones are 
responsible for high resolution and colour vision, and sight in well-lit conditions where 
photons are plentiful. The threshold for activation of the photopic responses in these cells 
is much higher than that of rods, so cones are only engaged in times of sufficient light 
abundance.12 
Both rods and cones are organized into an inner and outer segment containing 
photopigments which absorb photons (Figure 1.2). 14 The inner segment of the cell 
contains the components necessary for normal metabolic function (endoplasmic 
reticulum, Golgi apparatus, ribosomes, and many mitochondria required for powering the 
cell).15 The outer segment, connected to the inner segment by a modified cilium, 16 is 
organized into a number of flat membranous structures called the photoreceptor discs 
which are produced and secreted by the connecting cilium.16 These discs are the main 
functional unit of the human photoreceptor and contain the photopigment, rhodopsin. 
Rhodopsin is a member of the G-protein coupled receptor (GPCR) family of proteins, and 
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Figure 1.2: Image of a human rod photoreceptor cell illustrating the presence of the outer 
segment discs (top), and in descending order: the inner segment, nucleus, and synaptic 
body which terminates on neuronal cells. The outer segment discs contain the 
components necessary for the biochemistry of phototransduction. This image was 
obtained from en.wikipedia.org/wiki/Photoreceptor_cell, and has been released into the 
public domain for free use. (http://en.wikipedia.org/wiki/File:Rod%26Cone.jpg) 
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is activated by exposure to light. As photons are absorbed by Rhodopsin, cis-retinal, a 
vitamin-A derivative covalently bonded to the rhodopsin molecule, is converted to all-
trans-retinal which is then hydrolyzed from the Rhodopsin molecule. The all-trans retinal 
then enters a cycle to replenish the cis-retinal molecule, resetting the photoreceptor cell to 
allow for another response (Figure 1.3). The isomerization of cis-retinal to all-trans 
retinal creates a conformational change in the GPCR, and initiates the phototransduction 
cascade. 17 The cascade begins with activation of guanine nucleotide transducin 
molecules (G AT) which in turn activate phosphodiesterases (POE). These POE 
enzymes reduce the amount of cyclic guanine monophosphate (cGMP) within the cell, 
causing closure of a channel called the cyclic-nucleotide gated channel (CNG). When this 
channel closes, the cell hyperpolarizes, and transmits a signal to the neuronal cells 
through the bipolar and horizontal neurons. Malformation of the CNG channel, or 
mutation of the GNAT or POE class of enzymes can cause a number of conditions 
involving improper function of the photoreceptors. One such condition, achromatopsia, 
will be discussed in detail in Chapter 3 of this thesis. 
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Figure 1.3: Schematic of the biochemical recycling of cis-retinal in the photoreceptor 
cells. 11 -cis retinal is covalently bonded to an opsin molecule forming 11-cis retinilidene 
(Rhodopsin) and when stimulated by a photon isomerizes to all-trans retinilidene. A 
hydrolysis step then removes the molecule from rhodopsin, forming all-trans retinal. This 
is then transported to the Retinal Pigment Epithelium (RPE) where lecithin-retinol 
acyltransferase (LRA T) esterifies the molecule to all-trans retinyl ester. RPE65, an 
enzyme of the RPE then isomerizes the retinal molecule to 11-cis retinol. 11-cis retinol is 
then oxidized via 11-cis Retinol dehydrogenase (11 -cis RDH) to regenerate the 11-cis 
retinal molecule. The newly recycled 11-cis retinal is then transported back to the outer 
segment of the photoreceptor to be covalently bonded to the photopigment opsin 
(forming rhodopsin) and resetting the cycle. This image was obtained from 
http://en.wikipedia.org/wikiNisual_phototransduction and is published under the GNU 
Free Documentation License. 
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(ii) Neuronal Cells 
Besides the rods and cones, there are four types of neurons (horizontal, bipolar, 
amacrine, and ganglion) and one glial cell (Muller Glia) which exist in the mature retina. 
These cell types (including the photoreceptors) originate from a single progenitor cell 
population, and are organized into precise layers at the back of the eye. 18 
The photoreceptors terminate on neurons in the inner nuclear layer. When the 
photoreceptors generate a neuronal signal , the bipolar cells, which are postsynaptic 
(occur after) to the photoreceptors,13 transmit the signal to the Ganglion cells, the 'output 
cells' of the retina. 18: 19 The bipolar cells also receive signals from the horizontal cells and 
amacrine cells, which are interneurons (connecting neurons) between the photoreceptor 
and bipolar cells. 18 These interneurons function to transmit the neural signals from the 
photoreceptors to the bipolar cells, and ultimately to the ganglion cells. The seventh cell 
type within the retina is the Muller glial cells which exist throughout the entire thickness 
of the retina. These cells, unlike their counterparts, are not neuronal, but structural in 
nature and are responsible for maintaining retinal cell homeostasis.20 It has also been 
suggested that, due to their shape, these cells funnel light to the photoreceptors,2 1 and are 
a lso involved in retinal repair upon injury by dedifferentiation into multipotent progenitor 
stem cells.22 
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1. 2. 3 Retinal Structure 
All the cells described in the previous section make up the light sensitive tissue 
known as the retina. These cells are organized into a variety of structures within the retina 
important in the transduction of light energy into vision. These structures include the 
optic disc and cup which form the end of the optic nerve, and the macula/fovea (Figure 
1.3). 
The fovea and macula are important avascular areas located in the center of the 
retina predominated by photoreceptor cells. The macula is a large darkened spot with a 
small invagination about l.Omm long in the center referred to as the fovea (fovea 
centra/is) (Figure 1.4). These two structures contain the largest proportion of cone 
photoreceptors, and are therefore responsible for high visual acuity, central and distance 
vision, and colour discrimination. Towards the periphery of the retina, the number of 
cone photoreceptors decrease and number of rod photoreceptors increase, thus allowing 
low resolving peripheral vision. Loss or damage to the photoreceptors, and/or damage to 
the macula and fovea results in a loss of colour vision, high visual acuity, and central 
vision such as is seen in a group of progressive diseases called cone-dystrophies, or 
stationary cone disorders such as achromatopsia. Diseases which cause loss or damage of 
the rod photoreceptors or damage to the peripheral regions of the retina results in tunnel 
vision, and night blindness such as is seen with Retinitis Pigmentosa, a progressive 
condition which affects the rod photoreceptors. The retinal malfunction that this thesis 
examines is a form of cone malformation, called achromatopsia. 
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Figure 1.4: View of the retina of a right eye (oculus dexter; OD) upon funduscopy (view 
of the back of the eye using an ophthalmoscope). Important structures are indicated by 
white arrows and circles. The large dark area in the middle of the retina is called the 
macula, while the invagination (indicated by the darkest area) in the center of the macula 
is called the fovea. The fovea and macula contain only the cone photoreceptors 
responsible for high visual acuity. The large yellow spot to the right of the retina is called 
the optic disc, while the center is the optic cup. The optic disc is the area where all the 
retinal neurons become the optic nerve. The retinal vessels which nourish the retina with 
constant blood and oxygen supply enter the retina through the optic disc. 
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1.3 Formation of the Eye: Involved genes and pathways 
The formation of the eye is a complex process mediated by a number of 
interactions between tissues that eventually become the retina, and those that become the 
anterior chamber. During embryogenesis, the optic vesicle is formed from the ventral 
forebrain neuroepithelium (Figure 1.5 shown in purple)23 which then makes contact with 
the surface head ectoderm and begins to thicken, creating the lens placode (Figure 1.5 
shown in green).23: 24 During this process, the lens placode and distal optic vesicle 
invaginate to create the lens pit and optic cup (Figure 1.5), which gives rise to the neural 
retina and retinal pigment epithelium (RPE). The lens placode further invaginates to 
become the lens pit,25 and later forms the lens vesicle, which dissociates from the surface 
ectoderm to become the mature lens.23 These tissue-tissue interactions are mediated by 
transcription factors which determine the fate of each developing cell , many of which 
were discovered through studies of Xenopus laevis (African clawed Frog) which has 
informed a large portion of vertebrate retina development. 
During development of the Xenopus nervous system, an area of the neural plate 
(i.e. the precursor of the neural tube which forms the spinal cord and brain) becomes 
designated as the ' eye field ' and consists of a population ofmultipotent stem cells. The 
formation of the eye field is mediated by the inhibition of the bone morphogenic family 
of proteins (BMP) which are responsible for orchestration of tissue formation, and the 
canonical Wnt signals (a signaling pathway involved in embryogenesis).26: 27 This 
inhibition is carried out by Noggin, which inhibits BMP in high doses. Once the eye field 
is established, a number of other transcription factors such as Pax6, Six3, and Rx 1, 
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Figure 1.5 -Image of the developing eye. The purple area shows the neuroepithelium 
forming the optic vesicle (OV), which makes contact with the head ectoderm to form the 
Lens Placode (LP). The LP and OV invaginate to form the mature lens and optic cup 
(OC) respectively. (From Molly Weaver & Brigid Hogan. "Powerf ul ideas driven by 
simple tools: lessonsfrom experimental embryology" Nature Cell Biology 3, E165 -
E 167 (200 1 ). Reprinted by permission of the Nature Publishing Group, Liscense #: 
2953131304891 ). 
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te1med 'eye fie ld transcription factors ' (EFTF) are activated. These EFTFs assist in 
proliferation of multipotent progenitor cells while surrounding areas are undergoing 
cellular differentiation. This proliferation maintains a large pool of cells necessary to 
generate all the retinal cell types at different stages of development.28 As the eye field 
becomes specified, Six3 activates the Sonic hedgehog (Shh) pathway, which then defines 
the ventral diencephalon of the brain. Following this, the eye field designates two areas 
which will become the optic vesicles, which then invaginate to become the optic cup 
(Figure 1.4). At this stage, the retinal progenitor cells continue to proliferate and will 
generate the six types of retinal neurons (rods, cones, bipolar, amacrine, ganglion and 
horizontal). The retinal neurons develop in a time-dependent fash ion with gangl ion cells 
developing first, followed by cones, horizontal cells, amacrine cells, rods, bipolar cells, 
and Muller glial cells. The ability of a cell to differentiate into a particular neuronal cell is 
dependent on the time at which a progenitor cell exits the cell cycle. Early progenitors are 
competent to give rise to early-bom cells, while late progenitors generate late-bom cells. 
Typically, Ganglion cells are the first to develop fo llowed by cones, horizontal cells, 
amacrine cells, rods, bipolar cells, and finally Muller glia. Whether or not a cell will exit 
the cell cycle is regulated by transcription factors or signaling molecules such as Rx l , 
Vsx2 or Notch, which maintain cells in a proliferative, undifferentiated state by down 
regulating genes which promote cell-cycle inhibition, and neurogenesis.28 Down-
regulation of Rx l , Vsx2, or Notch, and activation of genes which promote cellular 
differentiation, such as Hairy2 , Zic2 and p27Xic , allow cells to exit the cell cycle and 
differentiate. 
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Mutations in the genes involved in these various processes create malformations 
in the eye's structure and function, causing visual defects. A widely studied example is 
PAX6, a gene originally cloned in the small eye mouse (sey), and is a homologue ofthe 
eyeless gene (ey) seen in Drosophila. This evolutionary conservation indicates that this 
gene has a highly important role in formation of the eye, even in lower organisms. P AX6 
is a homeobox transcription factor which has been called a ' master control ' gene in eye 
morphogenesis, due to its ability to control a large number of genes during eye formation. 
P AX6 was also the first gene discovered to play a role in human anterior segment 
disorders. During embryogenesis, P AX6 is expressed in the tissue from the surface 
ectoderm and neuroectoderms including the corneal epithelium, lens, and optic cup. 
Heterozygous mutations in this gene have been associated with a number of conditions, 
especially those of the anterior segment such as aniridia (complete or partial absence of 
the iris), congenital cataracts, and/or Peters anomaly (corneal opacities, and 
keratolenticular adhesions) which will be di scussed in Chapter 2? 9-31 P AX6 has also been 
shown to play a role in the formation of retinal neurons, as Pax6 knockout mice only 
develop amacrine cells, suggesting that Pax6 is necessary for production of all retinal 
neurons except amacrine cells. This is accomplished by down-regulating various basic 
helix-loop-helix (bHLH) transcription factors, such asHes bHLH, involved in the 
production of the other six neuron types.28 
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1.4 Vision Loss and Ocular Disease 
According to the World Health Organization (WHO) ocular disease causing 
vision Joss affects 285 million people worldwide of which 39 million are blind. This 
number is predicted to increase as the world population grows and ages.32; 33 This large 
prevalence of visual loss can have serious social and economic implications on a global 
scale. A study by the WHO in 2003 showed that the worldwide economic burden (loss of 
productivity) for those affected with blindness was $19 bill ion in the year 2000 and was 
predicted to grow to $50 billion by 2020 if no medical intervention (research/treatments) 
was carried out. A similar figure was proposed for those with residual vision and this was 
predicted to grow from $42 billion to $1 10 billion from 2000-2020.33 These large 
economic losses are coupled with the social stigma that goes with visual loss such as 
difficulty finding meaningful employment and lowered self-esteem/self-worth. 
A large number of diseases related to vision loss have been shown to have a 
genetic component. These conditions can be both complex (caused by gene-environment 
interactions), or Mendelian (caused by a single gene). Complex conditions pose particular 
challenges when studying ocular conditions as the environmental factors seem to play a 
large role and can be difficult to elucidate. Mendelian diseases (sometimes called 
monogenic disorders) are conditions caused by mutation of a single gene, and can be 
passed on from generation to generation. As only one gene is suspected to be causing the 
disease being studied, Mendelian conditions are much easier to study than complex 
conditions, especially through the study of fami lies where inheritance of a single gene 
mutation through generations can be observed. An example of Mendelian eye disease 
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which has been studied through a family-based approach is retinitis pigmentosa (RP). 
This condition affects 1 in 4000 individuals in the U.S. and is caused by mutations in 
over 50 genes and loci. Mendelian conditions of the eye can be nonsyndromic, such as 
RP which only affects the retina, or can be syndromic, which affect the eye and other 
systems. An example of syndromic eye disease is Usher Syndrome, a condition which 
has RP as well as hereditary hearing loss. These types of conditions are also caused by 
mutations of single genes, though the genes can be involved in different processes, 
creating multiple system malformations. The focus of this thesis is to examine 
nonsyndromic and syndromic Mendelian eye disorders, with the purpose of discovering 
genes involved the pathogenic mechanisms of the ocular condition. 
1.5 Why Study The Genetics Of Ocular Disease? 
1.5.1 Historical Contributions o.fOcular Genetics 
The study of ocular genetics has always been at the forefront of medical and 
experimental genetics. Conditions of the eye can present early in life , or can develop over 
time, and due to the eye' s external location, can be more easily observed in conditions 
with a structural change (i.e. cataracts). Conditions with a functional/internal change, 
such as those which affect the retina, are more difficult to diagnose than those with 
external changes due to ease of observation, though still remain easier in comparison to 
other conditions such as various cancers in terms of detection. The relative ease of 
phenotyping has made the genetic study of ocular diseases very attractive to researchers, 
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especially when seen in families. As a result, the field of ocular genetics has contributed a 
great deal to the scientific community through discovery of various genetic phenomena. 
These phenomena include X-linked inheritance, discovered through the study of colour 
blindness, 34 mitochondrial inheritance through study of Lebers hereditary optic 
neuropathy (OMIM 535000), Knudson's two hit hypothesis in cancer genetics via 
Retinoblastoma, 35 and digenic inheritance through study of RP. 36 
1. 5. 2 Recent Contributions of Ocular Genetics Studies 
As shown in the previous section, the study of ocular disease has always been 
important in the advancement of genetics and these studies continue to advance the 
science to this day. The hope and goal of any genetically-based research endeavor is to 
ultimately find a way to treat, or at the very least, attenuate symptoms of a particular 
genetic condition. Recently, the study of ocular conditions has taken this goal and made it 
a reality through the first successful attempts at genetic therapies. 
In 1990, the first FDA approved tests were carried out to cure a genetic disease 
called adenosine deaminase severe combined immunodeficiency (ADA-SCID) in two 
young patients. The results from these experiments were promising but only temporary. 
In 1999, tests were carried out to cure a genetic disease called ornithine transcarbamylase 
(OTC) deficiency (OMIM 311250). OTC deficiency is a defect in nitrogen metabolism 
which is usually fatal at birth, but less severe cases can be managed with proper diet. The 
cure for this condition came via an adenoviral vector carrying a normal copy of the OTC 
gene, a process termed 'gene therapy ' . The theory behind this work is that the adenoviral 
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vector would use the patient's normal translational machinery to produce a functional 
OTC enzyme. Unfortunately, following injection of the adenoviral vector the patient, 
Jesse Gelsinger, suffered anaphylactic shock and passed away.37 This tragedy was a 
major setback for many scientists in the field of genetic therapies, which then came under 
intense scrutiny from the public and government.38 
Recently, the field of gene therapy was revisited in human subjects for the first 
time since the death of Jesse Gelsinger through a study of a retinal condition called Leber 
Congenital Amaurosis (LCA). LCA is an autosomal recessive condition which presents at 
birth or early in life with severe vision loss or total blindness and absent photoreceptor 
response on electroretinogram (ERG) testing.39 This condition affects approximately 
1/80000 individuals worldwide40 and is genetically heterogeneous with 18 associated 
genes.4 1'42 One of these genes, RP£65, has been extensively studied in mouse, dog, and 
humans. RP £65 produces an enzyme of the RPE which produces 11-cis retinol in the 
vitamin A cycle (Figure 1.3), a molecule essential in normal retinal function. 39 In 2008, 
two trials, one in Philadelphia, USA 43 and one in London, England,44 were published 
back-to-back in the New England Journal of Medicine. These studies also used an 
adenovirus-associated vector (AA V) with a wildtype copy of RP£65, in hopes of 
producing a normally functioning protein. After administration of an AA V to six patients 
with LCA and mutations in RP£65 (one null mutation, five missense mutations) 
improved the vision in all tested individuals. 
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These trials have been successful in the eye as it is an easi ly accessible, 
compartmentalized, and immune privileged organ making it a very unique organ for 
gene-delivery .45 These characteristics have made it a great first step towards generalized 
genetic therapies. The LCA trials have ushered in a new era of retinal therapies and have 
led to a number of new exciting animal studies involving gene therapy for various ocular 
disorders, in hopes of developing other human trials. These conditions include a study of 
CNGA3 and CNGB3 gene therapy in achromatopsia in dogs,46 and mice,47: 48 which have 
had promising results. All these exciting experiments have created a flurry of other 
clinical trials for various conditions. A quick search of 'gene therapy' on the 
clinicaltrials.gov website reveals hundreds of planned, ongoing, and completed trials 
using gene therapies, and it will not be unsurprising to see many more added in the 
coming years. 
The advances made through gene therapies have been brought about by the long 
standing research of genetic ocular conditions. Without knowing the particular genes, 
mutations, and pathways involved with each individual disease, development of a 
treatment would be impossible. Treatment of patients with ocular disease will depend 
wholly on knowing which condition and which gene mutation the patient has, which will 
lead to a personalized form of medicine. This makes the discovery of gene mutations 
involved in ocular disorders all the more important for clinical practice, and for treatment 
development. Discovery of novel genes and mutations, such as is done in this thesis, will 
a llow us to gain more knowledge of the pathology of the condition, and the various 
pathways involved, paving the way for treatments like those listed above. 
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1.6 How to Study Ocular Disease 
As discussed in the previous section, to eventually develop a treatment for a 
particular ocular disease, one must first understand the pathological mechanisms 
involved. An effective method of discovering disease genes is through studies of 
monogenic ocular conditions. Due to the large number of monogenic (single gene) ocular 
disorders that have been identified, a very effective method for the study of these 
conditions is via family-based or population-based approaches. Founder populations such 
as that of the Mennonite, Hutterite, Icelandic, or as is used in this study, the 
Newfoundland population, offer unique resources for the study of monogenic disorders 
through availability of large pedigrees, and potential founder effects. 
1. 6. 1 Founder Effect and Founder Populations 
The founder effect is a phenomenon seen when a number of separately identified 
individuals share a single common ancestor often found through geneological or archival 
studies. This effect can be caused by genetic bottlenecks created through natural disasters 
(killing off a large portion of the population), or migration of a small group of individuals 
from a larger population to create a founder population. If a greater proportion of the new 
smaller population contains a rare pathogenic variant than the larger source population, it 
will become more freq uent as the population expands. This can result in a higher than 
normal prevalence of a disease phenotype. This situation can be exacerbated by limitation 
of intermarriage with other groups due to differences in culture, religion, language, or 
geography .49 If a rare mutation is present in one of the founders, it may become relatively 
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common as the population expands. As a result of the founder effect, individuals carrying 
mutations causing rare diseases may share a common ancestor49 and the mutation will be 
part of a disease-associated haplotype (a collection of alleles that are located close 
together on the same chromosome). With successive generations, meiotic recombinations 
will slowly reduce the size of the disease associated haplotype and only markers closest 
to the disease allele (i.e. are linked) will be shared amongst affected individuals of a 
founder population. This phenomenon of alleles that are physically close to one another 
on the chromosome and are inherited together is termed linkage disequilibrium (LD). An 
example of a population used in the context of ocular disease is that of the Pingelap 
Islands. This small island in the Pacific Ocean was home to a small population of about 
200 people, until a massive storm known as Typhoon Lengkieki decimated the island in 
approximately 1775, killing all but about 20 individuals (including 9 males).50 It is 
believed that this event created a genetic bottleneck in the Pingelap population, 
increasing the proportion of carriers for an autosomal recessive condition called 
achromatopsia (discussed in Chapter 3) creating an approximate di sease prevalence of 
about 10% amongst it' s now 250 individuals (as opposed to 0.003% in the USA). A study 
of this island population had found that the increased frequency of achromatopsia could 
be traced back to a single individual, named Nanmwarki Mwahuele. As founder 
populations, such as the Pingelapese, are of great use in gene discovery studies, the 
subjects and genetic conditions outlined in this thesis will concentrate on, and use 
individuals from the genetic isolates ofNewfoundland and Labrador, Canada. 
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1.6.2 The Newfoundland Population 
The province ofNewfoundland and Labrador on the East Coast of Canada 
includes the island of Newfoundland and the adjacent mainland, Labrador. The island of 
Newfoundland was originally discovered by an Italian navigator, Giovanni Caboto (John 
Cabot), in 1497. The island of Newfoundland is a collection of genetic isolates, separated 
by geographical and religious isolation, with a population of 509,348 (Newfoundland and 
Labrador Statistics Agency: http://www.stats.gov.nl.ca/ accessed June 29111, 20 12). The 
original approximately 20,000 immigrants from south-west England (Protestant), and 
southern Ireland in 1760 (Roman Catholic) settled in individual protected bays and 
coasts, along the coastal regions of the island to have access to the large fish stock. The 
original population had expanded to approximately 200,000 by 1890.51 Due to the 
differing religious beliefs there was also segregation between the Protestant and Irish 
Catholic settlers. 52 This has resulted in multiple separate founder clusters in the various 
bays and inlets surrounding the island. The existence of multiple founder effects and the 
large family size in the Newfoundland population has created a unique resource for 
studying genetic conditions and has led to the discovery of a number of founder 
mutations and novel genes. 
(i) Founder Mutation Discoveries in Newfoundland 
A number of studies in the Newfoundland population have identified identical 
mutations shared by multiple separate families, assumed (or proven) to be founder 
mutations. In the 1980s-1990s, a study of Multiple Endocrine Neoplasia type I (MEN 1; 
OMIM 1311 00), was carried out on the Burin Peninsula/Fortune Bay region of 
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Newfoundland. MEN! is an autosomal dominant cancer syndrome primarily affecting 
organs involved in the endocrine system, namely the pituitary, pancreas, and parathyroid 
glands. This condition is highly penetrant with over 94% penetrance by age 50, and is 
caused by mutations in the MENJ gene. The Newfoundland study identified a "founder" 
nonsense mutation in the MEN I gene in four large multiplex families. 53 Archival studies 
have so far demonstrated a common ancestor to three of the four fami lies. Also in the 
1980s-1 990s, Attenuated Adenomatous .r_olyposis Coli (AAPC; OMIM 611 73 1 ), an 
autosomal dominant cancer predisposition which can lead to a variable number of 
adenomatous polyps in the colon and rectum, was studied in five families from the North-
East coast of Newfoundland. This study led to the discovery of a splice mutation in exon 
four of the APC gene across all five families. 54 A common ancestor has subsequently 
been identified. Hereditary Nonpolyposis ~olorectal Cancer (HNPCC; Lynch Syndrome 
OMIM 120345) has been extensively studied in the Newfoundland population. A linkage 
study of two fami lies from Newfoundland identified the first HNPCC gene, MSH2, a 
mismatch DNA repair gene.55 Currently, 17 independently identified families from the 
same part of the province have this founder mutation. Four of these families have a 
demonstrated common ancestor. 
(ii) Gene Discoveries from the Newfoundland population 
As well as multiple founder mutation discoveries, the Newfoundland population 
has proven to be a resource to find novel genes, or novel associations of already known 
genes. Arguably the greatest accomplishment from a study of the Newfoundland 
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population has been that of a syndromic form of hereditary vision loss called Bardet-
Biedl Syndrome (BBS; OMIM 209900). BBS is an autosomal recessive condition 
characterized by retinal dystrophy, renal abnormalities, polydactyly, mental retardation, 
and mild obesity with a prevalence in Newfoundland of I in 17500.56 BBS is a 
genetically heterogeneous condition with 17 known loci or genes currently identified. 57 
The first locus, BBSJ , was originally described in 1994,58 but was refined to a lcM region 
in 1999 through a study of BBSJ-linked Newfoundland families. 59 This refinement 
eventually led to the discovery of the BBSJ gene in 2002.60 Secondly, the BBS3 locus, 
described in 1994,61 was refined to 3cM using a Newfoundland pedigree, leading to the 
discovery ofthe gene in 2004.62 The BBS5 locus was identified through homozygosity 
mapping of a large Newfoundland family in 1999.63 The gene at this locus 
(DKFZp7621194) was then discovered in 2004.62 Finally, the BBS61ocus and gene 
(MKKS) were discovered through a genome-wide scan of a large Newfoundland pedigree 
in 2000 and was the first gene to be described for BBS.64 The discoveries made in BBS 
through studying the Newfoundland population were very interesting, as one would think 
that a disease with such multi-system malformations as BBS, at an increased frequency as 
was seen in Newfoundland, would have a single genetic cause in a founder population. 
These studies revealed that the Newfoundland population is actually made up of multiple 
distinct genetics isolates rather than a single isolate. 
More recently, a discovery was made in the Newfoundland population which has 
had massive implications for clinical diagnoses and treatment in patients with 
Arrhythmogenic Right Ventricular Cardiomyopathy/Qysplasia (ARVC/D). ARVC 
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(OMIM I 07970) is a very severe autosomal dominant condition of the heart where the 
myocardium (heart muscle) becomes replaced with fibrofatty tissue, creating an 
aberration in the electrical activity of the heart. The first presentation of this disease is 
often sudden cardiac death, and affects males more frequently and at an earlier age than 
females. The age at onset in men is between 40-50 years of age, and in women between 
50-60 years of age. ARVC is genetically heterogeneous with 11 genetic loci and eight 
genes currently known.65-69 The eighth gene was elucidated through a study of 
Newfoundland families with a more severe form of ARVC than in other populations. The 
locus for the Newfoundland form of ARVC/D was originally mapped to 3p23 70 in an 
eight generation family from Newfoundland first identified in the 1980s and was called 
A R VD5.7 1 For many years after the mapping of the AR VD5 locus, a disease associated 
haplotype was used to assist in diagnosis of patients with ARVC, as the gene was not 
known. However, in 2008, a study of 15 families who were known to have ARVC (14 
families plus the original one from the 1980s) were used to refine the ARVD5 locus to 
2.36Mb on 3p25.72 Cascade sequencing ofthe positional candidate genes in this region 
identified a missense mutation (p.S358L) in TMEM43 which segregated with the disease 
phenotype in all 15 families. 72 
The discovery of genes causing BBS and ARVC are arguably the two largest 
contributions from studies of the Newfoundland population, though other novel genes 
and associations have been found as well. These include a study of non-syndromic 
hearing loss which identified mutations in the WFSI gene as an autosomal recessive 
cause of hearing loss, which was previously thought to only cause Wolfram-Syndrome 
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(OMIM 222300).73 Other examples of gene discoveries from using the Newfoundland 
population include MSH2 in Lynch Syndrome (the first identified gene for this 
condition)/4 HSN2 in hereditary sensory and autonomic neuropathy type 2/ 5 and IL l RN 
in interleukin 1 receptor antagonist deficiency. 76 
1.6.3 Gene discovery using afamily-based approach 
An effective method of studying monogenic conditions, especially in a founder 
population, is via a family based method. This approach has yielded great success in the 
past 20 years, and allows for multiple comparisons of variants within and between 
families, as well as the advantage of segregation analysis. Segregation analysis simply 
allows a researcher to track the inheritance pattern of a particular variant or marker 
genotype through a family. Thus, it is important to carefully select the disease of interest, 
and to thoroughly define the minimal diagnostic criteria for the disease, so that 
phenotyping can be done easily and accurately (though this is not always an easy task). 
The pedigree structure can then give insight into the mode of inheritance (autosomal 
dominant, recessive, X-linked, mitochondrial, or complex). An inaccurate diagnosis of 
the disease, either through phenocopies (individuals with the disease, but from another 
cause), variable age of onset, variable expression, and incomplete or reduced penetrance, 
or ill-defined diagnostic criteria can severely skew the results of segregation analysis, and 
either overlook or miss a very important result. 
Phenocopies, in the case of family studies, are members of a family that show the 
disease phenotype, but because of some extraneous factor (i.e. environment), rather than 
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genetics. A prime example of phenocopies is illustrated by the formation of cataracts in 
the anterior segment of the eye. If a researcher is studying a family with early 
onset/congenital cataracts, it is possible that there may be some family members with 
cataracts not caused by a genetic predisposition. For example, the use of some 
corticosteroids, and exposure to UV radiation has also been associated with cataract 
formation. Thus, it becomes possible that some members of the studied family have 
cataracts from environmental exposure. It becomes important to carefully review medical 
records and exclude individuals who may possibly have the phenotype in question for a 
different reason. 
Variable expression is when members of the same fami ly or people who share the 
same disease have varying severities of the condition or different tissues or organs 
involved. This can be problematic when trying to distinguish affected family members, 
from unaffected family members, as it may be possible that some individuals are 
affected, though they have a subcl inical phenotype (very mild affection which may go 
unnoticed during examinations). An example of variable expression will be discussed in 
Chapter 2 in a study of anterior segment dysgenesis. 
Penetrance is defined as the probability that a person with a particular deleterious 
mutation will express the associated disease or phenotype. For example, achromatopsia, 
which is discussed in Chapter 3 of this thesis, is a fu lly penetrant autosomal recessive 
condition. 77 This means that if a patient has a mutation on both copies of a gene known to 
cause achromatopsia, they will express the phenotype 100% of the time. An example of a 
Page 44 of 257 
low penetrance ocular condition is retinoblastoma, an aggressive eye cancer occurring in 
childhood.78 Studies have found that truncating (null) mutations (nonsense mutations, 
splice mutations) of RBI cause a high penetrance of retinoblastoma, whereas non-
truncating mutations (missense) confer a lower chance of developing retinal tumours. It 
has been shown that an inherited null mutation, accompanied by subsequent loss of 
heterozygosity through somatic mutation (Knudson' s Two Hit Hypothesis), causes high 
penetrance retinoblastoma. 79 The presence of a missense mutation leaves residual 
function of the RBI gene, lowering the chance for tumour formation, creating a low 
penetrance condition. 79 Thus, it is necessary to have a sense of the degree of penetrance 
in the disease being studied, as otherwise interesting mutations can easily be overlooked 
if the expected phenotype is not present in all affected individuals. It may be possible that 
a mutation is indeed causative, but is a mutation of reduced penetrance. 
I. 6. 4 Genetic Analysis of Families 
(i) Functional Candidate Gene Screening 
Once a disease, minimal diagnostic criteria, pedigree, and mode of inheritance are 
carefully laid out, one can begin searching for the genetic mutation causing the disease of 
interest in the family (or families). Typically, the first step in these cases is to begin 
searching for the putative mutation in genes already known to cause the condition 
(referred to as a 'candidate gene approach' ). Chapter 2 of this thesis describes such an 
approach by sequencing genes known to cause an anterior segment dysgenesis 
phenotype. This approach is also highlighted in the study of achromatopsia in Chapter 3, 
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where affected individuals from multiple famil ies were screened for mutations in the four 
known achromatopsia genes. This initial approach can save time and money in the long 
term as some cases may be able to be solved through the screening of previously 
associated genes. 
(ii) Genome Wide/Chromosomal Scans 
If a pathogenic variant is not found in previously described genes, or the disease 
in question is incredibly rare and has no previously associated genes or regions, one can 
begin a genome-wide search for the mutation in question. A genome-wide analysis is 
typically conducted by using a number of markers which span each of the 22 autosomes 
(or the X and/or Y chromosome in the case of sex-linked inheritance). These markers can 
either be microsatellites (repetitive elements of the genome), or .S.ingle Nucleotide 
E_olymorphisms (SNPs). The genotypes at each of these markers are then determined. 
Microsatellite markers are areas of the genome that contain repetitive sequences and 
often vary in length/size between individuals. As a result, these markers are considered 
poly-allelic, and have many different genotypes, whereas SNPs are biallelic, containing 
one of two alleles (e.g. either a C nucleotide base, or a G nucleotide base). Microsatellites 
can provide more information than S Ps due to being poly-allelic, but are less evenly 
distributed across the genome ( - 16,000 microsatellites) than S Ps. Although S Ps do 
not provide as much information as microsatellites due to their biallelic nature, there are 
currently microanay chips which allow the genotyping of millions of SNPs across the 
genome in a cheap and timely manner. 
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(iii) Linkage and Haplotype Analysis 
Once the genotypes of a set of markers have been determined, an analysis 
particularly effective in family studies can be carried out, called ' Linkage Analysis'. The 
purpose of this analysis is to link the individuals with a disease phenotype with a 
genotype at a particular marker (or markers), giving an idea as to where in the genome 
the disease gene is located. The position of the various SNPs and microsatellites are then 
determined (i.e. what chromosomal region) by comparison to the Human Genetic Map 
via various databases (UCSC Genome Browser,80 Ensembl,81 etc) and can then be placed 
in the order that they exist on the corresponding chromosome. The ordering of alleles in 
this manner is referred to as a haplotype and represents the physical position of these 
markers on a chromosome. During meiosis, chromosomes have the opportunity to 
recombine at matching regions on homologous chromosomes. This recombination 
rearranges the alleles of various genes on either chromosome, and is responsible for a 
great deal of the variation seen in humans. Despite this shuffling of genetic information, 
areas of chromosomes that are located physically close to one another tend not to 
recombine, and are said to be in linkage disequilibrium. The distance between two 
markers is determined by the likelihood of recombination between the two regions and is 
measured in centimorgans (eM). Iftwo loci are 1 eM apart, then the recombination rate 
between them is 1% and is generally considered to be approximately one million 
basepairs of the human genome. This is called a genetic map, or genetic distance, as 
opposed to a physical map or distance which is measured in basepairs. Recombination 
fraction (8) is another expression of the frequency of recombination between two 
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markers, and is directly related to genetic distance. A recombination fraction of 0.0 
means that the two markers are tightly linked, and will remain together after the 
recombination process whereas a recombination fraction of 0.5 means that the two 
markers are not linked, and will be subject to frequent recombination (50%). Thus, the 
goal of linkage analysis is to determine whether a genotype is tightly linked (8 =0) to a 
disease locus. 
Linkage analysis can be divided into two types: parametric and nonparametric 
studies. Parametric analysis requires knowledge of the phenotype in question, specifically 
how rare the disease allele is (common or rare disease), if phenocopies are commonly 
seen, the correct mode of inheritance, or penetrance. Non-parametric analysis does not 
require any of these inputs and tests for polymorphic marker genotypes that are identical 
between all ofthe affected members ofthe family, called Identity By Descent (IBD). 
Both these analyses use a statistical measure of linkage, referred to as the Logarithm of 
the Odds ratio (LOD). The LOD score is a computation of two probabilities during the 
analysis: 1) The probability that the observed phenotypes in a family are due to genetic 
linkage between loci. 2) The probability of observing the phenotypes in a family 
assuming there is no linkage between loci (8=0.5). A LOD score of 3 (8 =0) at a marker 
indicates a 1:1000 chance of this marker not being linked to the disease gene as 
log( 1000)=3, and is considered the threshold for linkage. The minimum threshold for 
linkage exclusion is -2, meaning that any LOD score below -2 can be rejected from 
further experiments. 
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These analyses allow a researcher to determine the position on a specific 
chromosome that a disease gene may reside. This region is called the 'critical region ' and 
is then studied in more detail. The use of both parametric and non-parametric analysis 
will be explained and used in Chapter 4 of this thesis. 
(iv) Critical Region Refinement 
Once the critical region of the genome has been detennined, this region can be 
'refined ' or made smaller. Generally, a smaller number of widely spaced markers or 
SNPs are used for the initial linkage analysis, to maximize speed and efficiency of 
computations. Thus, the critical region may be very large in the first steps of analysis. To 
refine this region, a number of markers spaced closer together than those in the initial 
scan are genotyped. This step is made easier by analyzing as many individuals in a single 
(or multiple) family(ies) as possible. This allows a higher resolution haplotype to be 
constructed. This haplotype can then be visualized on a pedigree to search for any 
recombinations within the critical region that may reduce its size. 
(v) Positional Candidate Gene Sequencing 
Genes within the now refined critical region are termed 'positional candidates' . 
Once the critical region has been defined, the positional candidate genes are prioritized 
for screening. For example, if one is studying a hearing loss family, any genes involved 
in the functioning or formation of the inner ear would be prioritized, whereas genes 
involved in retinal function, cancer, or immune system function may be put lower on the 
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priority list. One method for screening genes is the Sanger Sequencing method, which 
involves the incorporation of dideoxy nucleotide chain terminators. This method was first 
introduced by Frederick Sanger in 1977,82 and has become the gold standard fo r 
sequencing. Once the list of positional candidates has been made, Sanger sequencing is 
performed using primers surrounding the gene' s coding regions (i.e. areas of the gene 
that code for the corresponding protein). A smaller number of affected and unaffected 
family members can be used for this initia l sequencing screen, to maximize efficiency. 
This will, ideally, identify a number of potentia lly pathogenic variants. 
(vi) Variant analysis and Validation 
After the screening of positional candidate genes, a number of variants will likely 
be identified. These variants undergo a two-fo ld analysis: 1) the variants will undergo 
segregation ana lysis, to look for correlation between the variant and the phenotype (and 
can be added to the critical region haplotype to potentially reduce the size of the critical 
region), and 2) The variants will be analyzed for any potential effect on the translated 
protein . These effects include nonsense mutations (premature stop codon), missense 
mutations (mutated amino acid), or splice variations which may alter the mature RNA 
transcript. Any mutations which are of particular interest will be screened in the 
remainder of family members. This step will exclude a number of variants depending on 
the number of available family members, leaving a smaller number of variants to analyze. 
Next, variants of interest can be screened in ethnically-matched population controls. 
Variants which are found to occur frequently in the study population can be excluded 
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from further analysis, as they are likely polymorphic variants (SNPs) rather than disease 
causing mutations. In silica analyses are also avai lable to further characterize some types 
of mutations (i.e. SIFT, PolyPhen-2 for missense mutations, or BDGP splice prediction 
tool for splice site mutations). In order to further characterize splice site variations, RNA 
can be extracted from immortalized cell lines, or whole blood and then used to determine 
any altered splicing patterns. Ideally, if a variant which appears to be rare (based on 
database information and population controls), segregates with the disease, and has 
predictive deleterious effects upon in silica analysis, functional studies can then be 
carried out to determine the putative effect on the protein. 
(vii) Next Generation and Exome Sequencing 
Another, more recent, approach to gene discovery projects has been developed in 
the last five years. This new technology, called Next Generation Sequencing (NGS) or 
Massively Parallel Sequencing, allows for whole genome sequencing with a very rapid 
throughput. The major application of NGS technologies in the past two to three years has 
been that of exome sequencing. This teclmology is a revolutionary method to sequence 
all the coding regions ofthe genome (~ 1% ofthe genome) relatively quickly, while 
excluding the intronic and intergenic regions.83 Exome sequencing has had many 
successes over the past 3 years, and has proven its utility in gene discovery for a variety 
of diseases including infantile hepatopathy, non-small cell lung carcinoma, inflammatory 
bowel disease,84 and retinitis pigmentosa to name but a few. It has also shown great 
utility as a diagnostic tool, and has great advantages over linkage studies as no previous 
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information (though information on penetrance and mode of inheritance can ease 
analysis) is required for analysis. Despite these numerous advantages, analysis of exome 
sequencing data is not without its difficulties. Once exome sequencing has been carried 
out on a sample, a list of hundreds of thousands of variants is generated which can be 
difficult to deal with. To ease further analysis, this large li st is filtered for common 
variants by comparing the exome dataset to previously established databases such as the 
1000 Genomes project, dbSNP, the HapMap project, or the Exome Variant Server. These 
filters will remove many common, or already discovered SNPs and non-pathogenic 
variants, leaving a list of rare variations. This smaller list can then be filtered for variants 
with potentially pathogenic effects (nonsense, missense, or potential splice variations). 
This process is made easier by sequencing the exomes of multiple patient samples with 
the same disease, particularly from a single family. If multiple fami ly members are 
available for analysis, a segregation analysis of potentially pathogenic variants 
discovered through exome sequencing can be performed. This is accomplished by 
confirming the variant via Sanger sequencing, then tracing the putative mutation through 
family members. 
As previously stated, exome sequencing can also be used as a diagnostic tool if 
the disease phenotype is not well known, or if a particular feature of the phenotype is 
overlooked upon examination. An example of exome sequencing as a diagnostic tool is 
outlined in Chapter 3 ofthis thesis through a study of a Newfoundland family with 
achromatopsia. 
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1. 7 Summary and Study goals 
This thesis is an extension of research started by Dr. Jane Green over 30 years 
ago. Dr. Green reviewed the blind registration records maintained by the Newfoundland 
and Labrador division of the Canadian National Institute for the Blind (CNIB) and 
through ocular genetics clinics, obtained a plethora of family based information and 
pedigrees. This research project is a culmination of these three decades of work to finally 
solve the genetic basis for eleven of these families with three conditions. These 
conditions include Anterior Segment Dysgenesis (ASD; 1 family) , Achromatopsia 
(ACHM; 8 families) , and Microphthalmia-Dwarfism (MDW; 2 families). The discovery 
of novel genes and variants through this study can, in the future, provide patient care for 
these families as genetic and molecular therapies are developed and tested. This thesis 
approaches all three conditions from different standpoints, using all the techniques 
described in this introduction such as functional candidate screening, linkage analysis, 
and exome sequencing. 
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Chapter 2: A Novel non-stop mutation in FOXE3 causes an autosomal 
dominant form of variable anterior segment dysgenesis including Peters 
Anomaly 
Lance Doucette1, JaneS. Green 1, Bridget Femandez1, Gordon J Johnson 1, Patrick 
Parfre/ , and Terry-Lynn Young1 
I Faculty of Medicine , Memorial University of Newfoundland 
A shorter version of this chapter is published in the European Journal of Human 
Genetics 19: 293-299 (201 1) 
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2.1 Summary 
Anterior segment dysgenesis (ASD) is a spectrum of disorders which affect the anterior 
ocular chamber consisting of the cornea, iris, and lens. Clinical studies on a 
Newfoundland family over the past 30 years show that 11 relatives have a variable ocular 
phenotype ranging from microcornea to Peters anomaly, a severe form of ASD, 
segregating as an autosomal dominant trait. To determine the molecular etiology of the 
variable ASD in this family, we sequenced nine functional candidate genes associated 
with ASD (PAX6, PITX2, PITX3 , FOXCJ, CYPJBJ , CR YAA , GJA8, B3GALTL and 
FOXE3) and identified 44 variants. Segregation analysis revealed a point mutation (c.959 
G>T) in FOXE3, which codes fo r a transcription factor involved in the formation of the 
lens and surrounding structures, co-segregating with the variable dominant ocular 
phenotype. This novel mutation substitutes the stop codon for a leucine residue, 
predicting the addition of72 amino acids to the C-terminus ofFOXE3 (p.X359L). Two 
recent reports have also identified non-stop mutations in FOXE3 in patients with variable 
ocular phenotypes and have predicted an extended protein. Although FOXE3 is a lens-
specific gene, we successfully isolated eDNA from lymphoblasts of an affected family 
member and our sequencing results show that the mutant c.959T allele is absent, 
suggesting that it may be degraded at the RNA level. Though preliminary, our results 
challenge the notion that an extended FOXE3 protein causes ASD and instead suggests a 
mechanism of haploinsuffiency in the case of non-stop mutations. This study adds to 
several reports that suggest that autosomal dominant mutations within FOXE3 cause 
ASD and has important clinical utility especially for the diagnosis of mildly affected 
patients. 
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2.2 Introduction 
2. 2. 1 What is anterior segment dysgenesis? 
Anterior segment dysgenesis (ASD) is a clinically heterogeneous phenotype and is a 
spectrum of various malformations of the anterior chamber generally affecting the 
cornea, iris, and lens. Examples of these disorders include microcornea, congenital 
cataracts, scleralization of the cornea, and a severe condition known as Peters anomaly.85 
Microcornea is a mild form of ASD and patients are considered to be affected if their 
cornea measurement is < 11 mm. This condition is rarely seen in isolation and is usually 
associated with other ASD phenotypes such as congenital cataracts (cataract-microcornea 
syndrome OMIM 116150), or Peters anomaly (OMIM 604229). Peters anomaly (PA) is a 
congenital condition, originally described in 1906,86 and is characterized by an opaque 
cornea (called corneal leukoma), cornea-lens, and cornea iris adhesions and absent 
Descemet's membrane. PA was originally thought to be sporadic, though it has been 
described in both autosomal recessive and autosomal dominant inheritance patterns. This 
condition can be seen either in isolation, or as part of a syndromic condition such as 
Peters Plus Syndrome (Krause-Kivlin Syndrome OMIM 26 1540), a condition 
characterized by the ocular phenotype of Peters anomaly, but also extraocular features 
such as short stature, short fingers, and mental retardation. 
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2.2.2 The Genetics ofASD 
ASD is a complex trait and can be caused by mutations in many different genes.29 
In addition, it seems as though the same mutation can cause many different phenotypes, 
suggesting other modifier or stochastic events are important for disease progression. The 
majority of the genes involved in the pathogenesis of ASD are important transcription 
factors involved in neural crest cell migration. These genes include P AX6, 3 1 P ITX2, 87: 88 
FOXC1, 89 FOXE3 90: 9 1 and PITX3, 92: 93 which have been associated with disorders such 
as aniridia, Axenfeld-Rieger syndrome, Peters anomaly, and congenital cataracts. Genes 
that encode structural components of the eye, such as the crystallins (i.e. CRYAA)94 or the 
gap junction gene GJA8, 95 have also been associated with various forms of ASD such as 
congenital cataracts and microcornea-cataract syndrome respectively. CYP 1 B1 , a 
member of the cytochrome P450 family has been implicated in the pathogenesis of 
primary congenital glaucoma,96: 97 as well as Peters anomaly.98 BJGALTL has been 
shown to be the only gene involved in Peters Plus syndrome (Krause-Kivlin syndrome; 
OMIM #261540), a syndromic form ofPeters anomaly.99 
(i) PAX6 (OMIM 607108) 
P AX6 is considered a 'master control gene' involved in the development of the 
brain and ocular structures. 100 PAX6 homologues have also been described in Small Eye 
(Sey ) mice, and in eyeless Drosophila (ey), indicating the conservation of this impot1ant 
gene across various species. This gene is also essential in forming the lens placode in 
mammalian development. Heterozygous mutations of P AX6 have been implicated in 
many ASD conditions such as aniridia, cataracts, coloboma, and Peters anomaly. In very 
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rare cases, homozygous P AX6 mutations have been shown to be involved in 
anophthalmia (lack of eyes), as well as lethal neonatal brain malformations, indicating the 
importantance of gene dosage in this gene. This data also suggested that P AX6 plays a 
role in the migration and differentiation of neural progenitor cells. 30 
(ii) PITX2 (OMIM 601542) 
The Pituitary Homeobox 2 gene (P/TX2) , located on 4q25, was isolated in 1996 
through studies of a rare autosomal dominant condition called Axenfeld-!Ueger 
Syndrome (ARS; OMIM #180500).10 1. This condition is characterized by malformations 
of the anterior chamber, which consists of microcornea, corneal opacities, iris hypoplasia, 
and posterior embryotoxon, in which 50% of patients develop glaucoma. Systemic 
anomalies are also described, namely dental hypoplasia, excess periumblical skin and 
maxillary hypoplasia.102 PITX2 is known to be expressed in the areas affected in ARS 
(umbilicus, mandibular epithelium, and the periocular mesenchyme) and is only 
expressed in the pituitary gland, though few cases of ARS show any signs of pituitary 
malfunction. 
(iii) PITX3 (OMIM 602669) 
The Pituitary Homeobox 3 (P ITX3) gene, located on 1 Oq25, is a member of the 
bicoid class homeobox transcription factors , like its relative, PITX 2. When PITX2 was 
isolated in 1996, this prompted a search for other genes of this nature and human PITX3 
was subsequently discovered in 1997.103 PITX3 was then sequenced in 80 patients with 
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ASD phenotypes and a 17-bp duplication was identified in family with an ASD 
phenotype (corneal opacities, iris-lens adhesions) and a missense mutation in one family 
with autosomal dominant cataracts.93 More recently a 1-bp deletion in the coding region 
of PITXJ was found in a fami ly of English origin with autosomal dominant posterior 
polar cataract. 104 
(iv) FOXC1 (OM1M 601090) 
The Forkhead Box Domain C1 (FOXC1), a single exon gene located on 6q25.3 , is 
a member of a large group of transcription factors with a common DNA binding domain 
termed the 'forkhead domain ' . This gene was isolated in 1994 as part of a search for 
forkhead domain genes in humans, as the forkhead domain was already known to 
Drosophila, rats, metazoans, and yeast. 105 Since its discovery, mutations in FOXCI have 
been implicated in various ocular disorders such as primary congenital glaucoma, 106: 107 
ARS P I 1os· 1o9 d 1 · h · n1· · f · , eters anoma y · an most recent y, m t e progress to mvas10n o certam 
types of breast cancer through regulation of genes like NF-KB (an important transcription 
factor in immune function/responses) , 110 or MMP 17 (responsible for extracellular matrix 
d l. ) Ill remo e mg . 
(v) FOXEJ (OMIM 601094) 
The Forkhead Box Domain EJ (FOXEJ) , a single exon gene located on 1 p33 was 
discovered in 1995 11 2 and was later found to be highly expressed in the lens vesicle and 
lens placode during development, but only in the lens epithelium post-natally. 113 This 
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transcription factor is primarily responsible for the differentiation and proliferation of 
cells within the lens, and mutations can affect the formation of this important structure. 
Mutations within human FOXE3 have been shown to cause aphakia (lack of lens 
development) when in the homozygous state 11 4; 115 as well as other conditions such as 
sclerocornea, microphthalmia, and optic disc coloboma. 11 6 It has also been shown to 
cause various forms of ASD when inherited in an autosomal dominant manner (i.e. 
heterozygous transmission) such as congenital cataracts and posterior embyrotoxon.91 
(vi) CRYAA (OMJM 123580) 
The Crystallin alpha-A (CRYAA) gene, located on 2q22.3, is one of a large group 
of crystallin genes, responsible for formation and maintenance of transparency of the 
mammalian lens. These proteins share high sequence homology with the heat shock 
protein (Hsp) family of proteins, which form aggregates to sequester harmful proteins 
upon injury to protect the cell under stressful conditions. 11 7 Mutations of CRYAA have 
been shown to be the cause of autosomal dominant congenital cataract in a number of 
cases, 
116
-
11 8 
and one report showed that mutation of this gene can affect the ability of 
CRY AA to form aggregates, causing microcornea-cataract syndrome (OMIM 11 6150).119 
Interestingly, it has been suggested that due to its position on chromosome 2 1, CRYAA 
may play a role in the cataracts seen in Down Syndrome patients (trisomy 21 ). 
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(vii) GJA8 (OMIM 600897) 
The Gap Junction Alpha 8 (GJA8) gene, located on lq21.2, produces a gap 
junction protein, connexin 50 (Cx50) which is present in all cells of the lens, first being 
synthesized in the lens epithelium. 120 When lens epithelial cells differentiate into 
secondary fiber cells they lose their intracellular organelles, which otherwise might cause 
scattering of incoming light, in order to maintain transparency in the lens. 121 Due to lack 
of organel les, the inner lens fiber cells, have developed a complex network of connexin 
proteins to facilitate proper metabolism, and to transport small metabolites or secondary 
messengers between cells. 122: 123 Mutations of GJA8 have been associated with zonular 
I I 124 I . 12s II · pu veru ent cataracts, nuc ear progressive cataracts, as we as cataract-Imcrocornea 
syndrome. 126 
(viii) CYP1B1 (OM1M601771) 
CYP I B I , isolated in 1994 and located on 2p22.2, is a member of the Cytochrome 
P450 superfamily of genes which are responsible for xenobiotic and drug metabolism.127 
CYP 1 B1 has been primarily associated with cases of primary congenital glaucoma, !28: 129 
and is suspected to be involved in the metabolism of a yet-unknown molecule involved in 
proper eye development.97 Other studies have also implicated mutations in CYP 1 B1 in 
patients with Peters anomaly.98: 130 This gene is also involved in the hydroxylation of 17-
beta-estradiol, a compound postulated to be involved in breast cancers. 
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(ix) B3GALTL (OMIM *610308) 
Beta-1,3-Galactosy ltrans.ferase-Like (B3GALTL) was cloned in 2003, and codes 
for a 498 amino acid protein 131 responsible for the synthesis of a disaccharide found on 
repetitive elements (thrombospondin type-1 repeats) of many biologically important 
proteins. 132 This gene has been associated with a rare autosomal recessive condition 
termed Peters Plus Syndrome (AKA Krause-Kivlin Syndrome; OMIM 261540). This 
condition is characterized by the anterior segment dysgenesis phenotype of Peters 
anomaly but with other extraocular features such as disproportionate short stature, mental 
retardation, craniofacial malformations, and cleft lip/palate. The association of B3GALTL 
with Peters plus syndrome was first shown in a study using array-based comparative 
genomic hybridization (aCGH) which identified an interstitial deletion surrounding 
B3GALTL.99 Since then, a number of other mutations have been described in B3GALTL 
133 I'-
as causing Peters plus syndrome. - J) 
2. 2. 3 Current Study 
We previously reported a proband diagnosed with congenital Peters anomaly and 
a fami ly history of a variable form of autosomal dominant ASD, including microcornea, 
congenital cataracts, and sclera lization of the iris. 136 This study was undertaken to 
identify the genetic etiology of ASD in this Newfoundland family. Throughout the course 
of this study, I not only identify the causative gene but also present the progression of the 
ocular phenotype observed over a 30-year period and describe the functional candidate 
approach used to determine the causative gene. 
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2.3 Materials and Methods 
2. 3.1 Clinical Investigation of Proband and Relatives 
We studied a 4-generation family from the island of Newfoundland with mild to 
severe forms of ASD segregating as an autosomal dominant trait (Figure 2.1 ). The 
proband was diagnosed at birth in 1979 with Peters anomaly.136 Long-term clinical and 
ophthalmic examination of family members has continued since that time (Table 2.1) and 
has included visua l acuity measurements, refraction, direct and indirect ophthalmoscopy, 
slit lamp examination, tonometry, gonioscopy, corneal diameter measurements, axial 
length measurements (ultrasound) and external eye photographs as previously 
described. 136 Thirty-one of 66 known family members participated in this molecular 
genetics study (though clinical examinations were performed on a total of 52 family 
members), and ofthese, we have identified 11 cases of ASD across six sibships (Figure 
2 .1 ). Due to the variability of ocular phenotypes seen in this family, we (JG, GJJ) 
conducted repeated, complete slit lamp examination of the cornea, iris, angle and lens, 
and measurement of the corneal diameter on a number of individuals. These 
examinations provided evidence for minimal diagnostic criteria which included either 
corneal scleral ization, lens opacities, strands in the angle or small corneal diameter 
(< llmm). This study was approved by the Human Investigations Committee, Memorial 
University, St. John ' s, Newfoundland, Canada (HIC #02.116). 
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Figure 2.1: A four generation Newfoundland family segregating an autosomal dominant form of 
anterior segment dysgenesis (ASD). The proband ( 111-6: arrow) has congenital Peters anomaly . 
The phenotype in this fam ily ranges from a mild anterior segment phenotype such as 
microcornea, to a very severe form ca lled Peters anomaly. 
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-------------------------------- ----- - --- - ----- --- ------, 
T a ble 2.1 - C linical examina tio n of affected m em bers from Fa mily 0023 
Corneal 
Age at last Dia meter Axial Length V isual 
PID examina t ion Cornea (mm ) Lens (m m) Acu ity 
111-6 30 Right - Pete rs Anomaly R - 9.25 Cataract and adhes ion from R- 20. 1 R- 6/30 
Left- Peters Anoma ly L - 9.5 lens to cornea L - phth is ical L- N LP 
11- 14 57 Moderate sclerali zation R - 10 PSC and nuclear cataracts. R - 21.2 R - 617S 3 
L- 10 Extractions at 39 and 40 L - 20.9 L- 6/9 
Cataract extractions at 36 and 
11-5 68 Mode rate sclera lization R- 10 38 R - 21.5 NA 
L- 10 L - 22.2 
Cataract extractions at 32 and 
11 -7 65 Mode rate scleralizat ion R - 8.5 36 R- 21.3 HM 
L - 8.5 L - Enuc leated N LP 
Cataract extractions at 27 and 
11 - 16 59 NA R - MC 29 NA NA 
L- MC 
111-7 20 Mild scle ral ization R-N A AC, PSC , d iffuse SC cataracts. NA NA 
L - NA Extractions at 16 
111 -2 4 1 Mild scle ra lization R - 10.5 AC, PSC Cataract extractions R- 21.8 R - 619 
L - 10 .5 at 40 years L- 22.3 L- 6/6 
111 -3 39 Moderate scleralization R - 9.5 AP, Nuclear, PSC cataracts. R - 21.8 R- 6/9 
L - 9.75 Cataract Extractions at 2 1 L - 22 .8 L- 619 
IY-2 10 Left corneal opacity NA A P cataracts NA R- 6/6 
L- 619 
Central Corneal A P cataract extractions at 8 R - 6/ 18 
IV- I 6 opac iti es R - N A months NA L - 6/1 8 
L - 9 
PID = Pedigree Identifi e r AC = Anterior cortical; AP = Ante rio r polar; PSC = Poste rio r subcapsular; SC = Subcapsular; MC = 
M icrocornea; H M = Hand movements NLP = No light perception; NA = Not ava ilable 
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2. 3. 2 Selection and Screening of Functional Candidate Genes 
Genes involved in the structural development of the eye or with previous 
association with ASD, such as Peters anomaly and related disorders (i.e. Axenfeld-Rieger 
syndrome, Krause-Kivlin syndrome) were sequentially screened for mutations, namely 
PAX6, PITX2, FOXCJ, PITX3, CYPJBJ, BJGALTL, CRYAA, GJA8, and FOXE3 . PAX6 
encodes a transcription factor which has been implicated in aniridia and Peters 
anomaly .3 1· 137 PITX2 (RIEGJ) is primarily associated with Axenfeld-Rieger syndrome, a 
syndromic form of ASD with similar ocular phenotypes,88 though some mutations have 
been identified as causing non-syndromic Peters anomaly.87 PITX2 interacts with the 
transcription factor FOXCJ89: 138 and mutations in FOXCJ produce a similar phenotype as 
seen in P ITX2 mutants. P ITXJ has been associated with autosomal dominant congenital 
9293 139 
cataracts and Peters anomaly. · · Mutations in B3GALTL, a galactosyl transferase 
gene, cause Peters pi us syndrome, which consists of Peters anomaly, short stature, cleft 
I" lip, cleft palate and mental retardation. J J Though there have been no reports of 
incomplete or atypical forms of Krause-Kivlin syndrome showing only the ocular 
phenotype, B3GALTL was screened in this family to check for possible hypomorphic 
alleles which may cause the non-syndromic phenotype seen in this family. CRYAA, a 
member of the crystallin family which constitutes the major structural protein in lens 
fiber cells, has been associated with autosomal dominant cataracts, microcornea, and 
corneal opacities.94: 140 GJA8 encodes a gap junction protein which regulates ion and 
crystallin concentrations within the lens fiber cells.95 This gene has been associated with 
cataract-microcornea syndrome, and various other forms of cataracts. CYP 1 Bl is a 
member of the cytochrome P450 superfamily, and mutations in thi s gene have been 
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attributed to primary congenital glaucoma, and Peters anomaly.29: 98: 13° Finally, FOXE3 
is a lens-specific transcription factor which has been implicated in cases of ASD 
including autosomal dominant Peters anomaly,90 congenital cataracts,91 and autosomal 
recessive primary congenital primary aphakia. 114 
2. 3. 3 DNA Isolation and Primer design 
Genomic DNA was isolated from peripheral leukocytes by DG 141 and screened 
for mutations in the proband and five relatives with ocular phenotypes representing the 
full range of phenotypes found in this family (Figure 2.1 : (£edigree Identifier (PID) II-5; 
ll-14; III-2; III-6; IV-1 ), and two unaffected individuals (PIDs: II-1 0; II-15). 
Oligonucleotide primers were designed using the Primer 3 software 
(http://frodo.wi.mit.edu/) to amplify all coding regions, and UTRs of the following genes: 
PAX6 (NM_001604), PITX2 (NM_ 153426), PITX3 (NM_005029), CYPJBJ 
(NM_OOOJ04), FOXCJ (NM_001453), B3GALTL (NM_l 943 18), CRYAA (NM_000394), 
GJA8 (NM_005267), and FOXE3 (NM_012186). 
2.3.4 PCR Setup 
Polymerase chain reaction (PCR) was set up to amplify targets from genomic 
DNA (gDNA) using the KapaTaq PCR system. DNA samples were diluted to 10 ng/uL 
and 1 uL was added to a 19 uL of KapaTaq master mix (Appendix A). Betaine 
(1.75mM), a PCR enhancer which acts by disrupting hydrogen bonds to reduce secondary 
structure in DNA, and assist in denaturation was added to each master mix at 25% per 
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volume. Dimethylsulfoxide (DMSO) was used in instances where a sequence was 
particularly difficult to amplify due to CG rich composition at 5% per volume (i.e. 
FOXCJ and FOXE3 are CG rich genes which can be difficult to amplify). DMSO acts to 
disrupt the three hydrogen bonds between C-G bases, like that of Betaine and was used in 
combination with Betaine if the initial PCR reaction did not work. All plates were run on 
a TouchDown 54 (TD) program which begins at 64 degrees Celsius, to provide high 
specificity of primer annealing, and over five cycles drops to 54 degrees Celsius 
(Appendix B). Amplicons were run on a 1% agarose gel stained with SYBR Safe, which 
binds to DNA and fluoresces under UV light, (Invitrogen by Life Technologies) for size 
verification. Primer sequences for each gene can be found in Appendix F. Amplicons 
were purified using 50% S300HR sephacryl (Amersham Biosciences) and Multiscreen 
HTS filter plates (Millipore Corporation). Filter plates were prepared by addition of 300 
uL of Sephacryl, suspended in Tris-EDTA (TE) buffer, to the plates, these filter plates 
were then placed on a ' catch plate' and were spun at 3000 rotations per minute (rpm) for 
5 minutes. The contents of the catch plate were discarded, and the fi lter plate was placed 
on a 96 well PCR plate. DNA samples were added to each well of the filter plate, and 
spun for 5 minutes at 3000rpm. 
2. 3. 5 Bidirectional Sequencing 
Purified DNA (I uL) was added to 19 uL ofBigDye Terminator Kit v 3.1 
(Applied Biosystems) master mix (setup can be found in Appendix C) in a 96 well 
LightCycler sequencing plate. The plates were placed on a GeneAmp thermocycler and 
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run on the program ABI.SEQ (cycling conditions can be found in Appendix D). Once 
cycling was complete, precipitation was carried out as an extra purification step to 
remove excess salts and proteins. Sixty-five uL of95% ethanol, and 5 uL of 125 mM 
EDT A was added to each well of the LightCycler sequencing plates, which were then 
placed at -20 degrees Celsius for at least 30 minutes. The plate was then spun at 
3000rpm for 30 mins. The ethanol/EDT A solution was then decanted from the plate, and 
was spun upside down on a paper towel up to 200rpm to remove excess solution. A wash 
step was then performed using 150uL of70% ethanol. The plate was spun at 3000rpm for 
15 minutes and the ethanol decanted and removed from the plate. The plate was allowed 
to dry, then 15 uL ofHiDi Formamide was added to each well, and then placed on a 
GeneAmp thermocycler at 95 degrees Celsius for 2 minutes, then placed on ice. The 
plates were run on an ABI 3130xl DNA Analyzer. Electropherograms were inspected 
manually for quality and imported into Mutation Surveyor software v 3.2 (Transition 
Technologies) to detect sequence variants. All sequencing variants were checked for co-
segregation with the ASD phenotype in the family. Only one allele (FOXE3 c. 959G>T) 
co-segregated with the disease phenotype, so the population frequency of this variant was 
determined using population controls from Newfoundland.142 
2. 3. 6 RNA Isolation/eDNA synthesis 
One mL ofTrizol reagent was added to l.Ox106 Epstein Barr virus (EBV)-
transformed B lymphocytes from one affected individual (PID IV -1 ), in a 2.0 mL 
Eppendorftube. The solution was pipetted up and down to mix the solution, and was 
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allowed to incubate at room temperature for 5 minutes. Two-hundred uL of chloroform 
was added to the tube and the tube was shaken vigorously for 15 seconds then incubated 
at room temperature for three minutes. The tubes were centrifuged at 12,000x g for 10 
minutes at 4 degrees Celsius, and when removed were separated into an aqueous (top), 
interphase (middle), and organic layers (bottom). The aqueous phase was transferred to a 
1.5 mL Eppendorf tube and the other phases discarded. Five-hundred uLs of isopropanol 
were added to the the aqueous phase to precipitate the RNA from solution. The tube was 
incubated at room temperature for 10 minutes and was then centrifuged at 12,000 x g at 
four degrees Celsius for 10 minutes. A waxy pellet was observed on the bottom of the 
tube post-centrifugation, and the isopropanol solution was decanted from the tube and the 
pellet allowed to dry at room temperature. The pellet was resuspended in 25 uL of 
deionized water and was fo llowed by addition of 2 uL of DNasel (Ambion) followed by 
incubation at 37 degrees Celsius for 30 minutes to remove any gDNA contamination. 
Complementary DNA (eDNA) synthesis was performed using the Superscript III eDNA 
synthesis kit (Invitrogen by Life Technologies). Up to 5 ug of RNA (depending on the 
yield of the RNA extraction) was added to 8 uL of a mastermix cocktail prepared as per 
Appendix G using oligo dT primers. PCR was carried out using primers surrounding the 
stop codon of FOX£3 (FOXE3-cDNA-F and -R) and was analyzed by size fractionation 
using agarose gel electrophoresis and direct sequencing. A set of primers designed to 
amplify the intron between exons 5 and 6 of GAPDH (a widely expressed gene 
responsible for function of energy production via glycolysis) were used as an internal 
control to check for the presence of genomic DNA contamination. These primers amplify 
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a 170 bp fragment with a eDNA template, and a 278 bp fragment using a genomic 
template. Primers and experimental conditions are listed in Appendix F. 
2.4 Results 
2. 4.1 Long-term Clinical Follow-up 
The proband (PID III-6) is a 33-year old male born at 35 weeks gestation (Figure 
2.1 ). Bilateral dense corneal opacities were noted at birth and were initially attributed to 
maternal prenatal infection. Examination under anesthetic showed corneal opacification 
of the probaond ' s right eye from the temporal side past the midline and hazy cornea 
nasally (Table 2. 1; Figure 2.2A). Fine adhesions from the collarette of the iris to the 
cornea obscured the angle. The proband ' s left cornea was more densely opaque with a 
large central adhesion from the cornea to the lens and peripheral adhesions from the iris 
to the cornea (Figure 2.2B). Both globes were of normal size but corneal measurements 
were 1 Omm horizontally and 9mm vertically (N > or = 11 mm). At six months of age the 
proband had a corneal transplant of the more severely affected eye (left) and optical 
iridectomy of the right eye. Pathology review of the left corneal button indicated absent 
Descemet' s membrane, partial absence of Bowman 's membrane and thinning of the 
central cornea consistent with Peters anomaly. The corneal graft was rejected 6 weeks 
post-operatively and the eye became phthisical following subsequent attempts at re-
grafting. 
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A) 
q 
B) 
D) 
Figure 2.2: Eye phenotype of the proband (PID III-6) over time. A) Picture of the proband's 
right eye at 7 weeks showing corneal opacities consistent with Peters anomaly. B) Surgical 
drawing of the proband 's eye showing keratolenticular adhesion, and corneal leukoma (Pictures 
A and Bused with permission). C) Proband' s right eye at 30 years of age. D) Proband 's 
phthisical left eye at 30 years of age. 
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The proband was re-examined at 30 years of age by a clinical geneticist (BF; 
Figures 2.2C & 2.20 ) and found to be of normal intelligence. His height was 172 em 
(25%ile); ratio of upper to lower segment 0.98; arm span 170 em; weight 107kg 
(>95%ile); and head circumference was 62 em (this information was not available for 
other relatives). There was no facial dysmorphism apart from features related to a 
phthisical left eye due to post-operative complications: the left eyebrow was lower and 
the left palpebral fissure was shorter than that of the right eye. His palate was intact with 
a single uvula, and the philtrum was well-developed (philtrum length 2 em, 50-75%ile). 
Ears were large (length of 7.3 em), but were normal in position and contour. The only 
other minor physical anomaly was clinodactyly of the right 2nd and 3rct fingers and of the 
left 2nd finger. The lack of extra-ocular phenotypes seen in this patient allowed us to rule 
out Krause-Kivlin syndrome or other related syndromes as a possible diagnosis for this 
individual. 
The proband' s father (PID II-1 4) was examined at 27 years of age (the year the 
proband was born) and shown to have small posterior subcapsular and central nuclear 
cataracts, fi rst noted at age seven (Table 2.1 ). His visual acuity was 617S 3 in the right 
eye and 6/9 in the left eye. He had bilateral microcornea (corneal diameter of I 0 mm) 
and scleralization and vascularization ofthe cornea, particularly superiorly. Upon 
gonioscopy, fine iris processes were noted extending over the trabecular meshwork. 
Subsequently, he had cataract extractions at ages 39 and 40 because of decreasing visual 
acuity. 
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Three paternal aunts (PIDs II-5 ; II-7; Il-16) who had lens opacities documented in 
childhood had cataract extractions prior to 1979 (in their twenties or thirties) when 
mature cataracts developed. All three individuals presented with microcornea (corneal 
diameters of 8.5 mm - 10.5 mm), mild to moderate scleralization of the cornea with 
varying degrees of vascularization, particularly superiorly and inferiorly (Table 1 ). Three 
paternal cousins (PIDs III-2; III-3; III-7) had cataract extractions at ages 16-40 years. 
The cataracts were originally described as anterior polar, anterior cortical, and nuclear 
and posterior subcapsular cataracts. Six of these seven affected family members had 
favorable results post-operatively although one had vitreous hemorrhage, choroidal 
detachment and temporary hypotony of one eye. Individual PID Il-7 had serious post-
operative complications including retinal detachments with failed repair, failed corneal 
grafting and enucleation of a painful blind eye with hand movement vision only in the 
remaining eye (Table 2.1 ). 
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The youngest affected family members are PID IV -1 (6 years old) and PID IV -2 (1 0 
years old) (Figure 2.1 ). Individual PID IV -2 had anterior polar cataracts detected at birth but has 
not yet required cataract extraction. Individual PID IV -1 had a complicated pre and postnatal 
course with extreme premature birth at 24 weeks gestation. He was hospitalized for 4 Y2 months 
during which time he had necrotizing enterocolitis with perforation of the bowel, and successful 
treatment of retinopathy of prematurity. Because of the size and central location of his anterior 
polar cataracts, he had cataract extractions at 8 months of age (Table 2.1 ). He also had bilateral 
iridectomies due to central corneal opacities. His central acuity is recorded as 6/18 but his 
course continues to be complicated with a recent diagnosis of autism. 
A paternal uncle who died of pneumonia at 6 months of age in the 1940s was likely 
affected, as he had 'white eyes' and was registered blind with the Canadian National Institute for 
the Blind (PID II -9). Eight other paternal aunts and uncles and 15 paternal cousins had normal 
corneal diameters, and clear corneas and lenses upon examination (although some at older ages 
had a prominent arcus suggesting elevated cholesterol levels). 
Interestingly, there is no evidence that either of the grandparents had any form of ASD 
(DNA not avai lable). For instance, the proband's paternal grandfather (PID I-1 ) was examined 
and had corneal diameters of 11 mm, mild corneal scleralization, inferior arcus, and faint lens 
opacities including anterior polar specks, and anterior and posterior cortical spokes but retained 
6/7.5 and 6/6 visual acuity at 77 years of age. Two of his brothers had clear corneas and lenses 
in their 60s or 70s. The proband ' s paternal grandmother (PID I-2) had corneal diameter of 11.5 
mm, mild central endothelial corneal changes (Fuch's dystrophy), arcus senilis, and faint dot and 
spoke lens opacities when examined at 71 years. She subsequently had mature cataracts 
extracted at ages 78 and 81. Upon examination, her brother, sister, niece, and nephew all had 
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clear corneas and lenses, and were considered unaffected. The phenotypes seen in the 
grandparents can a ll be attributed to the aging process. It is possible that one had a subclinical 
phenotype or that gonadal mosaicism was present. 
2.4.2 Candidate Gene Screen Reveals Causative Variant in FOXE3 
Screening of the nine functional candidate genes in seven individuals (five affected; two 
unaffected PIDS: III-6, 11-14; II-5 ; III-2; IV-I ; II-10; II-15) revealed 44 sequence variants (Table 
2.2). When possible, variants were arranged into manually constructed haplotypes to check for 
segregation of a disease haplotype (Figures 2.3-2.1 0). Single variants were also checked for 
segregation. This analysis showed co-segregation (Figure 2.1 0; Yell ow Haplotype) between the 
ASD trait and a non-stop mutation within the transcription factor gene FOXE3 (c.959 G>T: 
p.X320L; Figure 3B) which caused the elimination of the functional opal stop codon (UGA) at 
the 3' end of FOXE3. The next avai lable stop codon is 213 bps downstream (in the 3' UTR) 
predicting the addition of 72 amino acid residues to the C-terminus of FOXE3. 
We then genotyped all avai lable members ofthe extended fami ly and found that the 
variant co-segregated with the disease phenotype (Table 2.2). This variant was not detected in 
141 ethnically-matched controls. To test whether this mutation would be present in the mRNA 
of FOXE3, RNA was isolated from a lymphoblast cell line of individual PID IV-1 and converted 
to eDNA. FOXE3 is a lens-specific gene, found only in the lens epithelium,90 as a result this 
approach was not guaranteed to succeed. However, we were able to amplify a 458 bp eDNA 
product from FOXE3 surrounding the c.959 G> T mutation (Figure 2.1 2A). Direct sequencing 
revealed that the c.959 G>T mutation was absent in the eDNA (Figure 2.12B), suggesting that 
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the mRNA transcribed from the 'non-stop' allele may be degraded before being translated, or it 
is possible that the RNA is not transcribed at all. 
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Table 2.2: Summary of seq uencing variants identified in nine functional candidate genes sequenced in 
five affected members with a range of ASD from mild phenotype to Peters anomaly, and 2 unaffected 
members. The novel pathogenic variant discovered in FOXE3 (c.959 G>T: p.X320L) is shown in bold. 
Gene Sequence Variants Location of Variant Protein Effect dbSNP ID Segregation 
PAX6 (llp13) c. -4393 G<A 5' UTR None Not listed No 
c. 1074 + 107 C<T lntronic None rs3026384 No 
c.1075 -174 G<A lntronic None rs2071754 No 
c.1225 + 44 T<G lntronic None rs3026393 No 
c.1746 + 21 deiA lntronic None Not listed No 
P/TXl (4q25) c.-485 C<G 5' UTR None rs2739200 No 
c.629- 105 C>A lntronic None Not listed No 
c.767- 81 A>C lntronic None Not listed No 
P/TX3 (10q24.32) c.285 C<T Coding 1951 rs2281983 No 
FOXC1 (6p25.3) c.l123_1124 ins CGG Coding ins 375 G rs71807729 No 
c.l361 ins CGG Coding ins 456 G Not listed No 
CYPlBl (2p22.2) c.-12 C<T 5' UTR None rs2617266 No 
c.142 C<G Coding R48G rs10012 No 
c.355 G<T Coding A119S rs1056827 No 
c.1294 G<C Coding V432L rs1056836 No 
c.l347 T<C Coding 04490 rs1056837 No 
c.1358 A<G Coding N453S rs1800440 No 
c.1633 + 210ins T 3' UTR None Not listed No 
c.1633 + 350 C>A 3' UTR None Not listed No 
c.1633 + 693 G> T 3' UTR None Not listed No 
c.1633 + 809 del A 3' UTR None Not listed No 
c.1633 + 875 A>G 3' UTR None Not listed No 
c.1633 + 2408 A<T 3' UTR None Not listed No 
B3GALTL (13q12.3) c.71 -5 del T lntronic None Not listed No 
c.271 - 58 de IT lntron ic None Not listed No 
c.271 - 67 T>C lntronic None Not listed No 
c.347 + 20 C<G lntronic None Not listed No 
c.348 T <C Coding H116H Not listed No 
c.596 + 20 dele lntronic None Not listed No 
c.597 - 168 deiA lntronic None Not listed No 
c.780 +58 A<G lntronic None Not listed No 
c.781 -124 G<C lntronic None Not listed No 
c.781 -31 ins CATA lntronic None Not listed No 
c.1065 - 142 T <C lntronic None rs1041073 No 
c. 1108 G<A Coding E370K Not listed No 
c. 1497 + 31 G>T 3' UTR None Not listed No 
c.1497 + 37 A>G 3' UTR None Not listed No 
c.1497 + 127 G>A 3' UTR None Not listed No 
c.1497 + 938 de IT 3' UTR None Not listed No 
c. 1497 + 1548 C> T 3' UTR None Not listed No 
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CRYAA (21q22.3) c.6 C<T Coding 020 Not listed No 
GJAB (lq21.1) c.1365 + 26 de lA lntronic None Not listed No 
FOXE3 (lp33) c.959 G>T Coding X320l Not listed Yes 
c.960 + 72 T>C 3'UTR None rs2820969 No 
c.960 + 77 A>G 3'UTR None rs6666370 No 
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c .347 + 20 C>G (C) (G) 
c .596 + 20 deiC (del) (C) (C) (del) 
c 597-168 deiA (A) (del) (del) (A) 
c.780 + 58 A>G (A) (G) (G) (A) 
c 731 - ·124 G>C GC cc 
c .781- 31 insCATA (-)(ins) (ins)(-) 
c .850 + 81 G>A (A) (G) (G) (A) 
c 1108 G>A:p.E370K (A) (G) (GJ (1'.) 
c .1497 + 31 G>T (T) (G) (G) ( T) 
c .1497 + 37 A>G (G) (A) (A) (G) 
c .1497 + 1548 C> T (T) (C) (C) (C) 
4 5 10 1 15 
II 
c.347 + 20 C>G (G) cc GG GC GC 
c .596 + 20 deiC (del) cc del del del C d~l c 
c .S97 - 168 dei.A. (A) del del AA A del A d~l 
c .780 + 58 A>G (.11,) GG A A AG AG 
c 781 - 124 G>C (C) c c GC GC GC 
c 781- 31 lnSC.A.TA (-) Ins rn~ 
- tns - tns 
c 850 + 61 G>A (A) GO AA AG AG 
c .11 03 G>A p E370k (.II,) GO AA A G AG 
c 1497 + 31 O>T (T) GG T T T 0 T 0 
c 1497 + 37 A>O (.A.) AA GG GA OG 
c 1497 + 1548 C>T (C) cc TC T C c c 
1 2 6 ... 
Ill 
CG 
c.347 + 20 C>G (C) GC C del 
c 596 + 20 del( (C) del C del A 
c 597- '168 deiA (A) A del GA 
c.780 + 58 A>G (A) .A. G CG c.?B·I - 124 G>C (C) c c 
rns -
c 78 1 - 31 tnsCATA (-) - rns G /l. 
c 850 + 81 G>.ll. (A) .A. G GA 
c 1108 G>Ap EJ701< (A) AO G T 
c .1497 + 31 G>T (T) T G AG 
c 1497 + 37 A>O (A) A .a. T C 
c 1497 + 1548 C> T (C) cc 
1 
IV 
c 347 + 20 C>G GC 
c 596 + 20 deiC del C 
c 597- 168 delA. AA 
c 780 +58 A>O .A. A 
c 781 -124 G>C cc 
c 781- 31 tnsCATA 
c .SSO + 8'1 O>A .A. A 
c '11 OS G>A.p E3701< 
·"-A 
c .1497 + 31 G> T T T 
c .1497 + 37 A>G AA 
c.1497 + '1548 C>T c c 
Figure 2.3 - Haplotype analysis of B3GALTL variants in family 0023. The proband is indicated 
by an arrow to the top left. Full shaded individuals have Peters anomaly whereas half-shaded 
individuals have other ASD phenotypes. Haplotypes were manually constructed using variants 
discovered through direct sequencing. Exclusion of B3GALTL as the causative gene in family 
0023 can be observed through the lack of a common haplotype between all five affected 
individuals. The yellow haplotype is shared by three affected individuals (II-5, II-14, and III-6) 
but is not passed onto III-2 or IV -2, thus excluding B3GALTL as the causative gene in family 
0023. 
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4 
II 
c 1633 + 2408 A<T (A) 
c .1633 + 875 A>G (A) 
c 1633 + 350 C>A (A) 
c .1633 +21 0insT (-) 
c :1358 A>G (A) 
c 1347 T>C (C) 
c 1294 G>C (C) 
c 355 G>T (G) 
c 142 C>G (C) 
c -13 C>T (C) 
1 
Ill 
c 1633 + 2408 A<T (T) 
c.1633 + 875 A>G (G) 
c 1633 + 350 C>A (A) 
c .1 633 +21 0 insT (Ins) 
c .1358 A>G (A) 
c .1347 T>C (C) 
C.'1294 G>C (C) 
c 355 G>T (T) 
c.I 42C>G (G) 
c -13 C>T (T) 
1 
IV 
c 1633 + 2408 A<T AT 
c 1633 + 875 A>G AG 
c '1633 + 350 C>A AA 
C 1633 +210 1nsT . ins 
c 1356 A>G AA 
c 1347 T>C cc 
c 1294 G>C cc 
c 355 G>T G T 
c 142 C>G co 
c-13C>T C T 
2 
AT 
.B. A 
A C 
AA 
C T 
CG 
GG 
cc 
cc 
c .1633 + 2408 A<T 
c .1633 + 875 A>G 
c 1633 + 350 C>A 
c1633 +210 insT 
c 1358 A>G 
c .1347 T>C 
c .1294 G>C 
5 
c .355 G>T 
c 142 C>G 
c .-1 3 C>T 
T T 
A ,!!., 
cc 
A A 
T T 
GG 
GG 
cc 
c c 
10 
AA 
GG 
f!.. A 
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cc 
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co 
C T 
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T C 
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CG 
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CA 
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GG 
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CG 
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Figure 2.4 - Haplotype analysis of CYP I BI in family 0023. CYP I BI can be excluded as the 
causative gene in family 0023 as the red haplotype which is shared amongst four of the affected 
individuals is not passed onto IV -1. 
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4 5 10 1 15 
II 
'""' . <H•G I'"' IH~ I~ ! ~ IH~ ~~~ ~ c 1075 - 174 G>A (A) c.1074+ '107 C>T (C) c -4393 G>A (G) 0 1'-. 
1 2 6 .... 
Ill 
""' . '""' ~ "' 1m ~H~ c 1075- 174 G>A (A) c .1074 + 107 C>T (T) c -4393 G>A (G) 
1 
IV 
c 1225 +44T>G 10 T ~ 
c 1 075 - 17 4 G>A A A 
c:I074 + 107 C>T C T 
c.-4393 G>A 0 0 
Figure 2.5 - Haplotype analysis of PAX6 in family 0023 . PAX6 can be excluded in this family as 
no affected individuals share common haplotypes. The yellow haplotype exists in three affected 
individuals, but is also present in unaffected individual II -10. The red haplotype only exists in 
two affected individuals (III-2 and II-5) but in no others. 
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c -59 G>T 
4 5 10 1 15 
II 
c -59 G>T (G) I 
1 2 6 
Ill 
c 6 C>T 
1 
IV 
c.-59 G>T 
Figure 2.6 - Segregation analysis of the c.-59 G>T found in GJA8 within family 0023. This 
variant is excluded as the mutant T allele only appears in individuals II -1 4 and III -6, but is also 
carried by the probands unaffected mother II-15. 
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II 
Ill 
c .6:'9-1 OS OA 
c-48SC~ 
1 
c 629-10S C.A 
c C><l 
4 
cc) O 
(G) 
1 
'")I (C) 
5 
1 
10 14 15 
Figure 2.7 - Haplotype analysis of PITX2 variants in family 0023. Exclusion of PITX2 can be 
seen as none of the affected members appear to share a common coloured haplotype. 
Page 84 of 257 
1 
c.26S ~T 
4 5 10 14 
I ce D 
1 2 6 
Ill 
IV 
Figure 2.8 -Segregation analysis of c.285 C>T in PITX3 found in family 0023 . This variant 
shows no segregation with the disease phenotype and was thus excluded P ITX3 as the causative 
gene in this family. 
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1 
c 1361n.COO 
4 5 10 14 15 
II 
c 136tt\I'COO •··· 
1 2 6 
Ill 
• · ·I 
1 
IV 
c , 3161 w.s<:00 ,. .,. I 
Figure 2.9 - Segregation analysis of an insertion in FOXCJ, c.l361 insCGG. This analysis 
excludes FOXCJ as the causative gene as three affected individuals do not have this mutation, 
while the unaffected mother of the proband does. 
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e C>t 
4 5 10 14 15 
e IIC•T l r rO TT l 
1 2 6 
t C•T 
1 
c6C•T <: I 
Figure 2.10 - Segregation analysis of the c.6C>T variant found in CRYAA within members of 
family 0023. As this variant only exists in three of the five affected individuals, and is a 
homozygote in the proband' s unaffected mother and the proband, CRYAA can be excluded as the 
causative gene in this family. 
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II 
Ill 
c9S90>T 
c 960+72 T>C 
1 
c 959 O>T 
4 
c 960•72 T>C 
(0)0 
(C) 
IV 
c 959 G> T 
c 960+72 T>C 
1 
c.959 O>T 
c .960+72 T>C 
5 10 14 15 
Figure 2.11 - Haplotype analysis of FOXE3 variants in family 0023 . A disease associated 
haplotype (yellow) can be seen segregating in an autosomal dominant manner with the affected 
individuals of Family 0023 . This data provides evidence that FOXE3 is causing the variable 
ASD phenotype seen in this family. 
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A) eDNA gDNA B) 
....... 3Q5- . -
.. T, __ G . 
_T, ..... L .A. c. c, 
- - ~- - - - -- -·- - - -- - -~ - --- - - ~ - - - '·· gDNA 
c. 959 G>T 
FOXE3 
255 
l G • J G • A G c c 
GAPDH 
170 bp 278 bp 
Figure 2.12: A) Agarose gel (I%) stained with SYBR Safe showing PCR amplification of FOXE3 from 
eDNA from a lymphoblastoid cell line ofPID IV-I (in quadruplicate). The internal control ofGAPDH 
amplifying a 170 bp fragment to check for presence of eDNA (and absence of gDNA) is shown below. A 
genomic control is shown to the right, and the 278bp fragment amplified from GAPDH exclusively in 
gDNA. B) (Top) Electropherogram ofthe novel, nonstop mutation in FOXE3 (c.959 G>T: p.X320L) 
identified in all affected family members. (Bottom) Electropherogram ofthe region surrounding the stop 
codon of FOXE3 from the eDNA of an affected patient (PID IV-1) isolated from a lymphoblast cell line. 
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2.5 Discussion 
Peters anomaly is a rare congenital disorder often regarded as a sporadic condition with a 
low risk of recurrence and attributed to aneuploidy or fetal alcohol syndrome. Inherited cases 
associated with malformations of the anterior chamber of the eye have also been described. In 
1986, we first reported a family with an autosomal dominant form of anterior segment 
dysgenesis with the proband exhibiting Peters anomaly .136 This four generation family from 
Newfoundland has had extensive clinical assessment over the course of 30 years, revealing a 
progression of the ASD phenotype in affected family members. For example, the father of the 
proband (PID II -14) had mild cataracts at the age of 7 and required cataract extractions at the 
ages of 39 and 40 due to decreasing visual acuity. Other affected family members (PIDs III-3 ; 
III-7; II-16) have also shown a non-static phenotype with mild cataracts noted at young ages 
progressing to mature cataracts causing decreased visual acuity in their 20s-40s, making 
extractions necessary. 
The anterior chamber is formed by three successive waves of embryonic cells derived 
from the neural crest. Aberration in the migration of these cells can cause anterior chamber 
defects such as microcornea, corneal opacities, or congenital cataracts. 143 Using a functional 
candidate gene approach, we looked for mutations in genes previously associated with ASD or 
Peters anomaly in this family and identified a novel non-stop mutation in FOX£3 (c.959 G>T: 
p.X320L; Figure 2.1 2B) which segregated with the variable ocular phenotype, and was absent 
from 282 ethnically matched chromosomes. Though rare, non-stop mutations are reported in a 
number of cases involving various diseases such as non-classic 3-beta-HSD congenital adrenal 
I I . 144 d . h h . d . f I . F X 145 1yperp asta, an excesstve emorr agmg ue to mutatwn o coagu at10n actor . 
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The normal interaction of mouse Foxe3 with genes responsible for cellular differentiation 
and proliferation provides an explanation for the presence of small lenses and other eye 
malformations seen in humans. In mice, Foxe3 encodes a DNA-binding transcription factor 
expressed during the formation of the lens placode and assists in the formation of the lens 
itself. 11 3 Mutations in Foxe3 reduce the ability of the transcription factor to bind DNA, causing 
formation of a small lens.90 Sometimes the anterior lens epithelium does not separate from the 
cornea, resulting in keratolenticular adhesions,90 which we observed in the proband with Peters 
anomaly. One explanation is that this adhesion is caused by a dysregulation of genes responsible 
for apoptosis within the corneal stalk which is thought to degrade during lens morphogenesis as a 
result of apoptosis.146 An alternative explanation is that mutation of Foxe3 may cause a 
dysregulation of cadherin proteins such as E-cadherin, which are present in the corneal stalk. 146 
Foxe3 also controls the expression of Cryaa. within the developing lens, and dysfunction of 
Cryaa. expression reduces the solubility of the crystallin protein complex causing crystallization 
and potential cataract formation. Foxe3 is responsible for the down-regulation of Proxl which 
controls a gene responsible for blocking cell-cycle progression (Cyclin dependant kinase 
inhibitor; Cdknlc). As Foxe3 expression becomes dysregulated, Prox l expression increases, 
subsequently increasing Cdknl c expression causing a reduction of cellular prol iferation in the 
anterior lens. 11 3; 147 Foxe3 also controls expression of Platelet derived growth factor receptor 
alpha (Pdgfra.) which is responsible for lens fiber differentiation within the anterior lens 
epithelium.113 Post-natally, FOXE3 is expressed exclusively in the anterior lens epithelium which 
is the only site of cell-proliferation within the lens. This restricted cellular expression is 
. . h h I h b d . FO' V£3 . . 11 3. 146 cons1stent w1t t e eye on y p enotype o serve m :.-·L mutatiOn earners. · 
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Mutations in FOXE3 and its involvement in human ASD and/or Peters anomaly were 
first identified by Semina eta!. who described two patients with apparent autosomal dominant 
posterior embryotoxon and congenital cataracts caused by a heterozygous single nucleotide 
insertion which altered the five terminal amino acids and added an additional Ill amino acids to 
the FOXE3 protein.91 A second report of FOXE3 and its involvement in ASD and/or Peters 
anomaly was published by Ormestad et al. , who identified a heterozygous missense mutation 
(p.R90L) coding for the Forkhead DNA-binding domain of the FOXE3 protein of a single 
affected individual with familial Peters anomaly, though no other DNA samples from the family 
were available to confirm segregation.90 Recently, lseri eta!. described four other families 
containing FOXE3 mutations , c.21 _24del: p.M7llfsX216, c.146G>C: p.G49A, c.244A>G: 
p.M82V, c.958T>C: p.X320ArgextX72, all of which are hypothesized to be pathogenic. 148 
Homozygous mutations within Foxe3/FOXE3 can also cause autosomal recessive congenital 
aphakia within mice (dyl mice) 11 3 and humans respectively. 11 4 Also, mice containing 
heterozygous mutations within Foxe3 showed histological ocular malformations upon 
investigation,90 further showing the abi lity of FOXE3 to cause dominant and recessive ocular 
conditions. It is interesting to note that mutations ofFOXE3 seem to cause a spectrum of 
malformations, all falling under the umbrella of ASD, which range from mild (microcornea, 
and/or congenital cataracts) to very severe (Peters anomaly). That a single mutation can give rise 
to a phenotype of variable severity is unsurprising and has been documented in a number of 
conditions, especially those of autosomal dominant inheritance. It is suspected that mutations in 
FOXE3 cause this variable phenotype either due to stochastic effects during cell migration in 
development, or potentially via modifier effects. It remains possible that different individuals 
carry protective or damaging variants in genes which interact with FOXE3 which may 
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exacerbate or ameliorate the expression of the disease, giving rise to the variable phenotype 
observed in family 0023. 
Two recent reports (Iseri et al. (2009) 148 and Bremond-Gignac eta!. (20 1 0) 149) identify 
similar non-stop mutations within FOXE3 (c.958T>C: p.X320ArgextX72 and c.959G>C: 
p.X320SerextX72 respectively) in patients with ocular diseases. lseri eta!. reported a family 
with autosomal dominant ASD 148 where the proband was diagnosed with unilateral Peters 
anomaly and in four family members segregating congenital cataracts, microphthalmia, and iris 
coloboma. Bremond-Gignac et al. reported a single patient with congenital cataract and no 
family history of ocular disease. 149 Both of these studies predict a similar 72 amino acid 
extension ofthe FOXE3 protein, though no functional analyses were performed to confirm this. 
It is possible that an extended C-terminus of the FOXE3 protein may interfere with post-
translational modifications, as the C-terminus is a common site for these types of alterations. 
This has been illustrated in another gene ofthe FOX family, called FOXA2, which has been 
shown to have a transcriptional activation domain in its C-terminal. 150 In order to completely 
elucidate the disease mechanism underlying ASD, functional studies must be done to confirm 
that an extended protein is produced, as our results suggest that these non-stop RNA species may 
be degraded. The mutation identified in the Newfoundland family (c.959 G>T) occurs in the stop 
codon of FOXE3 and according to our preliminary data from eDNA (lymphoblastoid cell line) of 
individual PID IV-1 , the mRNA transcript containing the non-stop allele is degraded (or not 
transcribed) suggesting haploinsufficiency of FOXE3 (Figure 2. 12), though the possibility of an 
extended protein cannot be ruled out without protein expression data. An alternative 
interpretation of the data is that the RNA containing the c.959 T allele may be more unstable 
than that of the wildtype, making it under-represented in total RNA. This could also explain why 
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the mutation was not detected by direct sequencing of eDNA, thus quantitative and translation 
based studies are required to confirm the absence of both the mutant RNA and the extended 
protein. It would be ideal to undertake quantitative and protein expression studies in a lens 
epithelial cell line, or a cell line more closely related to ocular structures, as the expression 
pattern of FOXE3 in these cells may differ highly from that within a lymphoblastoid cell line. 
Semina et al. (2001) also described an insertion which caused the addition of 111 amino 
acids to the FOXE3 protein.9 1 It is possible that this mutation described by Semina eta!., as well 
as the non-stop mutations described by Iseri et al. , and Bremond-Gignac eta!. would also 
undergo the same type ofmRNA degradation that we observe. Quantitative studies of the 
FOXE3 c.959 G>T mutation within human cells would be necessary to validate our hypothesis 
of RNA degradation. 
In summary, our results implicate FOXE3 in the pathology of ASD and corroborate other 
recent reports of ASD cases with FOXE3 mutations. Therefore, mutations within FOXE3 may 
explain currently unsolved ASD cases so FOXE3 should be screened. Cataract extraction in 
individuals with FOXE3 mutations is more likely to result in post-operative complications so 
identifying mutations carriers can affect clinical management. Discovery of genes and mutations 
causing ASD in famil ies is of particular clinical relevance. A molecular diagnosis of ASD cases 
through mutation screening can provide accurate risks of recurrence, especially in light of mild 
or subclinical phenotypes which may show progression over time such as those seen in the 
family in this study. 
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3.1 Summary 
Achromatopsia is a rare (1 /30,000 live births) retinal condition affecting the cone 
photoreceptors and presents with a loss of visual acuity, lack of colour vision, nystagmus, and 
photophobia. We obtained DNA from eight families (0094, 1442, 1491 , 1492, 1713, 1723, 1726, 
and 1734) from Newfoundland, Canada and screened available members for mutations within 
the four achromatopsia genes CNGA3, CNGB3, GNAT2, and PDE6C. This approach solved the 
genetic etiology of six of the eight families and yielded a total of 27 variants, five of which were 
pathogenic: two in CNGB3 (c.1148delC and c.886_896del11insT) and three within CNGA3 
(c.848 G>A: p.R283Q, c.1279 T>C: p.R427C, and c.1580 T>G: p.L527R). Two mutations, 
CNGB3 c.1148delC, and CNGA3 c.1580 T>G occurred in more than one family. Haplotype 
analysis of these eight families showed a common haplotype surrounding CNGB3 c.1148delC 
and CNGA3 c.1580 T>G across multiple families, suggesting that these mutations reside on 
founder haplotypes. One patient from family 1734 had only one mutation in CNGB3 
(c.1148delC) identified. The unsolved family (0094) was subjected to exome sequencing 
revealing seven homozygous variants exclusive to the affected individuals. Interestingly, 
amongst them was a novel mutation (c.1555 C>T: p.R519X) in CNNM4, the only gene known to 
cause Jalili Syndrome, a rare form of cone-rod dystrophy with a dental malformation, 
amelogenesis imperfecta. Review of archived records revealed tooth abnormalities in fami ly 
members with achromatopsia consistent with that of amelogenesis imperfecta; and represents the 
first report of Jalili syndrome in North America. This study highlights the genetic/allelic 
heterogeneity of achromatopsia, even within a founder population and highlights the importance 
of exome sequencing coupled with accurately maintained records as a diagnostic tool. 
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3.1 Introduction 
3.1.1 What is Achromatopsia? 
Achromatopsia, also referred to as rod monochromacy (OMIM #262300; OMIM 
#8216900; OMIM + 139340;0MIM*600827), is a rare autosomal recessive (AR), fully penetrant, 
congenital vision disorder affecting approximately 1 in every 30,000 individuals. 151 This 
condition affects the cone photoreceptors, resulting in a loss of high visual acuity, and colour 
vision from birth. In the past, this condition was thought to be stationary (the severity of the 
condition remaining the same over time), though recent evidence suggests that achromatopsia 
may be a progressive condition through physical changes in the retina/fovea, and the cone 
photoreceptors, as well as eventual rod involvement. Achromatopsia can also be categorized into 
complete (typical) and incomplete (atypical). The incomplete form of this condition, also called 
dyschromatopsia, has symptoms similar to complete achromatopsia, though with less severe 
visual dysfunction.152 Although being known for a number of years, achromatopsia was 
particularly well-defined in a founder of the Pingelap Island, offthe coast ofPapua, New Guinea 
in the Micronesian Atolls. 
The Pingelapese 
The Pingelap island of the Micronesian Atolls small island in the Pacific Ocean was 
home to a small population of about 200 people, until a massive storm known as Typhoon 
Lengkieki decimated the island in 1775, killing all but about 20 individuals (including 9 
males).50 It is believed that this event created a genetic bottleneck in the Pingelap population 
with an increase in prevalence of carriers of achromatopsia in the remaining population creating 
an approximate disease prevalence of about 10% amongst its now 250 individuals (as opposed to 
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the 0.003% in the U.S.A). It is believed that an individual, Nanmwarki Mwahuele, is the ancestor 
through three wives, of all achromatopsia carriers of the Pingelap. 153 This population was used to 
map the ACHM3 locus and to eventually identify CNGBJ. 154- 156 
3.1.2 Clinical Presentation and diagnosis of Achromatopsia 
Patients with achromatopsia have reduced visual acuity, loss of colour vision, congenital 
pendular nystagmus, central scotoma (loss of central vision), and a severe sensitivity to light 
(termed photophobia). 157 This condition can exist as either complete or incomplete 
achromatopsia. Complete achromatopsia is considered to be the more severe form of the disease 
and is associated with total loss of colour vision and severely reduced visual acuity . This loss 
varies from case to case but tends to be greater than 20/200 (considered legally blind). 
Incomplete achromatopsia presents similarly to complete achromatopsia but is less severe, with 
partial remaining colour vision, and better overall visual acuity (not usually greater than 20/80). 
Both types of achromatopsia are caused by malfunction of the three types of cone 
photoreceptors: short wave (red), medium wave (green), and long Wave (blue) . 
Achromatopsia can be diagnosed through a number of ophthalmic observations and tests. 
These tests include, but are not limited to, ~lectroretinography (ERG), Qcular ~oherence 
!omography (OCT), colour vision testing (Farnsworth D 15 colour arrangement, Ishihara colour 
test, Hardy-Rand-Ritler colour test), and in some instances physical changes can be seen upon 
funduscopy. 
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(i) Electroretinography (ERG) 
The gold standard for diagnosis of achromatopsia is an ERG which measures the 
response of photoreceptors to various stimuli. Full field ERG measures the entire retinal response 
to a light stimulus but is broken down into two types of responses, scotopic (rod response) where 
dim blue stimulus is used and photopic (cone response) when bright white light or a flicker 
stimulus is used. 158 Typically, during an ERG test, the pupil is dilated and the eyes are dark-
adapted for up to 30 minutes. These conditions are designed to be able to distinguish between the 
rod and cone responses. Rods respond more actively at low light conditions, and also to blue 
light stimuli, while cones respond to bright light stimuli and rapidly flashing stimuli but do not 
respond in the dark. To measure scotopic responses, a dim blue or white light flashes during dark 
adaptation. Photopic responses are measured under light adapted conditions (used to desensitize 
or 'bleach' the rods) using bright white flash stimuli, or a flicker test at 30Hz (regular repeating 
pattern offlashing light). 
In complete achromatopsia the dark adapted flash stimuli show normal amplitudes upon 
testing, which indicate a lack of rod involvement. However, the flicker responses to stimuli and 
light adapted flash stimuli show flat amplitudes, indicating sole involvement of the cones. 
Incomplete achromatopsia shows a normal dark-adapted response, but also shows residual 
photopic responses, which suggests a partial functioning of the cone photoreceptors. These 
patients also present with a higher visual acuity (typically better than 20/80), and less severe 
photophobia/nystagmus than patients presenting with complete achromatopsia. 158 
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(ii) Ocular Coherence Tomography (OCT) 
A second test used to identify achromatopsia in a patient with reduced vision is Optical 
Coherence Tomography (OCT). This test determines the functioning of the outer retina, and the 
retinal pigment epithelium. This is done by measuring the resting potential between the front and 
back of the eye (termed the corneo-fundal potential) which changes depending on the 
illumination of the retina. 159 This technology allows medical professionals to get an idea about 
the 3D structure and thickness of the retinal layers. 
Testing of achromatopsia patients using OCT has shown that the cone photoreceptors 
lose both the inner and outer segments of the cell. This loss of cone cells apparently increases 
with age, suggesting that achromatopsia is not as stationary a disease as was once thought. 160 
(iii) Colour Vision Testing 
A hallmark feature of achromatopsia is the lack or loss of colour vision in affected 
patients. There are three types of colour vision loss, all involving the different cone 
photoreceptors (red, blue, green). Protan, is a defect of the long wave (red) photoreceptors, and 
patients are described as Red-blind, or Red-weak depending on the severity of their loss. Deutan 
loss is the malfunction of the medium wave (green) photoreceptors, and patients are called 
green-blind or green-weak. Tritan, is the malfunction ofthe short wave (blue) photoreceptors, 
and this type of loss causes individuals to be blue-blind, or blue-weak. 
Colour loss in achromatopsia affects all three types of photoreceptor and is thus known as 
"total colour blindness". This lack of colour discrimination can be determined by a number of 
visual tests such as the Farnsworth color arrangement test, or the Ishihara colour test. The 
Farnsworth colour test requires patients to arrange a set of coloured discs based on the shade of 
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the discs. The order that the patient arranges the colours in is then charted, and assessed. Those 
without the ability to see colours often arrange the discs according to darkness instead of shade. 
Physical changes in the retina and fovea are seen in some cases of achromatopsia. Most 
patients have a normal fundus; 161 though some show some subtle changes in the appearance of 
the macula. These changes may present as a negative foveal reflex (no response from the fovea 
when illuminated), macular pigment changes and atrophy,162 or narrowing ofthe retinal 
vessels. 163 Individuals diagnosed with complete achromatopsia show no recordable cone 
response upon electroretinogram (ERG), absent colour vision and poor visual acuity whereas 
individuals with incomplete achromatopsia show residual cone function, better colour vision and 
h. h . I . 162 1g er v1sua acmty. 
3. 1.3 Molecular Genetics of Achromatopsia 
Achromatopsia has previously been shovm to be caused by mutations in one of four 
genes (CNGA3, 164 CNGB3,157 GNA T2, 165 PDE6C166) involved in the functioning of cone 
photoreceptors which are responsible for photopic responses, trichromatic color vision, and high-
resolution visual acuity. 155 More recently, a study of PDE6H has revealed a nonsense mutation in 
three individuals of two families from the Netherlands, and Belgium and identified PDE6H as 
the fifth achromatopsia locus. 167 
(i) CNGA3 (ACHM2; OMIM #216900) 
CNGA 3 (OMIM *600053) creates the alpha subunit of the cyclic nucleotide cGMP-gated 
cation channel (C G) found in the photoreceptor cells (the function of the CNG channel is 
described on page 22 of this thesis). The ACHM2 locus was originally mapped in 1997 using a 
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Jewish Iranian kindred to Chr2p 11.1-q 12.168 Just a year later, in 1998, the gene fo r ACHM2 was 
identified to be CNGA3 169 which was previously found to be involved in retinitis pigmentosa. 170 
CNGA3 pairs with CNGB3 in a two by two fashion (two A3 subunits, two B3 subunits) to form 
a heterotetramer, 171 in which CNGA3 is the major functional subunit. Mutations of CNGA3 
account for approximately 25% of achromatopsia cases worldwide, 161 and over 50 pathogenic 
missense variants have been discovered in this gene. This gene has also been associated with 
cone dystrophy, 161 autosomal recessive retinitis pigmentosa, 170 and Lebers congenital 
amaurosis. 172 
(ii) CNGB3 (ACHM3; OMIM #262300) 
The ACHM3 locus was first mapped in 1999 to a 6.5 eM interval located on Chr8:q21-
q22 by using an Irish population 156 and was confirmed in the previously mentioned Pingelap 
population. 155 This locus was then refined in 2000 to a 1.4 eM region and the causative gene, 
CNGB3, was determined by using the Pingelapese population. 157 CNGB3 (OMIM *605080) was 
also found to be causative in a case of achromatopsia previously thought to be due to a 
Robertsonian Translocation on chromosome 14 and uniparental disomy, 173 a locus previously 
referred to as ACHMJ .174 Currently, mutations of CNGB3 are known to cause approximately 45-
50% of achromatopsia cases, 175 the majority of which are null alleles such as nonsense or 
frameshift mutations. The most common of these mutations is c.1148de!C: p.T383IfsX13 , which 
is considered to be a founder mutation accounting for up to 80% of CNGB3 mutant alleles.173 
The translated protein is the beta subunit of the CNG channel , and pairs with its counterpart 
CNGA3 in a heterotetrameric fashion. 171 
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(ih) GNAT2 (ACHM4; OMIM #613856) 
ACHM4 was mapped to chromosome 1 p 13 in 2002, and the causative gene was found to 
be GNAT2 (OMIM 139340). 165 Mutations in this gene are thought to cause a small proportion of 
achromatopsia cases (- 2%). 173 The protein coded by GNAT2 is Guanine Nucleotide-binding 
protein Alpha-Iransducin .f_, a protein involved in the phototransduction cascade by activating 
phosphodiesterases (PDE) to regulate the amount of Cyclic Guanosine Monophosphate (cGMP) 
in the photoreceptor cell. Upon light stimulation an exchange of Guanosine DiQhosphate (GDP) 
for Guanosine I riQhosphate (GTP) on the transducin molecule occurs. 176 This exchange activates 
GNAT, and allows removal of inhibitory gamma domains from the PDE proteins, activating the 
PDE and lowers the amount of available cGMP in the cell. As cGMP concentrations lower in the 
cell , the CNG closes, causing hyperpolarization of the cell which then creates a neural response. 
(iv) PDE6C (ACHM5 OMIM *600827) 
PDE6C encodes a member of the phosphodiesterase family of enzymes present in the 
photoreceptors cells which is responsible for regulation of cGMP levels. This gene was mapped 
in 1995 to 1 Oq24 through a study using fluorescence {n §_itu hybridization (FISH).177 Recently, 
PDE6C was shown to cause achromatopsia through a study in the cpjll mouse strain which 
exhibited a phenotype much like that of achromatopsia patients with lack of cone function, and 
rapid cone degeneration, though in humans the lack of cone function is present at birth.166 The 
human homologue, PDE6C, is a cone-specific phosphodiesterase which works in conjunction 
with the transducin GNA T2 to cause hydrolysis and subsequent reduction of cGMP after light 
stimulation. 166 Chang eta!. tested achromatopsia patients who were negative for mutations in the 
three previously described genes and was able to identify mutations in PDE6C that caused 
achromatopsia in four fami lies. 
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(v) PDE6H (ACHM6 OMIM *601190) 
P DE6H encodes a second protein which belongs to the phosphodiesterase family of 
enzymes, the inhibitory gamma subunit of the PDE complex. The PDE complex is a homodimer 
comprised of two alpha-prime subunits (coded by PDE6C) and its activity is inhibited by the 
binding of the gamma subunit. As GDP is exchanged for GTP on the GNAT protein, the gamma 
subunit is sequestered allowing for activation of the PDE complex. The eDNA for P DE6H was 
originally isolated in 1996 from retinal tissue, and mutations were discovered to cause retinal 
cone dystrophy in 2005. More recently, Kohl etal. (2012) discovered a nonsense mutation in two 
siblings from Belgium, and in one individual from the Netherlands with incomplete 
achromatopsia. 167 
3.1 .4 A ims of this work 
This chapter describes eight families from the Canadian province of Newfoundland and 
Labrador with AR achromatopsia. The aim of this study was to identify the genetic defects in 
these eight families through bidirectional Sanger sequencing of functional candidate genes 
previously associated with achromatopsia, namely CNGA3, CNGB3, GNAT2, and PDE6C. This 
was undertaken in hopes of identify ing novel mutations in these four genes, or ideally to identify 
a novel achromatopsia locus through further studies involving individuals not solved by 
sequencing these four genes. Due to its relatively recent discovery, PDE6Hwas not examined 
during the course of this thesis. 
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3.3 Materials and Methods 
3.3.1 Patients and Ophthalmological Examination 
Families diagnosed with achromatopsia were identified through review of CNIB records 
or through referral to Ocular Genetics Clinics in St. John's or rural hospitals. Diagnosis of 
achromatopsia was confirmed through ophthalmological examination, visual field testing, colour 
vision testing, and ERG when possible. DNA was extracted from whole blood taken from 
participating patients. This study was approved by the Ethics Committee, Faculty of Medicine, 
Memorial University, St. John' s Newfoundland, Canada. (HIC#06.157). 
3.3.2 Functional Candidate Gene Selection and Screening 
Genomic DNA from all individuals was screened for mutations in the previously 
described achromatopsia genes CNGA3, CNGB3 and GNAT2. These three genes were selected 
for priority screening as they are known to cause the majority of achromatopsia cases worldwide. 
If no pathogenic variants were identified, the probands were then sequenced for PDE6C. DNA 
was isolated as previously described. 14 1 Oligonucleotide primers were designed using Primer 3 
software (http://frodo.wi.mit.edu/primer3/) and can be found in Appendix H. PCR, purification, 
and bidirectional sequencing for each gene was set up as per section 2.3.3 of this thesis. Due to 
its relatively recent association with achromatopsia, P DE6H was not studied in this thesis. 
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3.3.3 Variant and Haplotype Analysis 
Intragenic haplotypes were manually constructed, where SNPs were available, to check 
for segregation of a disease-associated haplotype. Bioinformatic analysis to assess pathogenicity 
ofmissense variants was carried out using SIFT,178 PolyPhen,179 and PANTHER.180 
3.3.4 Cloning 
Primers PDE6Cl7+ 18-F and -R were used to amplify DNA fragments and these were 
purified as per section 2.3.3. The amplicons were quantified using a NanoDrop 
spectrophotometer and 4 uL ofthe amplicons was added to the TOPO TA Cloning Kit 
mastermix (mastermix protocol can be found in Appendix I) to insert the purified fragment into a 
pCR ™4-TOPO® vector. The mixture was incubated at room temperature for 30 minutes and the 
entire plasmid solution was transferred to a 2 mL Eppdendorftube containing 50 uL ofTOP10 
Chemically Competent E.Coli cells and incubated on ice for 30 minutes. The bacteria were heat 
shocked at 42 degrees Celsius for 30 seconds to stimulate plasmid uptake and immediately 
transferred to ice where 250 ul sterile Super Optimal broth with Catabolite repression (S.O.C) 
medium. One-hundred and 150 uL of the bacterial solution were spread on LB/Agar plates with 
100 ug/mL Ampicillin using a sterile steel spreader, and the plates grown overnight at 3 7 degrees 
Celsius. 
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3.3.5 Mini-Prep 
After 24 hours of growth, the LB/ Agar plates were examined for E. Coli colony growth. 
Colonies were picked from the plate using a pipette tip and placed in a 15 mL centrifuge tube 
with 4 mL ofLB broth+Ampicillin. These tubes were placed on a shaker overnight at 37 degrees 
Celsius. After 24 hours of growth, the tubes were examined for a cloudy appearance indicating 
sufficient bacterial growth. Two mLs of the bacterial culture was used with the Qiagen Mini prep 
kit to isolate plasmids from the bacterial cells for subsequent sequencing. The bacteria were 
pelleted in a 2 mL Eppendorf tube at 13,000 rpm for five minutes, and the pellet was 
resuspended in 250 uL of Buffer Pl (a resuspension buffer). Two-hundred fifty uLs of Buffer P2 
(to bind DNA to the membrane) was added to the tube and inverted to mix the solution followed 
by addition of 350 uL Buffer N3. A white precipitate was observed and the tubes centrifuged at 
13,000 rpm. The supernatant was transferred to a QIAprep spin column and centrifuged at 
13 ,000 rpm for 1 minute, the flow-through discarded and 750 uL of Buffer PE (a wash buffer) 
was added to the filter membrane of the QIAprep column. The column was spun at 13,000 rpm 
and the flow through discarded; this step was repeated once again to dry the membrane. To elute 
the now purified plasmid from the filter membrane, 20 uL of water was added to the membrane 
and was allowed to incubate at room temperature for 1 minute. The QIAprep column was then 
transferred to a 1.5 mL Eppendorftube, and was spun at 13,000 rpm for 1 minute to isolate the 
plasmid. The solution was then quantified using a Nanodrop Spectrophotometer. The plasmid 
was then sequenced as per section 2.3.3 using a forward and reverse primer called M13-Forward, 
and M13-Reverse which were specific to the bacterial plasmid from the TOPO TA Cloning Kit. 
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3. 3. 6 Exome Sequencing 
DNA samples from the unsolved family (0094) were subjected to whole exome 
sequencing using three DNA samples from Family 0094 (two affected, one unaffected). Standard 
manufacturer protocols were followed to perform target capture with the Illumina TruSeq exome 
enrichment kit and sequencing of 100 bp paired end reads on Illumina Hi seq. Approximately l 0 
Gb of sequence was generated for each subject such that >90% of the coding bases of the exome 
defined by the consensus coding sequence (CCDS) project were covered by at least 20 reads. 
Adaptor sequences were removed and reads were quality trimmed using the Fastx toolkit and 
then a custom script to ensure that only read pairs with both mates present were subsequently 
used. Reads were aligned to hg19 with BWA,181 and duplicate reads were marked using Picard 
and excluded from downstream analyses. Single nucleotide variants (SNVs) and short insertions 
and deletions (indels) were called using samtools pileup and varFilter 182 with the base alignment 
quality (BAQ) adjustment disabled, and were then quality filtered to require at least 20% of reads 
supporting the variant call for SNV s ( 15% for indels ). Variants were annotated using both 
Annovar 183 and custom scripts to identify whether they affected protein coding sequence, and 
whether they had previously been seen in dbSNP131 , the 1000 genomes pilot release (Nov. 
20 1 0), or in approximately 240 exomes previously sequenced at the McGill Genome Innovation 
Center. 
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3.4 Results 
3. 4.1 Patients and Clinical Examination 
We obtained 21 blood samples from consenting family members for DNA extraction (13 
from affected; eight from unaffected individuals) across eight families identified with autosomal 
recessive achromatopsia. Diagnosis of achromatopsia was confirmed through ophthalmological 
examination, visual field testing, colour vision testing, and ERG when possible in a total of 13 
individuals across the eight families . Clinical descriptions of affected family members can be 
found in Table 3.1 , and Table 3.2. 
3. 4. 2 Candidate Gene Sequencing 
Screening of the three known achromatopsia genes, CNGA3, CNGB3, and GNA T2 
yielded 19 variants across all seven families (Table 3.3). Homozygous or compound 
heterozygous pathogenic variants were discovered in either CNGA3 or CNGB3 in six of the eight 
families (Table 3.4). 
3.4.3 CNGB3 mutations revealed in families 1442, 1492, 1713, 1734 
Affected individuals in two multiplex families , 1442 and 1492 (Figure 3.1 ), were 
homozygous for the most common mutation in CNGB3, c.1148delC: p.T383IfsX13. This 
mutation was also discovered in the proband of Family 1713, though it was compound 
heterozygous with a previously described 10 basepair deletion in exon 7 of CNGB3, 
c.886_896del11 insT: p.T296YfsX9. 184 There was no parental DNA from this family to check for 
segregation of both alleles, but no mutant alleles were found in either CNGA3 or GNAT2. The 
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individual from Family 1734 was noticed to have one copy of the c.1148delC: p.T383IfsX13 
mutation, though no other mutations were discovered in CNGB3. 
3. 4. 4 CNGA3 mutations revealed in .families 1491, 1723, and 1726 
Affected members of Family 1491 (Figure 3.1 ) were homozygous for the recently 
described c.l580 T>G: p.L527R mutation 185 which resides in the cGMP binding site of the 
CNGA3 protein. The p.L527R mutation was also observed in Family 1723 as a compound 
heterozygote with a previously described mutation c.l279 C>T: p.R427C (Table 3.4). We also 
observed c.1279 C>T: p.R427C as a compound heterozygote with c.848 G>A: p.R283Q in the 
proband of Family 1726 (Table 3.4). Parental DNA was unavailable for both Families 1723 and 
1726. 
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Figure 3.1 Pedigrees ofthe eight families (1442, 1491, 1492, 171 3, 1726, 1723, 1734 and 0094) 
diagnosed with achromatopsia. Numbers to the top right of the symbols correspond to the 
clinical information in Tables 3.1 and 3 .2. An asterisk at the bottom of a symbol indicates that 
that DNA was contributed by this individual. 
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YOB Nystagmus Colour Vision Visual Fields ERG Responses 
Visual Acuity (VA) 
. _:;:'~~~,. ..  , :::L:. First VA Recent VA ·'·'1rE:.*>;:.:. ~.:;~~ ,\ ' ',;, ,, . ,, .. 
R1442.1 1944 1982 2006 Yes 1985 ND ND 
20/200 OD 20/200 OD Farns 015 · Abn 
20/200 OS 20/400 OS Ishihara · Nil 
HRR- Nil 
R1442.2 1948 1985 ND Yes 1985 ND ND 
20/200 OD Farns 015 - Abn 
20/200 OS Ishihara - Nil 
HRR- Nil 
R149L1 1938 1996 2007 No ND ND ND 
20/200 OD 20/400 OD 
20/200 OS 20/400 OS 
R149L2 1937 1984 ND No 1984 1984 ND 
20/200 OD Farns 015 - Nil Centra l 
20/200 OS Ishihara- Nil Scotoma 
HRR- Nil OD/ OS 
R149L3 1938 1974 2006 No ND ND ND 
20/300 OD 20/400 OD 
20/400 OS 20/400 OS 
R149L4 1952 1982 2005 Yes 1982 1982 2005 
20/200 OD 20/400 OD Farns 015 - Nil Peripheral Rod- Reduced 
20/200 OS 20/400 OS Ishihara - Ni l Constrict ion and Delayed 
HRR- Nil OD/ OS Cone -Absent 
R1492.1 1943 1994 1995 Yes 1994 1994 1994 
20/200 OD 20/200 OD Farns 015 - Abn Peripheral Rod - Reduced 
20/200 OS 20/200 OS Ishihara - Ni l Constriction Cone - Absent 
HRR - Nil OD/ OS 
R1492.2 1958 1988 2006 Yes 2002 ND ND 
20/200 OD 20/200 OD 
Farns 015 - Nil 20/ 200 OS 20/ 200 OS 
Ishihara- Nil 
HRR- Nil 
R1713.1 1953 2009 ND No 2009 2009 2009 
20/200 OD Farns 015 - Abn Normal Rod - Reduced 
20/200 OS Cone - Absent 
R1723.1 1966 1983 2010 Yes 1983 2010 2010 
20/200 OD 20/ 200 OD Farns 015 - Abn R - Relative Rod - Normal 
20/200 OS 20/ 200 OS Ishihara- Nil peripheral Cone - Low 
HRR-Abn loss amplitude 
L- Central Irregular w ave 
scotoma; pattern 
relative 
peripheral 
loss 
R1726.1 1936 2008 2010 Yes ND ND 2010 
20/200 OD 20/200 OD Rod - Reduced 
20/200 OS 20/200 OS and Delayed 
Cone - Absent 
R1734.1 1975 1981 1990 Yes 1987 1982 1982 
20/400 OD CFOD Ish - Abn Central Rod· Normal 
20/300 OS CF OS HRR - Abn Scotoma Cone -Absent 
Farns 015 - Abn OD/ OS 
. . Table 3.1: Clmical descnption of affected mdividuals from seven of the eight families diagnosed with 
achromatopsia. YOB: Year Of Birth, OD: Oculus Dexter (Right eye), OS: Oculus Sinister (Left eye) CF: 
Counting Fingers, HM: Hand Movements, ND: Not Done, HRR: Hardy-Rand-Ritter Colour Test, Farns 
D15: Farnsworth DIS Colour Arrangement. 
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0094.2 
0094.3 
0094.4 
0094.5 
0094.6 
0094.7 
YOB Status CNIB Visual Acuity (VA) Nystagmus Colour Vision Visual ERG Responses Dental Abnormalit ies 
Reg. Fields 
First VA Recent VA . ~-
1959 Affected 1973 1987 2007 1973 1987 1987 1987 1973- 22 teeth extracted, 
20/300 OD CF OD Yes Ishihara- No Relative Rod-Borderl ine 'severe enamel dysplasia' . 
20/300 OS CF OS 1987 Response Peripheral Cone-Absent 1980- 11 teeth extracted 
Myopia No HRR- No Response Loss 
Farns D-15 -Abnormal 
1960 Unaffected NR 1982 2011 No Farns D-15- normal ND ND 1987- Upper teeth ext racted. 
20/20-1 OD 20/20"3 00 2010 - lower teeth extracted 
20/25+10S 20/25+1 OS 
1961 Affected 1973 1995 2011 1973 ND ND ND 1973- 32 teeth extracted, 
Required HM 8ft OD/OS Yes 'Severe enamel dysplasia' . 
escort b/c Bone spicules 1980- 10 secondary t eeth 
of VA extracted 
1963 Affected 1973 1982 2011 1973 1982 1987 1987 1973- 'Poor dentit ion and 
20/200 OD HM 8ft OD/OS Yes Ishihara - No Relative Rod-Normal defective enamel' not ed. 
20/200 OS Maculopathy 1982 Response Peripheral Cone-Abnormal 1984 - 28 teet h extracted 
Yes HRR- No Response Loss 
Farns D-15- Abnormal 
1964 Unaffected NR 2007 2010 No ND ND ND 2011 - 4 front teeth on plate, 
20/15 OD 20/25 OD 2 ot her teeth decayed 
20/15 OS 20/20-2 OS 
1966 Affected 1973 1982 1973 1982 ND ND 1973 - 'severe enamel 
20/200+1 Yes Ishihara- No dysplasia' noted 
ou ND 1982 Response 1977- irregu lar t eeth with 
Myopia Yes HRR- No Response brown discolouration, 
Farns D-15 -Abnormal marked wearing, 
jumbled eruption pattern 
1979- 17 teeth extracted 
Table 3.2: Clinical description of family 0094 from archived medical records, showing ophthalmological and dental examinations. 
YOB: Year Of Birth NR: Not Registered, OD: Oculus Dexter (Right eye), OS: Oculus Sinister (Left eye), CF: Counting Fingers, 
HM: Hand Movement, ND: Not Done, HRR: Hardy-Rand-Ritler Colour Test, Farns DlS: Farnsworth D1 5 Colour Arrangement 
Test. 
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Minor 
Allele 
Frequency Disease 
Gene Accession# Variant dbSNPID (%) Segregation SIFT Score Polyphen-2 
GNAT2 NM_005272 c. -32 A>G rs2304355 11.2 No NA NA 
c.119-69 C> T rs6658641 11.3 No NA NA 
c.546 G>A: p.T182T rs1799875 43.5 No NA NA 
Probably 
CNGA3 NM_001298 c.848 G>A: p.R283Q rs104893614 N/ A Yes Deleterious Damaging 
Probably 
c.1279 T>C: p.R427C NA N/ A Yes Deleterious Damaging 
Probably 
c.1580 T>G: p.LS27R NA N/ A Yes Deleterious Damaging 
CNGB3 NM_019098 c.702 T>G: p.C234W rs6471482 6.8 Yes Tolerated Benign 
c.892 A>C: p.T298P rs4961206 34.1 Yes Deleterious Benign 
c.886_896delllinsT: p.T296YfsX9 N/ A Yes NA NA 
c.919 A>G:p.I307V rs13265557 5.7 No Tolerated Benign 
c.1148deiC: p.T383fsX13 N/ A Yes NA NA 
c.1179-78 A>T rs34307542 6.8 No NA NA 
c.1179-38 T>C rs3735969 4.8 No NA NA 
c.1320+56 G>A rs67463707 7 No NA NA 
c.1320+239 G>A rs67858232 6.8 No NA NA 
c.1481-145 A>C rs13258590 33 .6 No NA NA 
c.2430+1303 G>A rs17683284 4.3 No NA NA 
c.2430+1639 C>A rs990192 43.7 No NA NA 
c.2430+1881 T>C rs990193 14.8 No NA NA 
PDE6C NM_006204 c.252 G>A: p. L84L rs113 1978 16.7 No NA NA 
c.723+53 G>A rs1223306 48.1 No NA NA 
c.808 T>A: p.S270T rs701865 42.8 No Tolerated Benign 
c. 1120-60 T>C rs1856563 3.4 No NA NA 
c.1270-7 A>G rs616522 29.5 No NA NA 
c.1380 C>G: p.T460T rs3737228 27.3 No NA NA 
c. 1629+81 C>G rs2275227 15.2 No NA NA 
c.2284-72 A>G rs10882298 38.7 No NA NA 
Table 3.3: A ll variants discovered through the screen ofCNGA3, CNGB3, GNAT2, and PDE6C. Variants 
cons idered pathogenic are shown in bold print. 
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Family Gene Allele 1 Allele 2 
0094 CNNM4 c.1555 C> T: p.R519X c.1555 C>T: p.R519X 
1442 CNGB3 c.1148deiC: p.T3831fsX13 c.l148deiC: p.T3831fsX13 
1492 CNGB3 c.1148deiC: p.T3831fsX13 c.1148deiC: p.T3831fsX13 
1713 CNGB3 c.l148deiC: p.T3831fsX13 c.886_896delll insT: p.T296YfsX9 
1491 CNGA3 c.1580 T>G : p.L527R c.1580 T>G : p.L527R 
1723 CNGA3 c.1580 T>G : p.L527R c.1279 C>T: p.R427C 
1726 CNGA3 c.848 G>A: p.R283Q c.1279 C>T: p.R427C 
Table 3.4: Pathogenic variants discovered in all seven families. 
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3. 4. 5 Haplotype Construction and Analysis 
All variants discovered through Sanger sequencing as well as genotypes from flanking 
microsatellite markers were used to create haplotypes in each family with mutations in CNGAJ 
and CNGBJ. Examination ofthese haplotypes allowed for interfamilial comparisons, and 
determination of founder haplotypes/mutations. 
(i) CNGBJ Haplotypes 
The haplotype surrounding the most common CNGBJ mutation, c.1148deiC, was 
constructed using family 1492, which has the most affected individuals with this mutation 
(Figure 3.2). This haplotype (shown in red) was then used to construct the haplotypes in families 
1442, 1713 and 1734. It can be noted that small differences in genotypes exist, denoted by the 
light green portions of the haplotypes as compared to that of 1492. The individual from Family 
1734 was heterozygous for the c.1148delC mutation, though a second mutation was not found. 
The c.ll48deiC founder haplotype can be seen in red, though it should be noted that though he 
appears to have the same haplotype as Family 1492 the genotype at D8S271 (260/264) can be 
switched to have the same haplotype as 1442. To confirm the proper orientation of the haplotype, 
parental samples would need to be obtained to perform segregation analysis of this marker. 
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A) Family 1492 B) Family 1713 
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Marker Genomic Coordinates (GRCh37/hg19) 
0 851838 84624454 
0 851119 27171877 
0 851707 87888313 
DSS271 89518245 
0 85273 88911428 
Figure 3.2: Haplotypes of family members carrying CNGB3 mutations. A) The haplotype 
surrounding the c.1148delC mutation was first constructed using Family 1492 and is denoted as 
the red haplotype which was homozygous between the two affected individuals. A 
recombination was observed between markers D8SJ707 and D8S273 in the proband (indicated 
by the arrow). B) Possible haplotypes from Family 1713. We were limited to information on one 
individual from Family 1713, so all possible haplotypes are shown. The red box indicates that 
this red haplotype shows most similarity to the red haplotype constructed in Family 1492.C) 
Like Family 1713, only one individual was available from this family . Only one haplotype was 
possible based on the multiple homozygous genotypes. The red box and arrow show the 
similarity to the red haplotype from family 1492. D) Possible genotype combinations from the 
individual of Family 1734. The red box and arrow show the similarities to the red haplotype seen 
in the three other families. This data suggests that the c.1148delC mutation may exist on a 
common founder haplotype. 
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(i i) CNGA3 Hapfotypes 
Four microsatellite markers were genotyped to construct haplotypes surrounding each 
mutation. Affected members of Family 1491 shared a homozygous haplotype surrounding the 
c.1580 T>G mutation (Figure 3.3) which showed some intra-familial variation at the most 3' 
marker D2S218 7. Assuming that family 1723 and 1491 are sharing the same haplotype, as they 
have the same mutation, the same yellow haplotype was also seen in Family 1723, in which the 
affected individual was a compound heterozygote for c.1580 T>G and c.1 279 C>T. As the 
yellow haplotype could al ready be infened from Family 1491 , this made the construction of the 
haplotype surrounding c.1 279 C>T possible (shown in light blue). The affected family member 
from Family 1726 did not show a common haplotype with Family 1723, despite harbouring the 
c. 1279 C>T mutation as one allele. 
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A) Family 1491 
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0 252311 99016618 
0252187 99105207 
Figure 3.3: CNGA3 haplotypes constructed using four microsatellite markers, one SNP and the 
pathogenic variants discovered through initial screening. A) The haplotype surrounding the c. l580 T>G 
variant was done first, as it is homozygous in Family 149 1, which has the most individuals avai lable for 
haplotype construction. The disease haplotype surrounding c. l 580 T>G is denoted in yellow, though 
there are slight differences at particular markers (i.e. D2S218 7 has genotypes of 122/ 126/ 128/134) 
denoted by differing colours. B) Possible haplotypes from fam ily 1723. One sample was obtained from 
this fami ly, and four haplotypes were possible. A similar haplotype surrounding c. 1580 T>G is seen in 
fami ly 1723 despite differences in the two most terminal markers (D2S2187 and D2S2222) and is denoted 
with a red box and arrow from Family 1492. The c.l279 C>T mutation was also seen in fam ily 1723. C) 
Four possible haplotypes based on information from the individual of family 1726. None of the 
haplotypes from this fam ily match the possible ones from 1723 who both carry the c.l 279 C>T mutation. 
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J 
• 
3.4.6 Unsolved Families (Families 1734 & 0094) 
(i) Family 1734 
Screening of the three previously associated achromatopsia genes CNGA3, CNGB3, and 
GNAT2 revealed one heterozygous pathogenic mutation (c.1148delC) in CNGB3 though a 
second pathogenic variant was not identified in this gene. This sample was then sequenced for 
PDE6C, the fourth known achromatopsia gene. This screen identified four confirmed 
homozygous SNPs (rsl223306, rs1856563 , rs6163 22, and rs10882298) all of which were 
excluded from further analysis due to their high frequency in the general population (Table 3.3), 
and one sequence anomaly. The sequence surrounding exons 17 and 18 of PDE6C showed an 
odd sequence which in the forward strand, started with high background but at nucleotide 
c .2259T became of better quality (Figure 3.4). This pattern was consistent across multiple 
attempts. It was hypothesized that this anomaly was being caused by an insertion/deletion event 
to cause the sequence to appear shifted, followed by a second insertion/deletion event to bring 
the sequence back into frame. To examine the nature of this sequence anomaly, this amplicon 
was inserted into a pCRTM4-TOPO® vector after amplification using primers PDE6C 17+ 18-F 
and PDE6C17+ 18-R and cloned into TOP1 0 Chemically Competent E. Coli cells as per 
manufacturers protocol and grown overnight on LB/ Agar plates. Six colonies were chosen from 
these plates, and the plasmid isolated and purified. Sequencing of the plasm ids and inserts 
revealed one clone with a sequence matching that of exons 17 and 18 of P DE6C (Appendix I 
pink). Two other clones were noted to have sequence which belonged to neither PDE6C, nor the 
plasmid, except for a 20 bp sequence consistent with the primer PDE6C 17+ 18-R (Appendix I). 
The remaining three clones showed small fragments of this aberrant sequence from partial 
ligations. The entire length of this unknown sequence was run through UCSC' s Blast-Like-
Alignment-
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PDE6C (NM_006204) Reference Sequence 
10,0001r-- ~~~~-~~~--~-~~----,--:-::-"""....,.....,.~- ,-.---~~:=:-o~------=-::-----=-=------::::-:-----
8,000 T G - T' 
Family 1734.1 Sequence 
2,000 -- ~ -1 1} -- -- --- --- ~~ 5- ------------- ~ ;?()- --------- 1* - -- ------- -h30 - - ---- -- -1-35 --- --- - -- ~40 -- - -- ---- -145 - - 150 
;~iik~ilisidf~ii~~~k:tb~ h~;J~~~ 
Figure 3.4 - Sequence surrounding exon 17 of P DE6C illustrating the presence of a sequence 
anomaly. (Top) Reference sequence of PDE6C (NM_006204.3) obtained from the NCBI 
Nucleotide database. (Bottom) Experimental sequence obtained from sequencing the proband of 
family 1734. The sequence to the left of the red arrow shows high background, whereas the 
sequence to the right of the red arrow shows much cleaner sequence. 
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Tool (BLAT) to determine the origin of this sequence. This analysis revealed a 99.2% sequence 
similarity to an intergenic region on chromosome 8q24.13, making it unlikely to be caused by 
two insertion/deletion events, as described above. To explore if this sequence anomaly was being 
caused by a potential translocation event from Chr8, three primers were designed: 
Primer 1) 1734.1-Chr8-F (GTGGAGGTTCCCAAACTTGA) which according to BLAT 
was specific to the intergenic region on Chr8q24.13 
Primer 2) 1734.1-PDE6C-R (A TTCCCAA TTCATGGGAG) which according to BLAT 
was specific to intron 18 of PDE6C 
Primer 3) 1734.1-Chr8-843bp-R (CTGGAACTGGGTAACAAGCAG) which was 
specific to Chr8q24.13. 
It was hypothesized that if a true translocation event had occurred, that Primers I+ 2 
would generate a band upon PCR amplification, indicating that the Chr8 region was in close 
proximity to the Chrl 0 region. Primer 3 was used as a control for the Chr 8 region and was 
hypothesized to amplify a band 843 bp in size when combined with Primer 1. PCR was carried 
out using a sample from the proband of 1734, and a control DNA sample from family 0094 
(0094.4) who did not show this sequence anomaly upon sequencing of PDE6C. Results from the 
experiment showed no amplification in either the experimental sample or the control using 
Primers 1 + 2, but Primers 2+ 3 showed the expected band in both the sample and control (Figure 
3.5). This suggests that the sequence anomaly in Figure 3.4 is not due to a translocation event. 
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Figure 3.5 - 1% Agarose gel stained with SYBR safe showing PCR amplification of two 
samples (1734.1 and 0094.4) using three primers. Primer 1 = 1734.1-ChrS-F, Primer 2 = 1734.1-
PDE6C-R, Primer 3 = 1734.1-Chr8-843bp-R. No amplification was seen using Primers 1+2 in 
either sample, suggesting that the sequence anomaly isn' t from a translocation event. The 
expected band for Primer 1 + 3 was obtained in both samples. 
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Upon receiving the primers, a note was attached from the manufacturer that Primer 2 
(1734.1-PDE6C-R) contained significant secondary structure which may interfere with some 
assays. It is possible that no amplification would be seen due to this fact, and that the sequence 
anomaly may still be due to a translocation event. To once again test this hypothesis, the 
chromosome 8 specific primer, Primer 1 ( 1734.1-Chr8-F) was paired with the reverse primer 
PDE6C-17+ 18-R from the initial sequencing of PDE6C. It was hypothesized that if 
amplification occurred in sample 1734.1 but not in sample 0094.4 that it would be possible that 
there was indeed a translocation event present. This experiment showed amplification in both 
samples (Figure 3.6), suggesting that perhaps the reverse primer (Primer 2) was binding to 
chromosome 8, even though BLAT analysis suggested it was specific toP DE6C. Next, two 
things were examined: 
1) If the secondary structure of Primer 2 is sufficient to stop amp I ification 
2) If the primer PDE6C-17+ 18-F had the potential to bind to other regions non-
specifically, like its complementary primer PDE6C-17+ 18-R. 
To examine the first question, PDE6C 17+ 18-F was paired with Primer 2. It was 
hypothesized that if amplification occurred, then the secondary structure was insufficient to stop 
PCR amplification, and that the result from Figure 3.6 suggested there was no translocation event 
in 1734.1. To answer the second question, PDE6C-17+ 18-F was paired with Primer 3 (1 734.1-
Chr8-843bp-R) which was shown to bind to multiple sites upon BLAT analysis. It was 
hypothesized that if amplification occurred, that PDE6C-17+ 18-F was also a nonspecific primer 
but would amplify a specific band when paired with a more specific primer (as seen in Figure 
3.6). The results from this experiment showed that a single band amplified in Lane 7 ofthe gel 
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Figure 3.6- 1% Agarose gel stained with SYBR safe showed amplification of 1734.1 and a 
control sample 0094.4 with Primer 1 and PDE6C17+ 18-R. Amplification was very weak, thus to 
better view the bands, the colour was inverted in this figure. 
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(Figure 3.7) suggesting that Primer 3 can in fact produce amplification, though not efficiently (as 
there was no amplification in the other lanes. The experiment addressing the second question 
showed three bands in total (Figure 3. 7), suggesting that PDE6C-17+ 18-F has binding sites other 
than PDE6C. It was also noteworthy that PDE6C-17+ 18-F and -R were difficult to amplify and 
sequence in all tested samples. Therefore, a second primer set surrounding PDE6C exons 17 and 
18 was designed and used to sequence this region in Family 0094 and Family 1734, which 
showed no pathogenic variants in any tested sample. 
Page 127 of 257 
Figure 3.7- 1% agarose gel stained with SYBR safe. Lanes 2-9 illustrate the combination of 
Primers 17+ 18-F and Primer 2, which was known to have significant secondary structure. The 
amplified band in lane 7 but in no other suggests that the reverse can amplify, but not efficiently. 
Lanes 10-17 illustrate the combination ofPDE6C-17+ 18-F and Primer 3, which is known to bind 
to multiple regions of the genome (though produces a single band when paired with a specific 
primer, see Figure 3.6). The amplification of three bands in both the experimental sample 
(1734.1 ) and the control sample (0094.4) suggests that the PDE6C-17+ 18-F primer has binding 
sites other than PDE6C. 
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(ii) Family 0094 
No pathogenic mutations were found in the affected members of Family 0094 in CNGA3, 
CNGB3, GNAT2 or PDE6C. To check for segregation of a disease associated haplotype in 
CNGA3, CNGB3, GNAT2 or PDE6C, which might suggest a regulatory mutation missed on 
initial sequencing, we constructed intragenic haplotypes with discovered SNPs as well as 
microsatellite markers, however no haplotypes co-segregated with the phenotype in this way 
(Figures 3.8-3.11) 
Exome sequencing was then carried out at the McGill University Genome Centre on 
pooled genomic DNA from two affected siblings and on genomic DNA from the unaffected 
parent. Pooling of DNA was done to both reduce costs, and to enrich for regions of the genome 
shared amongst affected individuals to ease identification of a pathogenic variant. Target capture 
with Illumina TruSeq exome enrichment kit and sequencing of 100 bp paired-end reads on 
lllumina Hi Seq yielded approximately 10Gb of sequence for each DNA sample such that >90% 
of the coding bases of the exome defined by the consensus coding sequence (CCDS) project 
were covered by at least 20 reads. Sequence reads were aligned and variants were called and 
filtered as previously described. 186 Exome sequencing yielded 11 ,292 non-synonymous coding 
variants in the affected pool versus 10,399 in the unaffected parental exome at ~80x 
coverage. We filtered the variants in the affected pool to remove those seen in more than one of 
~200 unrelated exomes sequenced at Genome Quebec, which left 255 variants. Of these 255 
variants, only seven were homozygous in the affected pool (one nonsense), which would be 
expected with consanguinity and an autosomal recessive mode of inheritance (Table 3 .5). These 
seven variants included a novel nonsense mutation (c. 1555 C>T: p.R519X) in CNNM4 (d_ncient 
Conserved f_rotein Domain 4; ACPD4; NM_020184), the only gene known to cause Jalil i 
Syndrome. We verified co-segregation of c. 1555 C>T: p.R519X with achromatopsia in Family 
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0094 by Sanger Sequencing, and this variant was not present in 236 ethnically-matched control 
chromosomes. 187 
A search of archival medical records from the 1970s for documentation of dental 
abnormalities revealed that each of the four siblings diagnosed with achromatopsia had markedly 
abnormal dentition as young children with enamel dysplasia, brown discolouration of teeth and 
irregular tooth eruption. These four siblings had undergone surgical extraction of all primary and 
secondary teeth (Table 3.2). At the time of the ophthalmological examination in 1982, all 
siblings had dentures which were not uncommon in rural NL as dental care in many outport 
communities was unavailable and extraction was a common treatment for common dental caries. 
Ocular re-examination of two of the siblings with achromatopsia in 2011 showed a further 
reduction of visual acuity to hand movements (HM) at 8 feet (previously 20/200 in IV -4) with 
additional macular and peripheral retinal changes noted (Table 3.3), revealing a progressive 
retinal phenotype, consistent with cone-rod dystrophy associated with Jalili syndrome, rather 
than achromatopsia which tends to be a stationary condition. 
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1 2 IV 
D8S1838 (190) (200) 200 200 
D8S111 9 (190) (181) 184 193 
rs6471482 (T) (G) G T 
rs4961206 (A) (C) CA 
rs13258590 (A) (C) c ,!!., 
D8S1707 (1 02) (98) 98 102 
D8S271 (264) (260) 268 258 
D8S273 123 123 127 127 
1 2 3 4 5 6 
v 
D8S1838 190 200 190 200 200 200 200 200 200 201) 200 200 
D8S1119 190 184 190 184 '18'1 184 181 193 181 193 190 184 
rs6471482 T G T G GG G T G T T G 
rs4961206 A C A C c c C A C A ,!!., c 
rs13258590 A C /l, c c c CA c ,1!., ,1!., c 
D8S1707 102 98 102 98 98 98 98 102 98 102 102 98 
D8S271 264 268 264 268 260 268 260 258 260 258 264 268 
D8S273 123 127 123 127 123 127 123 127 123 127 123 '127 
Figure 3.8: Partial pedigree of family 0094 with haplotypes of CNGB3 variants and marker 
genotypes. There are no common haplotype combinations within all four affected individuals. 
For example, PID IV-1 shares common haplotypes with her unaffected sister PID IV-2, which is 
not shared by any other sibling. PID IV -3 and IV -4 both share a blue haplotype though they have 
yellow or green haplotypes as their second haplotypes. This data, along with the fact that no 
novel mutations have been found in family 0094 within CNGB3, excludes CNGB3 as the 
causative gene in this family. 
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1 2 
IV 
D2S1258 I'"'' '"I ~"""I D2S2222 (220) (220) 220 218 D2S217S (124) (124) 124 119 D2S2311 (142) (152) '152 146 
1 2 3 4 5 
v 
D2S1258 I"""~ r "'l r172 ~ I"""~ r 172 ~ D2S2222 220 220 220 218 220 220 220 220 220 220 D2S217S 124 124 124 119 124 24 124 124 124 ' 24 D2S2311 142 152 152 146 152 152 152 152 152 '152 
Figure 3.9: Partial pedigree of family 0094 with haplotypes of CNGA3 marker genotypes. No 
SNPs or novel variants were discovered in CNGA3 within Family 0094 members, suggesting a 
highly conserved structure and sequence within the gene and protein. Three affected individuals 
(PID IV -3, IV -4, and IV -6) both share both the blue and yellow haplotypes, but this is excluded 
as one unaffected individual (PID IV -5) also shares these haplotypes. The fourth affected 
individual (PID IV -1) has a red and a yellow haplotype, providing further evidence for the 
exclusion of CNGA3 in this family. 
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6 
r6172 ~ 220 220 124 124 
'152 152 
1 2 
IV 
D10S583 (145) (147) 147 155 
D10S1755 (289) (293) 293 293 
D10S185 (146) (1 48) 148 156 
D10S200 (289) (293) 293 293 
rs1131978 (G) (A) ft. G 
rs1223306 (A) (G) GA 
rs701865 (T) (A) A T 
rs1856563 (C) (C) cc 
rs616522 (G) (G) GG 
rs3737228 (C) (G) GG 
rs2275227 (G) (G) GC 
D10S1680 (208) (206) 206 208 
D10S520 (208) (206) 206 208 
D1 OS571 (197) (205) 205 193 
1 2 3 4 5 
v 
D10S583 145 147 '147 155 145 155 145 155 147 155 
D'10S1 755 289 293 293 293 289 293 289 293 (293) (293) 
D10S185 146 148 '148 '156 146 156 146 156 148 156 
D10S200 289 293 293 293 289 293 289 293 293 293 
rs11 31978 G /1, A G GG GG .ll. G 
rs1223306 .ll. G G A ,ll, ,ll, ,11, .A. G .A. 
rs70'1865 T A A T T T T T .ll. T 
rs1856563 cc cc cc cc cc 
rs6·16522 GG GG GG GO GO 
rs3737228 CG GG CG CG GG 
rs2275227 GO GC GC GC GC 
D10S1680 208 206 206 208 208 208 208 206 206 208 
D10S520 208 206 206 208 208 208 208 208 206 208 
D1 OS571 '197 205 205 193 197 193 197 19.3 205 193 
Figure 3.10: Haplotypes of variants and markers surrounding and within the PDE6C gene. 
Individuals IV-3 and IV-4 share a common red and green haplotype, though individuals IV-1 and 
IV -6 share different a combination of haplotypes, suggesting that P DE6C is not the causative 
gene for ACHM in family 0094. 
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1 2 
IV 
D1 S2778 r~ (166)1 ~ 168 "'I rs2304355 (A) G) P.. A rs6658641 (C) (T) cc rs1799875 (A) (G) AA 
D1 S2651 (285) (271) 269 271 
D1S221 (221) (21 9) 219 21 9 
1 2 3 4 5 
v 
D1S2778 rr~ I'" "'I r~66~ r'"l I'" 166 ~ rs2304355 A .A. A .A. G .A. rs6658641 cc cc T C rs1 799875 AA G /l. A .A. GA 01 S2651 271 269 285 271 27'1 269 285 271 271 269 D1 S221 219 219 221 219 219 219 221 219 2'19 2'19 
Figure 3.11: Haplotypes of variants and markers surrounding and within the GNA T2 gene. Three 
of the affected individuals (PID IV-1, IV-3, and IV-6) share blue and yellow haplotypes though 
the unaffected sister (IV -5) also shares these same haplotypes. As well, individual IV -4 have two 
different (red and green) haplotypes providing further evidence for exclusion of GNAT2 as the 
causative gene in this family. 
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6 
r6166 ~ G A T C G .A. 
271 269 
219 219 
Coding Coding Variants Homozygous Homozygous variants seen in Number of Genes 
variants in variants in seen in < Variants seen in :::_2 previous exomes, and with previous 
Affected Unaffected 2 previous _::: 2 previous absent or heterozygous in association to retinal 
sample pool Sample exomes exomes Unaffected sam le disease 
11 ,292 I 0,399 25 5 7 7 
Table 3.5: Table of variant filtering from the exome dataset. As family 0094 segregated an 
autosomal recessive form of disease, the exome dataset was initially fi ltered for homozygous 
variations. One nonsense mutation was revealed to be previously associated with a retinal 
phenotype, c. 1555 C>T: p.R51 9X in CNNM4 . 
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3.5 Discussion 
Mutations in CNGA3 and CNGB3 have been shown to account for a majority of 
achromatopsia cases worldwide. In this study of the Newfoundland population, mutations of 
these two genes solved six out of the seven recruited families. Two families (1442 and 1492) 
were homozygous for the most common mutation in CNGB3 c.1148delC: p.T383IfsX13. A third 
family (1713) also had the c.ll48delC: p.T383IfsX13 mutation but it was a compound 
heterozygote with a 10 bp indel, c .886 896del11insT: p.T296YfsX9 (Table 3.4). It is likely that 
both these mutations undergo nonsense mediated mRNA decay as they introduce a premature 
stop codon early in the open reading frame, and the mutation exists >50bp from the terminal 
exon.
188 The c.1148delC mutation is the most frequent mutation causing achromatopsia 
worldwide, and this was also seen in the achromatopsia patients of the Newfoundland 
population. Of the 20 alleles that were studied in patients with achromatopsia, mutations in 
CNGB3 mutations accounted for nine ofthem (45%), while ofthese nine mutations, c.1 148delC 
accounted for eight of them (89% ). 
The other three families (1 491, 1723, and 1726) were solved by mutations in CNGA3. 
Affected members of Family 1491 were homozygous for the previously reported c. l580 T>G: 
p.L527R185 mutation which exists in the cGMP binding site of the CNGA3 protein (Figure 3.12). 
Conservation analysis by Lam et al. show that the L527 residue is highly conserved from Homo 
sapiens to Drosophila melanogaster thus suggesting that this residue is located within a 
functionally important domain of the CNGA3 subunit. Furthermore, in silica analysis using 
SIFT, Polyphen-2, and PANTHER (Table 3.3) suggest that the L527R variant is highly 
damanging. As the mutation exists in the cGMP binding site, it is likely that this mutation 
impedes the ability ofCNG to bind cGMP, disrupting the closure ofthe cyclic nucleotide gated 
channel (CNG) of the cone photoreceptor, though no functional analysis has been done on this 
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mutation to date. The p .L527R mutation was also seen in the single affected member of Family 
1723, as a compound heterozygote with c. l 279 C>T: p.R427C. Previous studies ofp.R427C 
show that this mutation impedes the trafficking of CNGA3 to the cellular membrane.189 It is 
possible that due to the relatively close proximity of p.R427C to p.L527R, that p.L527R may 
also act in this manner. The sixth family, 1726, also had the c.1279 C>T: p.R427C mutation as a 
compound heterozygote with c.848 G>A: p.R283Q. Of the 20 mutant alleles analyzed in this 
study, 10 ofthem were in CNGA3 (50%), and the most common mutation seen was the c.1580 
T>G: p.L527R mutation with seven out of these 10 (70%). This is of course biased as we have 
more information and samples on fami ly 1491, than on the other two families 1723 and 1726. 
Functional analysis of the p.R283Q mutation has shown that this mutation affects the 
ability of the CNG channel within HEK293 cells to conduct calcium flow. 189 The combination 
of p.R427C and p.R283Q in this patient potentially causes achromatopsia through reduction of 
functional CNGA3 subunits. This is most likely accomplished through the combination of 
aberrant trafficking and reduction of calcium influx. It is interesting to note that there are a 
multitude of pathogenic missense variants in CNGA3 which are known to cause achromatopsia, 
whereas the mutations in CNGB3 tend to be null alleles such as nonsense or frameshift mutations 
(Figure 3. 12A and 3. 12B), suggesting that the CNGA3 protein is more readily affected by 
mutation. This lends to the notion that the CNGA3 subunit is the major functional subunit of the 
CNG channel, and that mild mutations of CNGB3 can be compensated for by a functional 
CNGA3 subunit. 
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Figure 3.12: Protein schematic of A) CNGA3 and B) CNGB3 showing all functional domains 
and previously identified mutations and their approximate position within the protein. C) 
Hypothetical protein structure of CNNM4 based on the structure of its homologue CNNM2. All 
the previously described mutations and their approximate position in the various domains ofthe 
protein are shown. The novel nonsense mutation p.R519X is shown in bold print and its position 
between the two CBS domains of CNNM4, is indicated with a red marker. 
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To examine the potential existence of a founder effect within CNGA3 and CNGB3 in the 
Newfoundland population, haplotypes surrounding each mutation were constructed. This 
revealed a common haplotype (Figure 3.2) sunOLmding the c.1148delC mutation in CNGB3 
across all four families who have this mutation (1442, 1492, 1713, and 1734). Small differences 
can also be seen in the haplotype which suggests that either there are many haplotypes with this 
mutation in existence (suggesting a recurrent mutation), or that the haplotype has mutated over 
time. The latter notion seems to be the most likely, as it has been suggested that c. 1148delC: 
p.T383IfsX is a founder mutation in populations other than Newfoundland. 173 It is likely this 
mutation is an ancient mutation, and that the differences seen in the haplotypes in this study are 
most likely due to haplotype mutating over the course of time. As we were only able to obtain 
DNA from one individual of Family 1442 and 1734, all possible genotype combinations are 
shown in Figure 3.2. In order to confirm that the haplotype surrounding c.1148delC is indeed 
similar to that seen in Family 1492; parental DNA would need to be obtained, though this 
conclusion seems likely. 
The haplotypes surrounding the three mutations of CNGA3 were also examined. First, the 
haplotype surrounding c.1580 T>G in Family 1492 was examined, as we had the most samples 
available for genotyping, and we knew that family members were homozygous for this mutation. 
This haplotype (Figure 3.3) segregates with the disease phenotype except for the most terminal 
marker D2S2 18 7, which varies significantly between affected individuals. Like the situation for 
the CNGB3 haplotypes, we were only able to obtain one sample from fami lies 1723 , and 1726, 
and a ll possible genotype combinations are shown in Figure 3.3 . The disease haplotype is also 
observed in Family 1723 , who was compound heterozygous for c.1580 T>G and c.l279 C> T. 
The common haplotype seen in families 1491 and 1723 sunounding the c .1580 T>G mutation 
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suggests that these two families may share a common ancestor. The only other report of this 
mutation was in a population of European origin and was identified through exome sequencing. 
As the Newfoundland population is ofNorthern European origin, it would be interesting to 
examine if the c.1580 T>G mutation was on a common haplotype, suggesting a founder mutation 
ofEuropean origin. Interestingly, the c.1279 C>T mutation, which was shared between families 
1723 and 1 726 appeared to be on two separate hap1otypes, suggesting that this mutation has 
occurred on separate genetics backgrounds and could potentially be a recurrent mutation. This 
would need to be confirmed on samples from various populations. 
Two unsolved families, 1734 and 0094 remained after the initial screens of CNGA3, 
CNGB3, GNAT2, and PDE6C. The sample from Family 1734 showed only one mutation in 
CNGB3, c.ll48delC and a second mutation was unable to be found. Screening of PDE6C 
showed an interesting sequence anomaly (Figure 3.4), which was at first hypothesized to be due 
to an insertion/deletion causing a frameshift, followed by a second insertion/deletion renewing 
the reading frame. Cloning experiments revealed that this was not the case in this sample, and 
showed that one strand in fact showed 99.2% sequence similarity to a region on chromosome 8. 
It was then hypothesized that this abnormal looking sequence was caused by a potential 
translocation event from chromosome 8 to chromosome 10, and that we had sequenced the 
breakpoint of insertion. A number of primer combinations revealed that the primers PDE6C-
17+ 18-F and -R were in fact binding to other regions ofthe genome, and that this result was 
most likely due to the primers binding to this region in Chr8. It was also noteworthy that this 
region was particularly difficult to amplify, and sequence using these primers and that sequences 
from family 0094 did not show this particular variation, but sequences surrounding this region 
were of poor quality. A new primer set was designed and sequenced in all samples which 
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showed much more efficient amplification and sequencing results, revealing no pathogenic 
variations. Unfortunately, this case remains unsolved though it remains likely that the second 
mutation is to be found in a controlling region surrounding CNGB3 ( enchancer, repressor, splice 
variation) as the subject contains one mutation in this region already ( c .ll48delC). 
The most interesting result of this study comes from the remaining unsolved family 0094 
who showed no pathogenic variants, or common haplotypes amongst affected individuals in 
CNGA3, CNGB3, GNAT2, or PDE6C (Figure 3.8-3. 11 ). Exome sequencing of individuals from 
this fami ly revealed a novel nonsense mutation (c. l555 C>T: p.R519X) in CNNM4, the only 
gene known to cause Jalili syndrome, an extremely rare syndromic form of cone-rod dystrophy. 
The presence of a homozygous nonsense mutation in CNNM4, documentation of abnormal 
dentition in the archived medical records and the progressive nature of the retinal phenotype 
support the revised diagnosis of Jalili syndrome in Family 0094. The dental phenotype was 
missed in the initial assessment as the siblings were young adults when seen, and had dentures. 
Dental extraction and replacement with dentures was a common treatment for common dental 
caries in rural Newfoundland due to lack of routine dental services, thus the dental phenotype 
was missed at first examination. 
CNNM4 shows high sequence similarity to the cyclin family of genes, and although it has 
no cyclin activity in vivo, may play a role in metal ion homeostasis, as it interacts with the metal 
ion chaperone COXl l 190 and shows sequence simi larity to a known magnesium transporter 
CNNM2. 191 Others have shown that CNNM4 is expressed in both the neural retina and 
ameloblasts of developing teeth, supporting a role for CNNM4 in both the phototransduction 
cascade and in the biomineralization ofteeth.191 Based on the amino acid sequence similarity to 
CNNM2, we used both the CNNM2 crystal structure192 and the known domains of CNNM4 
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(Transmembrane, CBS, DUF21, and Cyclic nucleotide binding domains) 191 to produce a 
hypothetical structure of the 775 amino acid CNNM4 protein (Figure 3.12C), on which we have 
indicated the nine previously seen mutations. 187: 19 1: 193- 196 The novel transition (c.l555 C>T) 
identified in Family 0094 is located within exon 3 of CNNM4, and the resulting nonsense 
mutation (p.R519X) resides between the cyclin and CBS domains of the CNNM4 protein (Figure 
3.12C). It is predicted, that because the c.1555 C>T mutation occurs >50 bases from the terminal 
exon, the CNNM4 mRNA transcript would undergo non-sense mediated mRNA decay.188 
Whole exome/whole genome approaches hold promise for clinical diagnostics, 
particularly when targeted gene screening has failed to yield the underlying etiology. In this 
report, the molecular diagnosis was critical to making the correct clinical diagnosis. There will 
be times when grouping clinical features in individuals assumed to have only one disorder may 
not be appropriate as it is also possible to have a combined phenotype caused by mutations in 
more than one gene. This was recently illustrated in a study which describes a patient with Jalili 
syndrome and Neurofibromatosis type 1, due to mutations in both CNNM4 and NF 1. 196 
This study used a combination of functional candidate gene screening for cases of 
achromatopsia, whole exome sequencing, and a review of archived medical records to identify a 
novel disease-causing mutation in CNNM4 and a heretofore-unrecognized diagnosis of Jalili 
syndrome. We describe a number of disease causing mutations in CNGA3 and CNGB3 in 
achromatopsia as well as the first case of Jalili syndrome in North America and show the value 
of next generation sequencing as a diagnostic tool. In combination with accurate medical records 
this molecular data can be used not only to explain unsolved disease cases, but also to confirm or 
revise diagnoses. 
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Chapter 4: A Rare Form of Microphthalmia Associated with Proportionate 
Dwarfism (MDW) is Linked to a Large Region on Chromosome 16. 
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4.1 Summary 
This thesis chapter describes two families (0066 and 1499) from the South coast of 
Newfoundland with a Hallerman-Streiff like syndrome, which we refer to as Microphthalmia-
Dwarfism (MDW). The patients presented at bi11h with microphthalmia, a reduced axial length 
of the ocular globe and developed cataracts and corneal opacities at an early age, causing a loss 
of visual acuity. These patients were also noted, over time, to have short stature with 
proportionate limbs, as well as a progressive loss of hair (hypotrichosis), frontal bossing, and 
pointed nose due to loss of facial fat deposits. The phenotype has been described to be similar to 
that of the very rare Hallermann-Streiff Syndrome (Francois Dyscephalic Syndrome), a condition 
characterized by dyscephaly (malformation of the cranium and bones of the face), hypotrichosis, 
microphthalmia, cataracts, beaked nose, micrognathia, and proportionate short stature 
(dwarfism). It is possible that the MDW phenotype described here may be part of a spectrum 
including Hallermann-Streiff syndrome and the causative genes in these two conditions could 
play roles in similar or related pathways. We obtained a total of 31 DNA samples (five from 
affected individuals, 26 from unaffected individuals) across these two fami lies and performed 
Homozygosity Haplotyping (HH) and Linkage analyses using SNP genotypes from a 61 OK 
Illumina SNP array. These analyses suggested two overlapping regions on Chr16q21 (Linkage: 
30cM, HH: 8cM). Twenty-three genes were chosen in the overlapping 8cM region of 16q21 as 
determined by the HH analysis and bidirectionally sequenced. inety-eight variants were 
discovered in this screen, though none were determined to be pathogenic, but in combination 
with microsatellite markers were used to reduce the critical region to - 3cM. Exome sequencing 
was performed, and filtering for variants with emphasis on the 3cM critical region revealed no 
pathogenic variants shared between these two families. 
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4.2 Introduction 
-1. 2.1 What is Microphthalmia, and how is it caused? 
Microphthalmia is a condition which exists as part of a spectrum of disorders involving 
the formation of the globe of the eye (a detailed description of embryological globe formation 
can be found in Chapter 1 of this thesis). This spectrum includes anophthalmia (clinically 
defined as the lack of eyes) and coloboma, caused by improper closure of the choroidal 
fissure. 197 Combined, these malformations have a global incidence of 2110,000 live births, can 
affect one (unilateral) or both eyes (bilateral), and 1/3 of individuals with these malformations 
have extraocular features. 198 During embryogenesis, the formation of the eye is mediated by five 
broad embryological steps: 1) Optic vesicle outgrowth, 2) Optic lens/cup formation 3) Optic 
fissure closure 4) anterior and posterior chamber formation, and 5) and functional maturation. 199 
Interruption of any ofthese processes can lead to the many malformations involving the anterior 
chamber or to the globe as a whole. These processes are regulated by a number of important 
gene-gene and tissue-tissue interactions, controlled by important transcription factors expressed 
during embryogene i . 
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4. 2. 2 The Genetics of Microphthalmia 
The spectrum of anophthalmia and microphthalmia is caused by a wide range of 
transcription factors involved in the development of many components of the eye, nervous 
system, and other embryological structures. These genes include, but are not limited to OTX2, 
PAX6, SOX2, RAX, VSX2 , BCOR, CHD7, BMP4, FOXE3, STRA6, SMOCI , MITFand SIX6. 
(i) OTX2 (OMIM 60003 7) 
The Orthodenticle homeobox 2 gene (OTX2) is a five exon gene located on 14q21-22 
coding for a 297 amino acid protein. This transcription factor is a member of the bicoid sub-
family of homeodomain containing proteins, and is thought to play a role in the formation of 
various sensory organs, and brain structures. Mutation of OTX2 has been associated with both 
anophthalmia and microphthalmia in an autosomal dominant form, particularly in syndromic 
microphthalmia 5 (MCOPS5; OMIM #610125) which consists of various ocular phenotypes 
such as microphthalmia, coloboma, microcornea, or cataracts, as well as extraocular features 
such as developmental delay, joint laxity, and seizures. This condition has shown examples of 
both variable expression and incomplete penetrance in the literature. 197 
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(ii) SOX2 (OMIM I 84429) 
The SRY-BOX2 (SOX2) gene is quite possibly the most clinically relevant gene to studies 
of microphthalmia, being mutated in 10-20% of patients with bilateral defects. 199 This single 
exon gene located on 3q26.3- q27 encodes a 317 amino acid gene that works with a large number 
of other transcription factors such asP AX6 and OTX2 due to its low binding affinity to DNA via 
a C-terminal transactivation domain. 197 This very important gene is expressed in embryonic stem 
cells, and is responsible for early organogenesis in the central nervous system, 197 and in ocular 
tissues. In Xenopus (frog) studies, it has been shown to be involved in cellular proliferation as 
well as the differentiation of cells into non-neuronal cell types in the eye.200 Mutation of this 
gene is associated with syndromic Microphthalmia 3 (MCOPS3; OMIM #206900), which 
includes many extraocular features (micropenis, cryptorchidism, motor disabilities, 
neurocognitive delays, febrile seizures etc.) as well as microphthalmia/anophthalmia or 
coloboma. 
(iii) PAX6 (OM!M 607108) 
For information pertaining to PAX6, please refer to section 2.2.2 ofthis thesis. 
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(iv) RAX (OMIM 601881) 
The Retina and Anterior Neural Fold Homeobox (RAX) is a three exon gene located on 
18q21.32 which encodes a 346 amino acid transcription factor. This transcription factor was 
originally isolated from a Xenopus eDNA library and is thought to be responsible for the 
establishment and proliferation of retinal progenitor stem cells.20 1 RAX contains a conserved 
sequence upstream of its promotor region which has been shown to be a binding site for OTX2, 
and SOX2 which act synergistically to upregulate RAX expression.202 Through sequencing of 
patients with sclerocornea and anophthalmia in 2004, this gene was also shown to be involved in 
the pathogenesis of the AIM spectrum. Two missense mutations in RAX occurred in the DNA 
binding domains.203 
(v) VSX2 (AKA CHX10 OMIM 142993) 
The Visual System Homeobox Gene 2 VSX2 (AKA CHX10) was originally mapped to 
chromosome 14 in 1989. This gene produces a transcription factor of the homeobox family of 
factors, which is expressed in the developing retina204 and is generally thought to be a 
transcriptional repressor. 205 Mutations of this gene have been associated with autosomal 
recessive anophthalmia/microphthalmia with and without ocular coloboma in humans,205 
mice,206 and zebrafish.207 
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(vi) BCOR (OMIM 300485) 
BCL6 Corepressor (BCOR) , located on Xp 11.4, was cloned in 1990208 is known to 
repress transcription of BCL6 (OMIM I 09565), 209 a transcriptional repressor involved in 
formation of the germinal center in lymph nodes. Mutations of this gene have been associated 
with oculofaciocardiodental (OFCD) syndrome, a condition which includes 
microphthalmia/anophthalmia, anterior segment dysgenesis, with malformations of the facial 
structures (long philtrum, broad nasal tip, short nose etc), heart conditions (atrial and ventricular 
septal defect), and dental malformations.2 10 
(vii) CHD7 (OMIM 608892) 
Chromodomain Helicase DNA-binding protein 7 (CHD7), located on 8ql2.1 - 8ql2.2, IS 
a transcriptional regulator which binds elements in the nucleoplasm and is involved in the 
formation ofribosomal RNA.2 11 Most interestingly, CHD7 has been found to be expressed in 
undifferentiated neuroepithelium, which is instrumental in the formation of the eye. 212 Mutations 
of CHD7 have been associated with a condition known as CHARGE syndrome (Coloboma, 
Heart anomaly, choana! Atresia, Retardation, Genital hypoplasia, and Ear anomalies; OMIM 
#214800) which can include optic disc coloboma, and/or microphthalmia.2 13: 214 
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(vii) BMP4 (OMIM * II2262) 
Bone Morphogenic Protein 4 (BMP4), located on chromosome 14q22.2, is an important 
molecule in embryological signaling and is involved in the formation and development of the 
mesoderm, teeth, limbs, and also in bone induction/fracture repair.2 15 Consequently, mutations in 
BMP4 have been associated with a large number of disorders, including fibrodysplasia ossificans 
progressive,216 SHORT (Stature, Hyperextensibility of joints, Ocular depression, Rieger anomaly, 
Teething anomaly),217 and Orofacial cleft.215; 2 17 
(ix) FOXE3 (OMIM *60I094) 
For information pertaining to FOXE3, please refer to section 2.2.2 of this thesis. 
(x) STRA6 (OMIM *6I0745) 
Stimulated by Retinoic Acid 6 is a 20 exon gene located on 15q24.1 which produces a 
membrane receptor for Retinol Binding Protein I (RBP I) and mediates cellular uptake of 
vitamin A.218 This gene is thought to act in a time-dependent manner, but is also upregulated by 
increasing concentrations ofretinoic acid in the cell.219 Mutations in this gene have been 
associated with a syndromic form of microphthalmia, syndromic microphthalmia-9, which is 
often fatal at birth (or soon after) and includes respiratory malformations (unilobar lungs, 
pulmonary hypoplasia), cardiac malformations (atrial septal defect), and other organ system 
malformations (malrotation of the kidney). 
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(xi) SMOC1 (OMIM *606488) 
Spare-related Modular Calcium Binding Protein 1 was identified in 2002 through 
screening of a human fetal brain eDNA library.220 Mutations of SMOC1 have been associated 
with Waardenburg Anophthalmia syndrome, a condition characterized by ocular malformations, 
as well as limb anomalies.221 These findings suggest that SMOCJ has a role in both eye and limb 
growth and formation, though the exact role that it plays is currently unknown. 
(xii) MITF (OMIM *156845) 
Microphthalmia Associated Transcription Factor belongs to a class of transcription 
factors known as basic helix-loop-helix (bHLH) leucine zipper proteins. This class of 
transcription factors is involved in proper cellular formation, such as in the neural crest, which 
are important in ocular formation. 222 MITF has been an extensively studied gene, and is known 
to be involved in the formation of melanocytes which are important in the pigmentation of hair, 
skin, and eyes, and hearing function in the cochlea.223 The mouse MITF homologue, mi, has been 
shown to cause reduced eye size, and early onset deafness through changes in pigmentation in 
both ocular and ear structures.222 Mutations in MITF have been shown to cause Waardenburg 
Syndrome type II (OMIM 19351 0) which, much like the mouse model, shows early onset 
hearing loss, with microphthalmia. 
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(xiii) SIX6 (OMJM 606326) 
The Sine Oculis Homeobox 6 (SIX6) belongs to the SIX family of genes which are 
homologous to the ' sine oculis' (so) genes found in Drosophila. These genes produce a protein 
located in the nucleus which is required for development of the eye. Deletions of areas 
surrounding SIX6, on chromosome 14q23 have been observed in patients with bilateral clinical 
anophthalmia, and pituitary anomalies,224 though very few mutations in the SIX6 gene itself have 
been found (one mutation thought to be pathogenic is p.T 165A).225 
4. 2. 3 Hallermann-Stre !ff Syndrome 
Hallermann-Streiff syndrome (HSS; Francois Dyscephalic Syndrome) was a condition 
originally described in 1893 by Aubry, though was redescribed by Hallerman in 1948 and Streiff 
in 1950, which expanded the phenotype and separated it from other similar disorders (progeria, 
and mandibulofacial dysostosis).226 This condition is a very rare syndrome characterized by 
dyscephaly (craniofacial malformations), hypotrichosis (thinning of the hair on the head and 
pubic regions), microphthalmia, cataracts, beaked nose, micrognathia (small jaw), and 
proportionate short stature (dwarfism).226 Other manifestations do exist for this condition, though 
are not necessarily seen in all HSS patients, such as cardiovascular abnormalities,227 progeria,228 
dental abnormalities,229 and respiratory problems.230 HSS is typically thought to be a sporadic 
condition,226 though cases of HSS-related syndromes, or atypical HSS inherited in families have 
been described, though the mode of inheritance ofHSS is still not agreed upon. Recently, a 
condition with some overlapping features ofHSS, called Oculogentogigital gysplasia (ODDD 
OMIM: 164200) was shown to be caused by mutations in the gap junction protein, CX43.23 1 The 
gene for this connexin protein, GJA 1, was analyzed in a patient with an overlapping phenotype 
of ODDD and HSS, and mutations were found at a highly conserved Arginine residue. A second 
Page 154 of 257 
patient was analyzed for mutations in GJA 1, who had a full blown HSS phenotype, though no 
mutations were found .232 
-1. 2. -1 Current Study 
This thesis chapter will examine a never before reported form of syndromic 
Microphthalmia which is herein referred to as Microphthalmia-Dwarfism (MOW). MOW was 
noted in two families from the South coast ofNewfoundland in an apparent autosomal recessive 
fashion. Patients from these two families had microphthalmia, proportionate short stature, 
hypotrichosis, frontal bossing of the forehead, as well as a pointed nose due to the lack of fat 
deposits. This condition interestingly shows overlap with a similar condition called Hallem1ann-
Streiff syndrome (HSS; OMlM 2341 00), a condition characterized by all the aforementioned 
features but can also have micrognathia (small jaw), dental abnormalities, heart defects, and 
premature aging (progeria). HSS has previously been associated with GJA 1 in one patient.Z31 
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4.3 Materials and Methods 
4.3. 1 Patients and Clinical Observations 
We obtained DNA from 29 individuals as per section 2.3.3 on page 66 (five affected, 24 
unaffected) from two families who reside on the southern coast of the island of Newfoundland, 
Canada. We were also able to obtain detailed medical records on the five affected individuals 
who contributed DNA, and two additional affected members from family 0066 who were 
deceased at time of sample collection. 
4. 3. 2 SNP Genotyping 
Twenty-nine DNA samples (including DNA from all five affected individuals) were 
outsourced to the Genome Center at McGill University, Montreal, Quebec to undergo SNP 
genotyping on a 610K Jllumina SNP array. 
4. 3. 3 Homozygosity Haplotyping 
The SNP data was then analyzed using the homozygosity haplotyping (HH) method as 
described by Miyazawa et al. (2007).233This is a non-parametric method where all SNPs with a 
heterozygous allele are discarded from the dataset and only those S Ps with a homozygous 
genotype are kept. This allows for a ' Region of Common Homozygous Haplotype' (RCHH) to 
be constructed which, due to the lack of heterozygosity, is already in phase. This method is most 
useful for distantly related affected relatives, as siblings would share a large amount of 
homozygous haplotypes (HHs) through inheritance of the same parental material. Distantly 
related affected individuals are more likely to share common HHs without interference from 
sharing the same parental DNA. 
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-1.3.-1 Two-point and Multipoint Linkage Analysis 
The S P genotype data from the Illumina chip was given to biostatisticians at The Centre 
for Applied Genomics (TCAG) in Toronto, Canada. A number of techniques were used to 
determine LOD scores for these families. A model of autosomal recessive inheritance and a 
disease allele frequency of 0.001 were used for these analyses. 
(i) Theoretical Maximum LOD Scores 
The statisticians at TCAG generated a theoretical maximum LOD score for both families. 
This was performed using a simulated marker which segregates with the autosomal recessive 
disease phenotype, and a LOD score is calculated from this simulation. This score indicates the 
maximum possible score given perfect conditions and can be used as a method to evaluate the 
power of a pedigree before undertaking linkage analyses. 
(ii) Multipoint Linkage Analyses 
Multipoint linkage analysis was carried out on both families using a program called 
Merlin. This analysis required pruning of the pedigrees, which removed extraneous members 
from the pedigrees in order to maximize effectiveness and reduce time for analysis. The pedigree 
fo r Family 1499 was reduced to the 10 individuals from which we obtained DNA, across four 
generations. The pedigree for Family 0066 was reduced to those with samples, and necessary 
individuals to connect them. Relationships between pedigrees were also analyzed. 
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(iii) Full pedigree analyses 
In order to perform multi-point linkage analyses using the entire pedigrees, a program 
called SimWalk2 was used. SimWalk2 does not evaluate the LOD score exactly at the SNP 
positions, but instead provides scores at positions between the markers. Results from this 
analysis were summarized by taking the average of the LOD scores on the left and right of each 
SNP. The set ofSNPs used was pruned for quality, minor allele frequency, and linkage 
disequilibrium, and then every third marker was selected (for speed). 
The statistician used an approximate parametric analysis using Markov chain Monte 
Carlo as implemented in SimWalk2. Parameters included an autosomal recessive model, ful ly 
penetrant, with a disease allele frequency of 0.0001. In order to reduce the amount of time for 
analysis using large pedigrees, a total of 6617 SNPs were analyzed on the autosomes (the X 
chromosome was not analyzed). 
4. 3. 5 Sanger Sequencing of Positional Candidate Genes 
Seven samples (five affected, and two unaffected) were selected for screening of 
positional candidate genes (Fam 0066: IV-4, IV-13, and V-2 Fam 1499: III-2, IV-1 , and IV-2). 
We used the smaller 8cM region as determined by the HH analysis to select 23 positional and 
functional candidate genes for initial Sanger sequencing (Table 4.2). Primers were custom 
designed for all exons of ARL2BP, BBS2, CJ 60RF5 7, MMP 15, and HERPUDJ (Appendix L) 
using Primer3 Software (http://frodo.wi.mit.edu/). All primers were checked for specificity using 
the UCSC in silica PCR tool from the UCSC Genome Bioinformatics Database 
(http://genome.ucsc.edu/). PCR was set up as per Appendix A l using a Touchdown 54 program 
(Appendix B) and size fragmented on a 1% agarose gel stained with SYBR safe for confirmation 
of amplification. Bidirectional Sequencing of all amplicons was carried out using the protocol 
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outlined in Section 2.3.3 of this thesis and was run on an ABI 3130xl or ABI 3730. The other 18 
genes were sequenced at the Genome Center in McGill University on an ABI 3730. 
4. 3. 6 Variant Analysis 
All sequences were manually inspected using Mutation Surveyor 4.0.4 (Transition 
Technologies) and were double checked by two individuals (LD and DG). All identified variants 
were checked in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) and minor allele 
frequencies (MAF) were recorded from dbSNP and the 1000 Genome Project 
(www.lOOOgenomes.org). Variants with no rs numbers from dbSNP, or with low MAFs, and 
which could have a potential effect on protein function (i .e. nonsense mutation, missense 
mutation, splice variation) were checked for segregation on families 0066 and 1499. In silica 
analyses of each missense mutation and splice variation were carried out using SIFT (Sorting 
Intolerant From Tolerant),234 PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and 
PANTHER (Protein ANalysis THrough Evolutionary Relationships). 180 
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4.4 Results 
4. 4.1 Patients and Clinical Observation 
Seven affected individuals from both families (five from 0066 and two from 1499) 
(Figures 4.1-4.4) underwent clinical and ophthalmological assessment (Table 4.1 ). All the 
affected individuals were consistent in the diagnoses of microphthalmia, short stature, cataracts 
and other forms of anterior segment dysgenesis (glaucoma, corneal opacities/clouding), and the 
older affected individuals showed hypotrichosis. 
(i) 0066 V-4 
This female member of family 0066 was born in 1945 and is currently still alive. In 1971 , 
she was described as having NLP in both eyes, microcornea, microphthalmia, severe corneal 
opacities, bilateral glaucoma, and later had a bilateral enucleation and ocular implants placed. In 
2005, she was noted to be 119cm tall (<<3rd o/oile, 50th % for a 6.5 year old), and weighed 36.1 
kg (<3rd o/oile; 50111 o/oile for 6.5 year old). Pictures from when V-4 was younger showed that she 
had a full head of hair, but now at 60 years of age shows marked hypotrichosis, suggesting that 
this portion of the MD W phenotype may be later onset. Currently, she requires 2 liters of oxygen 
per day due to severe Chronic Obstructive Eulmonary Disease (COPD), and has generalized 
osteopenia with scoliosis. She is of normal intelligence, and communicates well though she has 
mild to moderate hearing loss related to frequent infections. A cytogenetic analysis was carried 
out on a sample from V -4, showing no major chromosomal abnormalities. 
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Symbol definitions 
0 0 Unaffected 
• • Micropthalmia-dvvarfism 
G 0 Carrier 
IT] ® Possibly aiiected 
~ ~ other eye clisease 
Figure 4.1- Circularized pedigree of Family 0066 with microphthalmia-dwarfism from 
Newfoundland. All the patients have unaffected parents, consistent with an autosomal recessive 
mode of inheritance. 
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II 
Ill 
Figure 4.2- Condensed pedigree of Family 0066 showing the four affected individuals (shaded) 
across three sibships. Individuals with numbers to the upper left of their symbol contributed 
DNA to this research project. We were able to obtain DNA and information on family members 
over four generations. Individuals who contributed DNA to this project are denoted by a number 
to the upper left of their symbol (except for V -15 and V -14, for whom medical records were 
available, but no DNA). 
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Figure 4.3 - Circularized pedigree of Family 1499. This pedigree illustrates a large number of 
individuals with only two affected brothers. 
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II 
Ill 
IV 
Figure 4.4 - Condensed pedigree of Family 1499 highlighting the one affected generation from 
the circular pedigree. Individuals with numbers to the top left of their symbol have contributed 
DNA to this research project, thus giving potential information from four generations of 
individuals. 
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0066 0066 0066 0066 0066 1499 1499 
V-4 V-13 V-14 V-15 VI-2 V-1 V-2 
YOB 1945 1940 1931 1949 1978 1998 1993 
Gender Female Male Male Male Female Male Male 
Microphthalmia + + + + + + 
Cataracts + + + + + + 
Anterior Segment 
Dysgenesis (Corneal 
+ + + + + + Opacities/Clouding, 
Glaucoma) 
Short Palpebral Fissues + + + + + + 
Nystagmus NA + + + + + 
Proportionate Short Stature + + + + + + 
Brachycephaly + + + + + + 
Beaked/Pointed Nose + + + + + + 
Micrognathia - - - - - -
Frontal Bossing + + + + + + 
Skeletal Malformations 
(Kyphosis, Scoliosis, etc) + + + - - -
Hypogonadism/Irregular 
+ + + + + + Periods 
Hypotrichosis + + + + - -
Skin Atrophy - + + + - -
Respiratory Issues (COPD, 
+ - + + - -Bronchitis) 
Dental Abnormalities* NA NA NA NA - + 
Hearing Loss + + + - - + 
NA: Not available. *: Most patients had dentures at time of observation. 
Table 4.1- Clinical information of the affected members from Families 0066 and 1499. 
Conditions noted with a + means the individual showed this phenotype, whereas a - symbol 
means that they did not. Listed conditions include the clinical features associated with 
Hallermann-Streiff Syndrome including dyscephaly, hypotrichosis, microphthalmia, cataracts, 
beaked nose, micrognathia, and proportionate short stature. All affected individuals have 
microphthalmia, short stature, beaked nose, frontal bossing, short pa lpebral fissures, and an 
anterior segment phenotype (including cataracts, nystagmus, and/or corneal opacities). Only the 
o lder individuals exhibit Hypotrichosis, respiratory issues, and frequent infections. 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
-
+ 
-
-
-
-
+ 
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(ii) 0066 V-13 
This male member of family 0066 was born in 1940 and passed away in 1994. Cl inical 
examinations showed frontal bossing of the forehead, hypotrichosis of both the head and pubic 
region, and microphthalmia. Ophthalmological examination in the late 70s showed rro light 
gerception (NLP) in the left eye, indicating total blindness, and light _Qerception (LP) in the right 
eye. He was noted to have microphthalmia, severe optic nerve damage due to glaucoma, 
cataracts in the right eye, and horizontal/vertical nystagmus bilaterally. He was measured to be 
127cm tall with a head circumference Jess than the second percentile at age 49. Further 
examination of medical records revealed chronic bronchitis and COPD along with skeletal 
dysplasia, hypogonadism, atrophic skin, and 50% hearing Joss due to frequent ear infections. At 
the time of death, he was described 71 kg in weight, though limbs were noted to be of 
proportionate size, consistent with proportionate short stature. He was also noted to suffer from 
Diabetes Mellitus, and Diabetes Insipidus indicating further endocrine system problems. 
(iii) 0066 V-14 
This male member of family 0066 was an older brother to 0066 IV-13 , being born in 
1931 and passing away in 198 1. Unfortunately, we were unable to collect DNA from this 
individual as he had died before we were able to obtain a sample, though we were able to obtain 
detailed medical records. In 1989, it was noted that he had only light perception in his right eye, 
and no light perception (NLP) in his left eye. He had been diagnosed with glaucoma and 
microcornea at age 14 V -14, like his younger brother, was described as having COPD and 
chronic bronchitis, which contributed to his death. He was also noted to have hypotrichosis of 
the head and pubic region, dry atrophic skin, hypogonadism, severe osteoporosis, kyphosis, 
scoliosis, and hearing loss due to frequent infection. A small mandible was also observed, but no 
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mention of micrognathia was seen in the reports. At the time of death, he was 150 em tall and 7 5 
kg in weight. 
(iv) 0066 V-15 
This male member of family 0066 was born in 1949 and died in 1988. Ophthalmological 
examination showed that this individual had bilateral cataracts, nystagmus, microphthalmia, and 
NLP in both eyes. An autopsy report described V -15 as being 150 em in height and 60-70 kg in 
weight. DNA was unavailable from this individual. 
(v) 0066 VI-2 
This female member of fami ly 0066 was born in 1978, and is currently living. 
Ophthalmological investigations showed bilateral microphthalmia, short palpebral fi ssures, and 
bilateral cataracts. She had no vision in her right eye, with LP and colour discrimination in her 
left eye. At the age of27, she was noted to be 138.5 em tall (<3rd o/oile), and weighed 39.5 kg 
( <51h percentile) with a head circumference of 57 em (>971h o/oile ). She had no hypotrichosis, no 
skin atrophy, and no hearing loss or dental/jaw abnormalities. She is of normal intelligence and 
currently holds a Bachelor degree in Psychology. A karyotype was carried out on a sample from 
this individual which showed a normal chromosome count. 
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(vi) 1499 IV-1 
One of the two affected brothers of Family 1499, IV -1 , was born in 1993 and is currently 
sti ll alive. At birth, he was noticed to have horizontal pendular nystagmus, shallow anterior 
angles, bilateral corneal opacities, macular hypoplasia, and correctopia (displacement of the 
pupil). His birth weight (7lbs, 6oz) and length were normal, but at five years of age he was 
96.52 em tall (3rd %ile), weighed 34.5 kg (3rd %ile), and had a head circumference of 52.5 em 
(50111 %ile). He was of normal intelligence, and is currently attending school using assistive 
technologies because of his poor vision. He has had normal pubescent growth with facial and 
pubic hair growth (though has hypogonadism) and has not shown any hypotrichosis. Some dental 
abnormalities were noticed as he had thin enamel and soft teeth. Human growth hormone tests 
were carried out to determine if this was the cause of his short stature, though these tests came 
back normal. At 16 years, he was 151.5 em tall (<3rct %i le), and weighed 87.9 kg (90-97'h %ile) . 
He sti ll did not exhibit any hypotrichosis at this age. 
(vii) 1499 IV-2 
The younger brother of 1499 IV -1 , 1499 IV -2, was born in 1998 with normal birth weight 
(7lbs, 4oz). In 2010, he was 134 em tall (3rd %ile), weighed 33 .2 kg (25-50%ile) and had a head 
circumference of 55 em ( + 1 SD). He was severely photophobic, and had microphthalmia, short 
palpebral fissures, and had multiple surgeries to remove cataracts and to alleviate symptoms of 
glaucoma. His visual acuity at 9 years of age was 20/800 in his right eye, and NLP in his left eye. 
His nose was described as thin, delicate, and pointed with a short philtrum which was thin but 
well developed. There were no observed dental malformations, and he had normal dentition. He 
was also noted to have hypogonadism. Like his brother, he was not noted to have hypotrichosis, 
or any respiratory issues, and was of normal intelligence. 
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4.4.2 Homozygosity Haplotyping (HH) Analysis 
The genotype data from the Illumina 61 OK SNP array underwent HH analysis by 
bioinformaticians at the McGill Genome Center in Montreal, Quebec, Canada. By using a 
theoretical cutoff of > 3 centimorgans we identified a homozygous haplotype shared across all 
five affected individuals, on chromosome 16q 12.2-21 (Figure 4.5). This region ranges from 
Chr16:55661080-62017481 and contains 136 genes according to the BIOMART tool from the 
Ensembl Genome Browser (http://useast.ensembl.org/index.html). 
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Figure 4.5- HH analysis from the SNP genotyping of Families 0066 and 1499. A cutoff of>3cM reveals 
two regions of Region of Common Homozygous Haplotype (RCHH). The region on chromosome 16 
spans 8.5cM and is bordered by rs28971 0 and rs219568. A second region can also be noted on 
chromosome 3 bordered by rs11922267 and rs4602330 which spans 2.3 eM. 
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4. -1.3 Linkage Analyses 
(i) Theoretical Maximum LOD score 
Theoretical LOD scores were calculated at the Toronto Center for Applied Genetics 
(Nicole Roslin) for both family 1499 and 0066 to gauge the power of both pedigrees for linkage 
analyses. Family 1499 was a straight forward analysis containing four generations of people al l 
linked through I 0 DNA samples. The theoretical maximum LOD score for this family was 
0.602. The second pedigree, 0066, was more complicated due to the size of the pedigree, and the 
number of individuals between family members which had no genotypes. There are three 
individuals in fami ly 0066 with D A who are known to be affected. Analysis also suggested a 
very distant relationship between 1499 II -1 and 0066 IV -13, though the exact relationship was 
unclear. There were no inbreeding loops known, though it is likely that several ofthe founders 
are distantly related due to the geographic location on the sparsely populated South coast of 
ewfoundland. 
Under a fully penetrant autosomal recessive model, a disease causing a llele must be 
entering Family 0066 at least four times, complicating this analysis. To alleviate the conditions 
here FastLINK 3.00 was used to simulate a completely informative multi-allelic marker which 
was linked to the disease locus. Each replicate was analyzed using Superlink 1.7 under the same 
model as the generating model. The disease causing allele was assumed to have a frequency of 
0.0001. To avoid the ambiguity of having un-genotyped individuals in the pedigree, everyone 
was assumed to have genotypes. This method provided a maximum LOD score for Family 0066 
of 3.957 after 1000 simulations. Since LOD scores can be additive when a disease is believed to 
be caused by the same locus in two or more families, the total LOD score for families 0066 and 
1499 was calculated to be 4.559 
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(ii) Multipoint Linkage Analyses 
Multipoint parametric analysis was carried out using Merlin. Unfortunately, this places 
computational limits on the analysis due to the size of the pedigrees. Both pedigrees were pruned 
and analysis was run using an autosomal recessive model with full penetrance and a disease 
allele frequency of0.0001. This analysis revealed a LOD score of 4.539 (8 =0) at SNP 
rsl875233 on chromosome 16ql2.2, only 0.020 away from the theoretical maximum LOD. The 
next highest LOD score (0.403) was seen on chromosome 18 at rs4594329 (Figure 4.6) 
Sim Walk2 does not evaluate the LOD score exactly at the SNP positions, but instead 
provides scores at positions between the markers. These results were summarized by taking the 
average of the LOD scores on the left and right of each SNP. The set of SNPs used here was 
after pruning for minor allele frequency and linkage disequilibrium, and then every third marker 
was selected (for speed). 
Since SimWalk2 does not provide LOD scores at each SNP, obligate recombinants 
cannot be observed. Therefore, LOD scores were calculated at each SNP using a singlepoint 
analysis. This used an exact procedure, and the complete pedigrees were used. However, since 
it was a singlepoint analysis, the LOD scores were quite a bit smaller. The maximum LOD score 
was ~2 . 2. However, the obligate recombinants are noted with a LOD score of -1000, and so the 
linked region is bounded by rs2024477 and rs4887996. This is, however, a large region of about 
33 eM. The region bounded by rs4131945 to rs4387626 (about 19 eM), linkage is never 
excluded, meaning that the LOD score never drops below -2. The set of SNPs used here was 
after pruning for minor allele frequency and linkage disequilibrium. 
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Figure 4.6 - Multipoint linkage analysis performed using Merlin and trimmed pedigrees. A total 
of 6627 SNPs were used to perform the analysis. A model of autosomal recessive inheritance and 
a disease allele frequency of 0.0001 was used. One region exhibited a maxLOD score of 4.539 (8 
=0) at SNP rsl875233 on chromosome 16ql2.2. The second highest LOD score from this 
analysis was 0.403 at rs4594329 on chromosome 18. 
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4. 4. 4 Sanger Sequencing of Positional Candidate Genes 
Initially, we used the smaller region on chromosome 16q21 bound by rs28971 0 and 
rs219568 as determined by the HH study which spanned 8.5 eM and contained 136 genes. We 
selected 23 genes based on function, previous association with disease, and potential 
involvement in the MOW phenotype (Table 4.2). In addition to the coding genes in this region, 
primers were designed to amplify SNORA46 and SNORA50 along with 10 other non-coding 
genes including micro RNAs (miRNAs) and other snoRNAs (Appendix M) which existed in the 
much larger linkage region. Sequencing of these 12 additional non-coding genes revealed no 
variants in any of the DNA from affected individuals or from two unaffected family members 
(0066: III-4 1499: III-2). These genes were sequenced either at Memorial University or the 
Genome Center at McGill University and 98 variants were discovered upon analysis (Table 
4.2).Three genes (NDRG4, SETD6, and GOT2) contained mutations which were of particular 
interest. 
(i) NDRG4 c.873+3 G>A 
This mutation was of interest due to its proximity to the intron exon boundary of exon 14 
within NDRG4. Mutations close to this boundary have the potential to disrupt proper splicing 
patterns by either exon skipping, or intron inclusion. NDRG4 873+ 3 G>A is seen in the 1000 
Genome Project' s database, but shows a Minor Allele Frequency (MAF) of 0.02% in a British 
and Puerto Rican population (Accessed June, 20 12), and has never been seen as a homozygote 
according to the individual genotypes within the database. This mutation was found in one of 
142 (0.7%) screened control chromosomes from the island ofNewfoundland. The potential 
effect of this variant was tested by designing three primers, which when multiplexed, would 
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Table 4.2- Table of all sequencing variants found in the 23 selected genes from the HH region. 
All variants are named according to HGVS guidelines. Columns include position of the mutation 
within the gene (intron, ex on, or UTR), any effect on the protein, dbSNP ID (if available), Minor 
Allele Frequency (MAF) from the 1000 Genome Project, whether the variant segregates in an 
AR fashion with the MDW phenotype, and SIFT/PolyPhen-2 Scores for missense variants. 
Gene Protein MAF Disease 
Gene Variant Position Effect dbSNP 10 dbSNP Segregation SIFT Score PolyPhen Score 
HERPUDl c.1-146 G>A 1 (5' UTR) NA rs37025 26.20% Yes NA NA 
c.1-86 T>G 1 (5' UTR) NA rs37024 41.80% No NA NA 
c.554+23 G>C lntron 5 NA NA NA No NA NA 
c.554+64 A>G lntron 5 NA rs2133783 38.30% Yes NA NA 
CPNE2 c.180+86 A> T lntron 2 NA rs8053682 41.30% No NA NA 
c.180+87 G>C lntron 2 NA rs8047463 41.13% Yes NA NA 
c.1061+319 G>T lntron 11 NA NA NA No NA NA 
c.1302+39 C>G lntron 14 NA rs2305693 7.86% Yes NA NA 
ARL2BP No Variant s NA NA NA NA NA NA 
CIAP/Nl c.-131 G>A 5'UTR NA NA NA NA NA NA 
c.154 C>G Exon 2 Q52E rs11557674 3.29% No Tolerated Benign (0.069) 
c.157+16 C>T lntron 2 NA rs72780616 3.29% No NA NA 
POLR2C c.137-24 A>G lntron 2 NA rs223839 48.95% Yes NA NA 
c.174 T>C Exon 3 VlSOV rs4937 27.47% Yes NA NA 
c.387+8 C>T lntron 5 NA rs601194 46.90% Yes NA NA 
c.439+ 100 G>A lntron 6 NA rs223874 26.51% Yes NA NA 
CCDC102A c.286 C>T Exon 2 R96W rs12935069 4.20% Yes Tolerated Benign (0.00 ) 
c.585+82 A>G lntron 2 NA rs8045906 48.40% Yes NA NA 
c.825 G>A Exon 4 A275A rs28446687 18.37% Yes NA NA 
GPR114 c.-7 G>A 5' UTR NA rs1004363 43.05% Yes NA NA 
c.140+181 C>T lntron 3 NA rs1859259 40.22% Yes NA NA 
c.140+269 G>A lntron 3 NA rs1859260 42.96% Yes NA NA 
c.846 C>T Exon 9 R282R rs9937918 46.44% Yes NA NA 
Probably Damaging 
CCDC135 c.151 G>A Exon 2 D51N rs55645458 1.55% No Tolerated (0.967) 
Possibly Damaging 
c.557 G>C Exon 5 (1865 rs7196016 28.15% Yes Tolerated (0.585) 
c.859-26 C> T lnt ron 6 NA rs12933056 17.78% Yes NA NA 
c.1077+22 G >C lntron 7 NA rs2122486 17.69% Yes NA NA 
Probably Damaging 
c.1298C>T Exon 10 P433L rs3809611 19.70% Yes Deleterious (0.826) 
c.2296 T>C Exon 16 C766R rs2923147 38.44% Yes Tolerated Benign (0.00) 
KIFC3 c.381+105 T>C lntron 4 NA rs2965789 32.31% Yes NA NA 
c.699 T>C Exon 6 L233L rs2967165 33.82% Yes NA NA 
c.765+32 G>A lntron 6 NA rs2965790 47.35% Yes NA NA 
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c.765+62 T>C lntron 6 NA rs2967166 36.01% Yes NA NA 
c.939+72 T>A lntro n 7 NA NA NA Yes NA NA 
c.940-44 A>G lntron 7 NA rs3803590 33.82% Yes NA NA 
c.1803 C>T Exon 14 D601D rs2967172 47.30% Yes NA NA 
c.2003-21 T>A lntron 15 NA rs2965799 44.42% Yes NA NA 
C160RF57 c.99-36 G>A lntron 2 NA rs3743560 43.60% Yes NA NA 
c.265+43 C>G NA NA NA No NA NA 
c.S04-60 C> T lntron 5 NA rs4784022 49.68% Yes NA NA 
CCL22 c.S A>C Exon 1 D2A rs4359426 7.90% Yes Tolerated Benign (0.00) 
KATN81 c.289+65 A >G lntron 4 NA rs2967152 28.56% Yes NA NA 
c.704+4 C>T lntron 9 NA rs2965797 43.28% Yes NA NA 
c.726C>T Exon 10 024 20 rs2965798 47.07% Yes NA NA 
ZNF319 c.1536 G>A Exon 2 K512K rs3743556 35.33% Yes NA NA 
c.1749+20 A>G Exon 2 rs3743555 35.33% Yes NA NA 
MMP15 c.213-17 C>T Exon 3 NA rs2241774 22.12% No NA NA 
C160RF80 No variants NA NA NA NA NA NA NA 
CCDC113 c.628-249 G>C lntron 5 NA rs11076235 49.36% Yes NA NA 
c.628-242 C>G lntron 5 NA rs11076236 49.36% Yes NA NA 
c.628-117 C>T lntron 5 NA rs11076237 49.31% Yes NA NA 
PRS554 c.-6-16 G>A lntron 2 NA rs2288013 9.37% No NA NA 
c.75 T>C Ex on 3 Y25Y rs2288012 25.96% Yes NA NA 
c.263+56 A>G lntron 4 NA rs3803582 9.73% No NA NA 
c.263+60 T>C lntron 4 NA rs3803583 8.55% No NA NA 
c.263+61G>A lntron 4 NA NA NA No NA NA 
c.264-112 A>G lntron 4 NA rs4784916 31.17% Yes NA NA 
Probably Damaging 
c.544 A>G Ex on 6 5182G rs3815803 54.6% Yes Tolerated (76.7) 
c.718 G>A Ex on 7 V2401 rs1052276 9.69% No Tolerated Benign (0.122) 
c.883 A>G Ex on 7 T295A rs2241414 9.69% No Tolerated Benign (0.000) 
NORG4 c.223+90 G>A lntron 4 NA rs2427787 30.62% Yes NA NA 
c.612+ 13 A>G lntron 9 NA rs2271948 41% Yes NA NA 
c.612+ 77 A>G lntron 9 NA rs40185 100%* Yes NA NA 
c.672 G>A Exon 10 V224V rs17821543 4.07% Yes NA NA 
c.873+3 G>A lntron 14 NA rs142344402 0.002% Yes NA NA 
c.1062 A>G Exon 16 53545 rs42945 21.34% Yes NA NA 
SETD6 c.193 T>C Exon 2 L65L rs4784046 26.14% Yes NA NA 
c.263-64_263-50dup lntron 3 NA NA Yes NA NA 
c.902-77 G>A lntron 7 NA rs2280397 45.98% Yes NA NA 
c. 1338 G>A Exon 9 E446E rs3607 25.50% Yes NA NA 
c.*26 G>A 3'UTR NA rs3169293 4.16% Yes NA NA 
CNOTl c.103-32 C>G lntron 2 NA rs34014750 4.16% Yes NA NA 
c.1216-69 G>A lntron 11 NA rs72790275 25.50% No NA NA 
c.1584+22 dup T lntron 11 NA NA NA Yes NA NA 
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c.1704+ 110 G>A lntron 14 NA rs9936144 22.53% No NA NA 
c.2332+99 G>A lntron 18 NA rs41445346 20.48% No NA NA 
c.2891+43 C>T lntron 21 NA rs1568399 46.12% Yes NA NA 
c.2919 G>A Exon 22 Q973Q rs11866002 46.12% Yes NA NA 
c.3201 + 124 G> T lntron 23 NA rs7184114 35.29% No NA NA 
c.4006+ 12 A>G lntron 29 NA rs224 1570 46.16% Yes NA NA 
c.4434+90 G>A lntron 31 NA rs41260 21.70% Yes NA NA 
c.4716 C>T Exon 34 Y1572Y rsll540994 46.16% Yes NA NA 
c.4801-83 G>A lntron 34 NA rs246195 22.35% Yes NA NA 
c.S415-61 G>A lntron 38 NA rs2244453 20.70% Yes NA NA 
c.5646+88 T>G lntron 39 NA NA NA No NA NA 
c.*82 G>A 3'UTR NA rs17821549 4 .16% Yes NA NA 
GIN 53 c.198 T>G Exon 3 L66L NA Yes NA NA 
GOT2 c.213 T>C Exon 2 N71N rs257636 32.08% Yes NA NA 
c.228 T>G Exon 2 V76V rs14221 29.71% Yes NA NA 
c.246+252 C> T lntron 2 NA rs257634 41.91% Yes NA NA 
Possibly Damaging 
c.562 G>A Exon 5 G188S rsll076256 3.98% No Tolerated (0.727) 
c.816 C>T Exon 7 (272( rs1058192 28.47% Yes NA NA 
c.853+ 100_853+ 103del lntron 7 NA NA Yes NA NA 
c.1037 T>G Ex on 9 NA rs30842 26.19% Yes NA NA 
SLC38A7 c.883+19 deiC lntron 8 NA NA Yes NA NA 
c.l286+51 T>C lntron 11 NA rs9923128 34.69% Yes NA NA 
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amplify a 232 bp fragment in eDNA, and a 675 bp fragment in gDNA (Figure 4.7). If the 
c.873+ 3 mutation caused an intron inclusion, a fragment of 350 bp would be amplified, whereas 
if the mutation caused exon skipping we would see no amplification, as the reverse primer exists 
in exon 15, which would be skipped. PCR using a touchdown thermocycler program revealed a 
232 bp fragment in two affected family members, and in one unaffected control that did not have 
the NDRG4 mutation, and a 675 bp in gDNA controls (Figure 4.7). 
(ii) SETD6 c.263-64 _263-50dupl5 
This mutation was of interest as it appeared to be a microsatellite expansion of a CCT 
repeat towards the middle of intron 2 and is not reported in dbSNP. It was hypothesized that this 
could potentially alter splicing patterns by affecting the position of the branch site towards the 
center of the intron. A set of primers was designed which would amplify a 1000 bp fragment in 
gDNA, and a 635 bp fragment in eDNA. PCR at TD54 using 5% DMSO showed a 635 bp 
fragment in the two affected control cDNAs and one unaffected eDNA (Figure 4.8). The eDNA 
samples from affected family members shown in lanes 2-4 ( 1499 IV -1 ) and 6-8 (1499 IV -2) 
show the same size fragment as that of the unaffected control sample who lacks this mutation in 
lanes 10-12 (Figure 4.8). No cell lines were available for testing from Family 0066. Interestingly, 
there was a second band weakly amplified in the eDNA samples between the 400-500 bp ladder 
standard, that did not amplify in the genomic DNA. This band corresponds to a second isofonn 
of SETD6 (NM _ 024860) where 2 18 bps are spliced out, leaving a 457 bp fragment. SETD6 is 
not known to be involved in eye development. 
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Figure 4. 7 - 2% Agarose gel run at I OOV for two hours. Lanes I and 18 contain a I 00 bp ladder used to 
determine fragment size. Lanes 2-3 contain eDNA from a Lymphoblastoid cel l line from individual IV-I 
offamily 1499 in triplicate. Lanes 6-8 contain eDNA from a Lymphoblastoid cel l line of affected 
individual IV -2 from fami ly 1499, and lanes I 0-12 contain eDNA from an unaffected individual from 
another family with hereditary deafness (and does not have the NDRG4 mutation). All eDNA samples 
show a band at the expected 232bp position, but do not show the 675 bp fragment seen in gDNA (lanes 
14-16), which would suggest gDNA contamination. Ifthe c.873+3 mutation caused splice alterations the 
bands from the affected samples would be 350bp (intron inclusion) or would not have amplified (exon 
skipping) due to the position of the primers. The bands in the affected individuals coincide with that of 
the unaffected control sample, suggesting that the c.873+3 mutation in NDRG4 has no discernible effect 
on splice variation. 
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Figure 4.8 - 1% agarose gel ran at 100 volts for 1 hour. Primers were designed within exon 12 
and exon 15 of SETD6, which would amplify a 1000 bp fragment in gDNA, and a 675 bp 
fragment in eDNA. The eDNA samples (run in triplicate) seen on the gel all show a fragment 
between the 600 and 700 bp fragments on the ladder which corresponds to the expected 675 bp 
fragment but did not show the 1000 bp fragment existent in gDNA (seen in lanes 14-16) which 
eliminates the possibility of gDNA contamination. The bands from the sample lanes (2-4 and 6-
8) show a size consistent with that of the eDNA control (lanes 6-8), suggesting that the SETD6 
duplication has no discernible effect on splicing in this assay. An unexpected band between 400-
500 bp can be faintly seen under each eDNA sample. 
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(iii) GOT2 c.853+100_853+103del4 
This four basepair deletion was not found in dbSNP and occurred towards the center of 
an intron. It was suspected that this could affect the consensus sequence surrounding the branch 
point required for proper intron splicing. One-hundred f01iy two control chromosomes were 
screened from the Newfoundland population and found this mutation in 115 of them (- 80%). 
Due to the high frequency of this variant in the Newfoundland population, no further studies 
involving this variant were carried out. 
4.4.5 Haplotype Construction and Critical Region Reduction 
Analysis of positional candidate genes within the HH region revealed 98 variants in total. 
These genotypes were used along with genotypes from microsatellite markers surrounding the 
HH region (16q 12-21) to construct haplotypes amongst the five affected individuals, and two 
parents. Analysis ofthese haplotypes reduced the critical region to a region between a variant in 
HERPUDJ c.554+23 G>C and DJ6S3132 which spans approximately 3cM, decreased from the 
original 8cM as denoted from the HH analysis (Tables 4.3 and 4.4). 
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Table 4.3 - Table showing all variants and microsatellite marker genotypes in the five affected 
individuals across both families, used to define the critical region on chromosome 16q21 . The 
critical region is highlighted in yellow and can be defined between markers D 168673-D 1683132 
where the genotypes differ between all the affected individuals. This haplotype spans a region of 
~ 3 eM and is shared in a homozygous fashion between all five affected individuals and is 
heterozygous in two unaffected parents seen in Table 4.4. 
Family_0066 Family 1499 
IV-13 IV-4 V-2 IV-1 IV-2 
Allele Allele Allele Allele Allele A llele Allele Allele Allele Allele 
Gene Variant SNP# 1 2 1 2 1 2 1 2 1 2 
016$673 274 278 278 200 200 278 200 294 200 294 
HERPU01 c.1-146 G>A rs37025 A A A A A A A A A A 
c.1-86 T>G rs37024 T T T G T G T G T G 
c.554+23 G>C G G G c G c G G G G 
c.554+64 A>G rs2133783 A A A A A A A A A A 
CPNE2 c.180+86 A> T rs8053682 A A A A A A A A A A 
c.180+87 G>C rs8047463 c c c c c c c c c c 
c.1302+39 C>G rs2305693 G G G G G G G G G G 
CCL22 c.5 A>C rs4359426 c c c c c c c c c c 
CIAPIN1 c.-131 G>A A A A A A A A A A A 
c.154 C>G rs11557674 c c c c c c c c c c 
c.157+16 C>T rs72780616 c c c c c c c c c c 
POLR2C c. 1 37-24 A>G rs223839 G G G G G G G G G G 
c.174 T>C rs4937 c c c c c c c c c c 
c.387+8 C>T rs601194 T T T T T T T T T T 
c.439+1 00 G>A rs223874 A A A A A A A A A A 
01653057 195 195 195 195 195 195 195 195 195 195 
CCOC102A c.286 C>T rs12935069 T T T T T T T T T T 
c.585+82 A>G rs8045906 G G G G G G G G G G 
c.825 G>A rs28446687 A A A A A A A A A A 
c. 1140A>G rs28756858 G G G G G G G G G G 
c.1258+14 T>A rs28649020 A A A A A A A A A A 
GPR114 c.-7 G>A rs1004363 A A A A A A A A A A 
c.140+181 C>T rs1859259 T T T T T T T T T T 
c.140+269 G>A rs1859260 A A A A A A A A A A 
c.846 C>T rs9937918 T T T T T T T T T T 
CCOC135 c.151 G>A rs5564545 G G G G G G G G G G 
c.557 G>C rs7196016 c c c c c c c c c c 
c.859-26 C>T rs1 2933056 T T T T T T T T T T 
c.1077+22 G >C rs2122486 c c c c c c c c c c 
c.1298 C>T rs3809611 T T T T T T T T T T 
c.2296 T>C rs29231 47 c c c c c c c c c c 
KATNB1 c.289+65 A>G rs2967152 G G G G G G G G G G 
c.704+4 C>T rs2965797 T T T T T T T T T T 
c.726C>T rs2965798 T T T T T T T T T T 
KIFC3 c.381+105 T>C rs2965789 c c c c c c c c c c 
c.699 T>C rs2967165 c c c c c c c c c c 
c.765+32 G>A rs2965790 A A A A A A A A A A 
c.765+62 T>C rs2967166 c c c c c c c c c c 
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c.940-44 A>G 
c.1803C>T 
c.2003-21 T>A 
ZNF319 c.1536 G>A 
c.1749+20 A>G 
C160RF57 c.99-36 G>A 
c.265+43 C>G 
c.504-60 C>T 
MMP15 c.213-17 C>T 
CCDC113 c.628-249 G>C 
c.628-242 C>G 
c.628-117 C>T 
PRSS54 c.-6-16 G>A 
c.75 T>C 
c.263+56 A>G 
c.263+60 T>C 
c.263+61 G>A 
c.264-112 A>G 
c.544 A>G 
c.718 G>A 
c.883 A>G 
016$3038 
GINS3 
NDRG4 
SETD6 
CNOT1 
c.198 T>G 
c.223+90 G>A 
c.612+13A>G 
c.612+77 A>G 
c.672 G>A 
c.873+3 G>A 
c.1062A>G 
c.193 T>C 
c.263-64_263-50dup 
c.902-77 G>A 
c. 1338 G>A 
c*26A>G 
c.1 03-32 C>G 
c.976 A>G 
c.1216-69 G>A 
c.1584+22 dup T 
c.1704+110G>A 
c.2332+99 G>A 
c.2891+43 C>T 
c.2919 G>A 
c.3201+124 G>T 
c.4006+12 A>G 
c.4434+90 G>A 
c.4716 C>T 
c.4801-83 G>A 
c.5415-61 G>A 
c.5646+41 A>G 
c.5646+88 T>G 
rs3803590 
rs2967172 
rs2965799 
rs3743556 
rs3743555 
rs3743560 
rs4784022 
rs2241774 
rs11076235 
rs11076236 
rs11076237 
rs2288013 
rs2288012 
rs3803582 
rs3803583 
rs4784916 
rs3815803 
rs1052276 
rs2241414 
rs2427787 
rs2271948 
rs40185 
rs17821543 
rs42945 
rs4784046 
rs2280397 
rs3607 
rs3169293 
rs34014750 
rs72790275 
rs9936144 
rs41445346 
rs1568399 
rs11866002 
rs7184114 
rs2241570 
rs41260 
rs11540994 
rs246195 
rs2244453 
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c.•a2 G>A rs17821549 A A A A A A A A A A 
SLC3BA7 c. 883+ 19 deiC del del del del Del del del del del del 
c.1286+51 T>C rs99231 28 c c c c c c c c c c 
GOT2 c.213 T>C rs257636 c c c c c c c c c c 
c.228 T>G rs14221 G G G G G G G G G G 
c.246+252 C>T rs257634 T T T T T T T T T T 
c.562 G>A rs11076256 G G G G G G G G G G 
c.816 C>T rs1 0581 92 T T T T T T T T T T 
c.853+1 00_853+1 03del del del del del Del del del del del del 
c.1037 T>G rs30842 G G G G G G G G G G 
0 16$494 188 188 188 188 188 188 188 188 188 188 
0 16$3094 169 169 169 169 169 169 169 169 169 169 
016$3132 264 272 272 282 272 282 264 264 264 264 
0 16$3089 193 193 193 193 193 193 193 183 193 183 
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Table 4.4 - Table illustrating the haplotype presented in Table 4.3 within unaffected parents. The 
portion shared by the affected individuals is highlighted in yellow, and can be seen in the 
heterozygous state in these two parental samples. 
Family 0066 Family 1499 
V-2 111-1 
Allele A llele Allele A llele 
Gene Variant SNP# 1 2 1 2 
0 16$673 280 200 278 294 
HERPU01 c.1-146 G>A rs37025 G A G A 
c.1 -86 T>G rs37024 G T T G 
c.554+23 G>C c G G G 
c.554+64 A>G rs2133783 A A G A 
CPNE2 c.180+86 A> T rs8053682 A A T A 
c.180+87 G>C rs8047463 c c G c 
c.1302+39 C>G rs2305693 G G G G 
CCL22 c.5 A>C rs4359426 c c c c 
CIAPIN1 c.-131 G>A A A G A 
c.154 C>G rs11557674 c c G c 
c.157+16 C>T rs72780616 c c T c 
POLR2C c.1 37 -24 A>G rs223839 G G A G 
c.174 T>C rs4937 c c c c 
c.387+8 C>T rs601194 T T c T 
c.439+100 G>A rs223874 A A A A 
016$3057 195 195 191 195 
CCOC102A c.286 C>T rs12935069 T T T T 
c.585+82 A>G rs8045906 G G G G 
c.825 G>A rs28446687 A A A A 
c.1140 A>G rs28756858 G G G G 
c.1258+14 T>A rs28649020 A A A A 
GPR114 c.-7 G>A rs1004363 A A A A 
c.140+181 C>T rs1859259 T T T T 
c.140+269 G>A rs1859260 A A A A 
c.846 C>T rs9937918 c T c T 
CCOC135 c.151 G>A rs5564545 G G A G 
c.575 G>C rs7196016 G c G c 
c.859-26 C>T rs12933056 c T c T 
c.1077+22 G >C rs2122486 G c G c 
c.1298 C>T rs3809611 c T c T 
c.2296 T>C rs2923147 T c T c 
KATNB1 c.289+65 A>G rs2967152 A G A G 
c.704+4 C>T rs2965797 c T c T 
c.726C>T rs2965798 c T c T 
KIFC3 c.381 +105 T>C rs2965789 T c T c 
c.699 T>C rs2967165 T c T c 
c.765+32 G>A rs2965790 G A G A 
c.765+62 T>C rs2967166 T c T c 
c.940-44 A>G rs3803590 A G A G 
c.1803 C>T rs2967172 c T c T 
c.2003-21 T>A rs2965799 T A T A 
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ZNF319 c .1536 G>A 
c.17 49+20 A>G 
C160RF57 c .99-36 G>A 
c.265+43 C>G 
c.504-60 C>T 
MMP15 c.213-17 C>T 
CCDC113 c.628-249 G>C 
c.628-242 C>G 
c.628-117 C>T 
PRSS54 c.-6-16 G>A 
c.75 T>C 
c.263+56 A>G 
c.263+60 T>C 
c.263+61 G>A 
c.264-112 A>G 
c.544 A>G 
c.718 G>A 
c.883 A>G 
01683038 
GINS3 
NDRG4 
SETD6 
CNOT1 
SLC38A7 
c.198 T>G 
c.223+90 G>A 
c.612+13 A>G 
c.612+77 A>G 
c.672 G>A 
c.873+3 G>A 
c.1062 A>G 
c.193 T>C 
c.263-64_263-50dup 
c.902-77 G>A 
c. 1338 G>A 
c.*26 A>G 
c.1 03-32 C>G 
c.976A>G 
c.1216-69 G>A 
c.1584+22 dup T 
c.1704+11 0 G>A 
c.2332+99 G>A 
c.2891+43 C>T 
c.2919 G>A 
c.3201+124 G>T 
c.4006+12 A>G 
c.4434+90 G>A 
c.4716 C>T 
c.4801 -83 G>A 
c.541 5-61 G>A 
c.5646+41 A>G 
c.5646+88 T>G 
c.*82 G>A 
c.883+19 deiC 
c.1286+51 T>C 
rs3743556 
rs3743555 
rs3743560 
rs4784022 
rs2241774 
rs11076235 
rs11076236 
rs11076237 
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rs3815803 
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rs2241 414 
rs2427787 
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rs1 7821543 
rs42945 
rs4784046 
rs2280397 
rs3607 
rs3169293 
rs34014750 
rs72790275 
rs9936144 
rs41445346 
rs1568399 
rs11866002 
rs7 184114 
rs2241570 
rs41260 
rs11540994 
rs246195 
rs2244453 
rs1 7821549 
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G 
A 
G 
c 
c 
c 
c 
G 
T 
G 
c 
A 
T 
G 
G 
G 
G 
A 
215 
T 
A 
A 
G 
G 
G 
A 
T 
wt 
G 
G 
A 
c 
G 
A 
wt 
A 
A 
c 
G 
T 
A 
G 
c 
G 
G 
G 
G 
G 
del 
c 
A 
G 
A 
c 
T 
c 
c 
G 
T 
G 
c 
A 
T 
G 
G 
G 
G 
A 
215 
G 
A 
G 
G 
A 
A 
G 
c 
dup 
A 
A 
G 
G 
A 
G 
dup 
G 
G 
T 
A 
G 
G 
A 
T 
A 
A 
A 
T 
A 
del 
c 
G 
A 
G 
G 
c 
T 
G 
c 
c 
A 
c 
G 
c 
A 
G 
A 
A 
G 
215 
T 
A 
A 
G 
G 
G 
A 
T 
wt 
G 
G 
A 
c 
G 
A 
wt 
A 
A 
c 
G 
T 
A 
G 
c 
G 
G 
G 
G 
G 
wt 
c 
A 
G 
A 
c 
T 
c 
c 
G 
T 
G 
c 
A 
T 
G 
G 
G 
G 
A 
215 
G 
A 
G 
G 
A 
A 
G 
c 
dup 
A 
A 
G 
G 
A 
G 
dup 
G 
G 
T 
A 
G 
G 
A 
T 
A 
A 
A 
T 
A 
del 
c 
Page 186 of 257 
GOT2 c.213 T>C rs257636 c c c c 
c.228 T>G rs14221 G G G G 
c.246+252 C>T rs257634 T T T T 
c.562 G>A rs11076256 G G A G 
c.816 C>T rs1 058192 c T T T 
c.853+1 00_853+103del wt del wt del 
c.1037 T>G rs30842 T G G G 
016$494 178 188 178 188 
0 16$3094 169 169 169 169 
016$3132 278 282 268 264 
016$3089 181 193 187 183 
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Re•seq Genes 
HERPUDI I RSPR.,'I.. COQ9 1 GPR97 I CNGBI t CCDCI 13 ill NDRG4 1 GOT2 1f 
HERPUDI I RRL26P I DOK4 t KRTNB I I TEPP I CCDCII3 1f NDRG4 I 
HERPUDI I PLLP H GPRI14 .. CNGBI llllfl PF S'S'S4 I NDRG4 I 
CETP II CCL22 I GPR56 .... TEPP I G I NS3 H 
NLRCS • CX3CLI ~ GPR56 HI : NP3 19 j GINS3 H 
CPNE2 .. CCL I 7 ~ GPR56 Hjl C 16orf57 I G I NS3 H 
FRMI92R If< POLR2C I K!FC3 H M~1P15 il NDRG4 .... 
CIRPINI I KIFC3 H C l6or- • s o II NDRG4 f-11 
CCOCI 0211 I< Klf'C3 .. CSNK2ti2 11f NORC4 >-It 
OPR56 ti C16orf57 r NDRC4 I 
OPR56 ti CI60r.57 NDR04 I 
GPR56 Hjl SETD6 I 
GPR56 Hjl SETD6 I 
GPR56 .. CNOT I •tH 
CCDCI 3 5 . CNOTI •tf-1 
CNOTI _.H 
CNDTI JIH 
$N(tF-A1 6 I 
SNOFAS&I 
SLOU17 t 
Figure 4.9: Screen capture from the UCSC Genome Bioinformatics database of the critical 
region between markers HERPUDJ c.554+23 G>C - D16S3132 (Human Feb 2009 
GRCh37/hg19 Assembly). This region spans approximately 3 eM and contains a small cluster of 
71 genes followed by a rather large intergenic region with a sole pseudogene LOC644649. 
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4. 4. 6 Exome Sequencing 
(i) Sample Pooling Strategy 
Following the Sanger sequencing and haplotype analysis, we sent away 8 genomic DNA 
(gDNA) samples (five affected, three unaffected) for whole exome sequencing to the Genome 
Center at McGill University. Genomic DNA samples from three affected individuals from 
Family 0066 were sent away and pooled, with the assumption that these three samples would 
contain the same autosomal recessive mutation and similarly the two gDNA samples from 
Family 1499 were pooled. 
(ii) Variant Filtering 
Exome sequencing was carried out as per Section 3.3.4 of this thesis. The exome dataset 
was filtered for rare variants, which would be consistent with an autosomal recessive mode of 
inheritance (homozygous or compound heterozygous), shared between both Families 0066 and 
1499, and within the chromosome 16 critical region determined through linkage, HH analysis, 
and critical region reduction. 
As a double check, the exome dataset was checked for mutations in genes related to 
microphthalmia and its associated syndromes (OTX2, PAX6, SOX2, RAX, VSX2, BCOR, CHD7, 
BMP4, FOX£3 , STRA6, SMOCJ, MITF, and SIX6) , as well as GJAI , which is associated with 
ODDD and HSS-like phenotypes. No pathogenic variants were found during this analysis. 
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0066 Filtering 
Filtering for variants in the chromosome 16 critical region revealed 314 variants, 271 of 
which were common SNPs. Of the remaining 43 variants, there were three missense mutations, 
five synonymous mutations and no truncating mutations (frameshifting deletions, or nonsense 
mutations). The three missense mutations were in CNGBJ (p.A961 V), ZNF319 (p.K512K), and 
P RSS54 (p.S 1820). These variants had a minor allele frequency (MAF) of 2.2%, 66.8%, and 
54.6% respectively from the 1000 Genomes Project. 
1499 Filtering 
Filtering for variants in the chromosome 16 critical region revealed 294 variants, of 
which 261 were common SNPs. Of the remaining 33 variants, there were two missense variants, 
five synonymous variants, and no truncating mutations. The two missense mutations were in 
CNGBJ (p.A961V) and PRSS54 (p.S182G) having a 2.2% and 54.6% MAF respectively from 
the 1000 Genomes Project. 
4. 4. 7 CNV Analysis 
To examine the hypothesis of CNV s in this region, we asked a bioinformatician at 
Genome Quebec (Alexandre Monpetit) to analyze the SNP data from the Illumina 61 OK Quad 
Chip for CNVs in this region. This quick analysis revealed that the individuals were sharing a 
large homozygous region, as was previously suspected, but the copy numbers of each SNP were 
normal, suggesting that this area does not contain any CNV s of interest. 
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4.5 Discussion 
4.5. 1 MDW and HSS 
Microphthalmia is a condition caused by the malformation of the optic vesicle during 
embryological development, and is part of a broader spectrum of disorders including clinical 
anophthalmia and coloboma. This study presents a syndromic form of this spectrum, which we 
refer to has microphthalmia-dwarfism (MOW) and which has not previously been described. It is 
not surprising to find rare conditions associated with microphthalmia, as up to 113 of 
microphthalmia cases are associated with extraocular features. 198 
Interestingly, the individuals with MOW bear great similarity to individuals with 
Hallermann-Streiff syndrome (HSS; OMIM 2341 00). HSS is an autosomal recessive condition 
consisting of brachycephaly with microphthalmia, proportionate short stature, fronta l bossing, 
hypotrichosis, cataracts, and a pointed/beaked nose, all of which are seen in the two families with 
MDW. Despite the similarities of these conditions, the individuals with MDW do not show a 
progeroid (premature aging) component like those of some HSS patients,228 and do not exhibit 
micrognathia (small jaw). It is quite possible that both HSS and MDW are caused by mutations 
of the same (or functionally similar) gene(s), which would account for the similarities between 
these conditions. Interestingly, assessment of patient 0066 IV -4 provides detailed clinical data 
over the course of many years. In her earlier years, pictures showed that she had a full head of 
hair, but at the age of 60 she had marked hypotrichosis, though always blind, having 
microphthalmia and cataracts. Her facial structure and appearance was certainly not that of 
classic HSS in the pictures from her youth, though more recent pictures in her 50s and 60s show 
a much more similar looking phenotype to HSS as described by Cohen in 1991. This very 
interesting observation suggests that perhaps the MDW phenotype observed in Families 0066 
and 1499 is indeed part of the HSS spectrum, but a milder, progressive form of the disease. 
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Other, younger, patients (1499 IV -1 , IV -2 and 0066 V -2) from these two families also do not 
show the same features as their older relatives, such as hypotrichosis, respiratory issues (COPD, 
chronic bronchitis), hearing loss, and frequent infection. However, they may develop these 
phenotypes later in life, again suggesting that this condition may be a more mild progressive 
form ofHSS. 
4. 5. 2 Linkage Analyses and HH mapping 
Elucidating the genetics of MDW posed to be a potentially interesting and challenging 
endeavor as this condition seems to be related to HSS, a condition with little to no knowledge of 
monogenetic involvement. We began these analyses through genotyping all available samples 
from families 0066 and 1499 on a 61 OK Illumina SNP array in hopes of identifying a putative 
locus through linkage analyses. This particular array was chosen over a more densely populated 
chip, due to the lower cost and the lower number of markers required for linkage analysis. The 
reduced number of SNPs eases the speed of analysis, but still provides sufficient coverage due to 
the large number of SNPs available in comparison to microsatellites. This strategy proved quite 
useful as we were able to determine a multi-point linkage on chromosome 16 of 4.535 on band 
q12-21 which spanned approximately 30 eM. This large region contained over 300 genes, which 
is not an ideal situation for Sanger sequencing of positional candidate genes (as Sanger 
sequencing can only sequence a maximum of ~ 700-1000 bp at a time). 
While the linkage analyses were being performed, a HH analyses was also carried out 
using samples from affected individuals of both families. This analysis revealed the same, but 
smaller region on chromosome 16q 12-2 1 which spanned ~8. 5 eM between SNPs rs28971 0 and 
rs219568. This, combined with the linkage data, suggested that the affected members from 
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fami lies 0066 and 1499 were either sharing a common homozygous region on chromosome 16, 
or were potentially carrying a heterozygous deletion of this entire region (this is discussed further 
in section 4.5.5). This region was also significantly smaller than the 30 eM region as indicated by 
the linkage analysis, and contained only 71 genes. 
4.5.3 Positional Candidate Gene Selection and Sequencing 
For ease, positional candidate gene selection was based on the smaller region as 
determined by the HH analysis presented in section 4.5.2. Ofthe 71 genes in this region (Human 
Feb 2009 GRCh37/hg19 Assembly), we chose 23 genes for preliminary direct sequencing based 
on function and previous disease association. Genes associated with i) cellular 
proliferation/growth or ii) the cell cycle (NDRG4, ARL2BP), iii) were transcription factors or 
proteins related to DNA replication/transcription (CCDC102A , POLR2C, CCDC135, ZNF319, 
CCDC113, CNOTI , GJNS3), iv) a cellular function involving proper function/growth 
(HERPUDI , CIAPINJ, GPR114, KIFC3 , KATNBI , MMP15, CPNEJ, SLC38A 7, PRSS54), v) or 
mitochondrial function/energy production (GOT2) were chosen. Other genes were chosen based 
on previous disease associations such as C160RF57 in poikiloderma/neutropenia, or if they had 
no previous association but could be plausibly involved such as SETD6 (histone methylation) or 
C160RF80 (no known function or association). 
Sequencing of these 23 genes revealed 94 variants in total (Table 4.2), 82 with a previous 
dbSNP number. Eleven of these variants were missense mutations and all underwent in silica 
analysis using SIFT (Sorting Intolerant From Tolerant), PolyPhen, and PANTHER. The scores 
from these analyses (when a missense mutation), along with minor allele frequencies (MAF) 
from the 1000 genome project were used to determine putative pathogenicity of each variant. 
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Three variants, c.878+3 G>A in NDRG4, c.263-64_263-50dup in SETD6, and 
c.853+ 100 853+ 1 03del in GOT2 were of interest due to low MAF and potential splicing effects. 
The GOT2 variant, c.853+ 100_853+ 103del, was a four bp deletion ofGTGT in intron 7. 
This variant was chosen for further analysis as it had no previous rs number from dbSNP, and 
also showed segregation with the MOW phenotype. One hundred and forty two chromosomes 
from the NL population were tested for this mutation, and 115 carried this variant. ( ~80%). The 
high frequency at which c.853+ 100 _ 853+ 1 03del occurred in the Newfoundland population 
excluded this variant from any further analysis. 
The c.873+3 G>A transition in NDRG4 occurs close to exon 14, making it a potential 
splice variant and is a previously described SNP (rs142344402). This SNP only shows a 0.2% 
frequency in all genomes (0.006 AMR and 0.004 EUR) according to the 1000 Genomes project 
(accessed June 1 i '\ 20 12), and has never been described in the homozygous state. Segregation 
analysis of this variant was carried out amongst all remaining family members, and appeared to 
segregate in an autosomal recessive fashion with the MOW phenotype. The rare occurrence of 
this SNP, the segregation of the allele, its potential for splice variation and the fact that it has 
never been seen as a homozygote made this variant interesting to study. This variant was first 
checked in normal population controls from an ongoing colorectal study, and was found in 1 of 
142 control chromosomes (0.7%) indicating that this variant is also rare in the ewfoundland 
population. To search for a potential effect of this variant in the MOW families, three primers 
were designed to amplify a 325 bp fragment in eDNA and a 675 bp fragment in gDNA through 
multiplex PCR. Two lymphoblastoid cell lines from family 1499 of the proband (IV -1 ) and his 
brother (IV -2) were available for testing. The results from this experiment showed a fragment 
size consistent with the expected 325 bp which was confirmed in an unaffected control from a 
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separate project. This suggests that the c.873+ 3 G>A variant is likely benign, having no negative 
effect on splice variation in NDRG4, and is simply riding on a rare haplotype in the 
Newfoundland population. This was further confirmed through in silica analyses of the potential 
splice variation using BDGP (Donor scores 0:0.85 A:0.97) and NetGene2 (Donor scores: G 
0.95, A: 1.00), both of which predict a slightly stronger splice donor due to this mutation, but no 
negative effects. 
The mutation in SETD6 (c.263-64_263-50dup) was also tested for potential splice 
variation as it was a duplication towards the center of intron two. This experiment utilized cDN A 
from individuals IV-1 and IV-2 from family 1499, and used two primers which would amplify a 
675 bp fragment in eDNA, and a 1000 bp fragment in gDNA. This experiment was analyzed 
using gel electrophoresis and showed a band at the expected 675 bp fragment in eDNA, which 
also showed up in an unaffected control sample. Interestingly, there appeared to be second 
fragment in between the 400-500 bp ladder controls. This band was weak, but appeared in 
multiple iterations of this experiment, and also showed up in the control sample. According to 
the UCSC Genome Browser, there are currently two known isoforms of SETD6 
(NM_001160305 and NM_02486). Upon inspection, it appeared that isoform NM_02486 is 
missing a total of 218 bp from ex on 2 that the longer isoform, NM _ 001160305, includes in its 
open reading frame (ORF). This isoform would thus produce a band of 457 bp, and accounts for 
the second band seen on the gel in Figure 4.8. These results suggest that both isoforms of SETD6 
are expressed in lymphoblastoid cells lines, though based on the intensity of the observed bands 
in Figure 4.8 the longer isoform (NM_001160305) is expressed more readily. The presence of 
the 675 bp fragment in all three samples (two affecteds, one control) suggests that the 15 bp 
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duplication (c. c.263-64_263-50dup) is unlikely to cause any splice variation in the MDW 
patients. 
4. 5. 4 Exome Sequencing and Analysis 
Once variant analysis had been carried out from the Sanger sequencing data, we 
outsourced DNA from families 0066 and 1499 to the Genome Centre at McGill University for 
exome sequencing. We employed a pooling strategy in which we created an affected and 
unaffected pool for each of the two families. This was done as it was expected that all the 
affected individuals would share the same homozygous, or compound heterozygous mutation. 
We also filtered the variant list for those genes in the critical region on chromosome 16q21. 
Filtering for the critical region in both families 0066 and 1499 revealed two shared missense 
mutations, CNGBJ (p.A961 V), PRSS54 (p.S 1820). The PRSS54 variant can be easily excluded 
as this mutation has been seen in 54.6% of samples from the 1000 Genomes proj ect, making it 
likely that this is a common polymorphism. The CNGBJ variant, while rare can, also be excluded 
as this gene functions solely in the rod photoreceptors, and mutations are known to cause 
autosomal recessive retinitis pigmentosa. 
Unfortunately, no rare variants of potential causative effects were shared between the 
affected members of both families in this critical region on chromosome 16. This is an 
interesting result, as we initially expected the causative mutation to easily fall out during 
filtering, using these criteria. This data led us to believe that perhaps the mutation was not in a 
coding gene, but perhaps a non-coding one. This region contained two genes which fit these 
criteria, SNORA46 and SNORA50. SNORA 46 and SNORA50 are H/ACA small nucleolar RNA 
(snoRNA) genes which are transcribed from their host gene (the gene in which they reside), 
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CNOTI. The HI ACA class of snoRNA molecules is responsible for a process known as 
pseudouridylation, which creates a post-transcriptionally modified nucleoside, pseudouridine.235 
Pseudouridine is important in the structures of various RNA molecules such as small nuclear 
RNAs (snRNAs), or transfer RNAs (tRNAs), though the exact mechanism in which they work is 
unknown. 
4. 5. 5 Other Analyses and Future Directions 
The lack of any pathogenic variants found in the critical chromosome 16 region is a very 
interesting result. We had expected exome sequencing to reveal the mutation with relative ease, 
especially with the convincing locus on 16q21 revealed through linkage, HH, and critical region 
analyses. Certainly, with exome sequencing being a rather new and unperfected technology, the 
causative gene may have been overlooked in analysis, or have been missed in the sequencing 
itself. The second possible conclusion from this data falls in line with the hypothesis of the 
causative mutation potentially being in a non-coding gene, or an intergenic region. 
Recently, a microdeletion on 16q 11.2-q 12.1 has been shown to cause a case of Lenz 
microphthalmia,236 thus we examined the possibility of copy number variation (CNV) as the 
cause of MOW. The haplotypes shown in Table 4.3 and 4.4 show that the yellow haplotype 
segregates with the disease but is heterozygous in two unaffected parents. This makes the 
presence of a large heterozygous deletion (which would give the appearance of a homozygous 
haplotype) in the affected family members unlikely. To further examine the hypothesis ofCNVs 
in this region, we asked a bioinformatician at Genome Quebec (Alexandre Monpetit) to analyze 
the S P data from the Illumina 610K Quad Chip for C Vs in this region. This quick analysis 
revealed that the individuals were sharing a large homozygous region, as was previously 
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suspected, but the copy numbers of each SNP were normal, suggesting that this area does not 
contain any CNV s of interest. It is certainly possible that a deleterious CNV may exist between 
probes in the 61 OK SNP Illumina Quad-Chip that we used for this study. This possibility could 
be explored through further studies using a higher density SNP array, or array comparative 
genomic hybridization (aCGH) which are sensitive arrays designed to pick up variations in copy 
numbers. 
Figure 4.9 depicts the critical region from the MDW study according to the UCSC 
Genome Browser, and contains a small gene cluster (7 1 genes) followed by a particularly large 
intergenic region of about 2 eM. Another possibility for this study is that the mutation lies in the 
large 2 eM intergenic region, and may be a point mutation creating or disrupting an enhancer or 
repressor site. This phenomenon has been examined in multiple association studies of prostate 
cancer which have identified associations with multiple SNPs in a gene desert on 8q24. This 
region has been shown to be an enhancer region for a tumour suppressor gene called MYC. 
Functional studies of this region have shown that this region interacts with the MYC promotor in 
both prostate and colorectal cancer cell lines through a conformational change of the DNA.237 
To fully examine this hypothesis, this large intergenic region would need to be sequenced 
through next generation sequencing technologies to identify any potentially pathogenic variants. 
It is also very interesting to note that the critical region on chromosome 16 appears to 
contain a number of genes which explain (or could potentially explain) components of the MDW 
phenotype. For example, CI60RF5 7 causes both poiki loderma (a condition of the skin which 
can cause thinning of the skin leading to prominent veins, and discolouration of the skin), and 
neutropenia, a lack of neutrophils in the blood stream leading to frequent infections.238 This 
made this gene an exciting candidate as the individuals from the MDW family have both 
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atrophic/dry skin with prominent veins, as well as frequent infections. Other genes in this region 
are involved in other aspects of immune function (NLRC5), cholesterol and fat metabolism 
(CETP), which is interesting as individuals with MDW lose facial fat deposits over time. It is 
possible that this cluster of 71 genes is being controlled by a common promotor/regulatory 
element, and that disruption of this region would cause dysregulation of gene expression, 
resulting in the MDW phenotype. Though, again, further analysis would be required to confirm 
this through Next Generation _Sequencing (NGS) or aCGH in the case of CNV s to identify the 
putative mutation. Quantitative expression studies would then need to be conducted upon 
discovery of a variant to help confirm pathogenicity, and regulation. 
This project was very interesting, as it illustrated the strength of so called 'old ' 
techniques such as linkage analysis, and also highlighted the limitations of newer technologies 
like exome sequencing. Though powerful, NOS is currently in the infancy stages of becoming 
mainstay tools for genetic analyses as the sheer amount of data is rather difficult to deal with. It 
also creates a problem when coverage of particular areas is low either from random error, or is 
particularly hard to sequence due to the nature of the region (i.e. CG rich areas, repetitive 
regions, or areas near the centromere). This project shows that again, while powerful, exome 
sequencing is not the 'magic bullet' solution to all conditions thought to be Mendelian or 
monogenetic in nature. This is not entirely due to limitations ofNGS, but that in some cases, 
diseases thought to be Mendelian or monogenic in nature, may in fact be more complex than 
originally thought. It is certainly likely that as researchers are better able to handle the sheer 
amount of raw sequence data produced by the NGS platforms, that we' ll begin to see more and 
more conditions solved through mutations in non-coding areas. 
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It' s interesting to note that these regions which were once thought to be 'junk DNA' or 
'evolutionary leftovers ' can in fact be playing a much larger role than originally thought. A 
consortium called the Encyclopedia of DNA Elements (ENCODE), started in 2003 , aims to 
identify the function ofthese so called 'junk DNA' regions. This group has published numerous 
papers on the location and functions of these D A elements, and suggests that up to 80% of the 
human genome is involved in biological function, and not solely the 1-2% of coding DNA 
originally thought to control the majority of biological processes.239 Recently, much excitement 
has been generated about the function of non-coding transcripts (RNA species) in organization of 
chromatin in the nucleus. It has been shown that 274 tRNA genes show localization to the 
nucleolus of Yeast. It is suspected that this clustering has a major impact on the spatial 
organization of the genome. Secondly, repetitive elements of the genome such as Short 
Interspersed Nuclear Elements (SINE) have been shown to contain RNA Polymerase III (Pol III) 
binding sites, and it has been hypothesized that these species participate in chromatin remodeling 
within the cell.240 
Other non-coding elements code for multiple types of regulatory components such as 
binding sites for transcription factors, regulatory RNA species such as microRNA molecules 
(miRNA), or long non-coding RNA (lncRNA), or trans and cis acting enhancers. The two RNA 
molecules (miRNA) and (lncRNA) have been implicated in various conditions such as 
cardiovascular disease, various cancers, and neurodegenerative conditions (such as Alzheimer' s, 
Parkinson 's, and Huntington's).241 Interestingly, and perhaps most applicable to the hypothesis 
that a regulatory mutation in the non-coding region of chromosome 16 for MDW, is the 
discovery of a regulatory element on 8q24 for prostate cancer. It was found that a SNP within a 
'gene desert' of chromosome 8 (rs6983267) which had been previously associated with prostate 
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cancer in a number of association studies was within a cis-acting enhancer of the gene MYC, a 
known proto-oncogene (a gene that when mutated can promote cancer grown).237 While prostate 
cancer is a complex trait, and MDW seems to be a recessive condition, the possibility remains 
that perhaps a mutation in this intergenic region of chromosome 16 could be having a negative 
impact on the expression of nearby genes, and perhaps giving rise to the MDW phenotype. 
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Chapter 5: General Discussion and Conclusions 
The goal of this thesis was to use the genetic isolates ofNewfoundland and Labrador to 
identify disease genes in various ocular disorders. These conditions included ASD, a variable 
autosomal dominant defect of the anterior chamber of the eye including Peters anomaly; 
achromatopsia, an autosomal recessive malfunction of the cone photoreceptors; and MDW an 
autosomal recessive syndromic form of microphthalmia. The use of genetic isolates and founder 
populations for gene discovery projects has been very successful in the past,49 and the population 
of Newfoundland and Labrador is no exception in that regard. Researchers in NL have 
successfully identified a number of founder mutations, and have had past successes in gene 
discovery projects.53-55: 59:72: 142 This thesis highlights the advantages of using the genetic isolate 
of Newfoundland for gene discovery projects, and also examines some ofthe limitations 
involved with the current perception of monogenic diseases. 
ASD is an autosomal dominant condition of the anterior ocular chamber, consisting of 
various malformations of the iris, the cornea, and the lens. This thesis examined a single 
multiplex family from Newfoundland which segregated a variable form of this condition. 
Affected individuals carried a spectrum of disorders ranging from mild phenotypes such as 
microcornea, to more severe forms such as Peters Anomaly. ASD is also a very genetically 
heterogeneous condition with over a dozen known genes and loci. The variable expression and 
the genetic heterogeneity of this disorder made this a potential ly challenging study. As 
highlighted in the general introduction, this project began with the sequencing of functional 
candidate genes which had been previously associated with ASD. Nine genes were chosen and 
sequenced in this fashion, and we identified a novel mutation in FOXE3 (c.959 G>T). Up to this 
point, only a handful of publications had described FOXE3 mutations in ASD. The gene product, 
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FOXE3, is known to be a lens specific transcription factor responsible for proper lens formation 
during embryogenesis. The mutation discovered through this method (c.959 G>T) was of great 
interest as it was a rare type of mutation, referred to as a non-stop mutation (a mutation of the 
stop codon in a gene). This type of mutation is rarely seen, and the exact effects of its action in 
FOX£3 have simply been hypothesized to cause an extended protein though no functional 
studies have been carried out to confirm this. To further examine this hypothesis, we used eDNA 
from an affected individual to identify that the c.959 G>T mutation was in fact absent in eDNA 
according to Sanger sequencing. This preliminary data suggests that the mutation discovered in 
fami ly 0023 is degraded at the mRNA level. Of course this result is strictly based on the 
limitations surrounding Sanger sequencing, which is unable to determine quantitative levels of 
eDNA, and thus mRNA. To further examine this hypothesis, quantitative studies using PCR 
based methods could be carried out to quantify the amount ofthe mutant transcript (if any). 
The second project described in this thesis concerns a rare autosomal recessive condition 
known as achromatopsia. Achromatopsia is a retinal condition affecting the cone photoreceptors, 
and is caused by mutations in one of four genes, CNGA3, CNGB3, GNAT2, and PDE6C. Much 
like the situation with ASD, all four previously associated genes were sequenced in individuals 
from eight families from Newfoundland. Six of these families were solved through this method 
and affected individuals had mutations in CNGA3 and CNGB3 (three with mutations in CNGA3, 
and three with mutations in CNGB3) while an individual of a seventh; unsolved fami ly had one 
mutation in CNGB3 identified. The possibility of founder mutations was also evaluated, and it 
was found that the c. ll48deiC mutation in CNGB3 appears to be on the same disease associated 
haplotype in all four families (1442, 1492, 171 3, and 1734). The limitation ofthis conclusion lay 
in the fact that only one affected sample was available from families 1442, 1713 and 1734. 
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Although, only one sample from an affected individual was available from Family 1442, 
all marker/SNP genotypes were homozygous and thus a haplotype was able to be established fo r 
this individual. A second founder mutation was also found in CNGA3 within this population, 
c.1580T>G: p.L527R. We compared haplotypes across the two families who harboured this 
mutation (1 491, and 1723), though only one sample was available from family 1723. This 
showed a common partial haplotype surrounding this mutation suggesting that this may be a 
recurrent founder population in the population ofNewfoundland. Interestingly, this mutation has 
also been described by Lam et al in 2011 through exome sequencing of a single patient of 
'European Descent' . The Newfoundland population is known to have been peopled by a group of 
individuals ofNorthern European descent, thus it would be interesting to obtain a sample from 
the patient described by Lam et al, and compare haplotypes. This could provide further evidence 
fo r p.L527R as a founder mutation, and could provide evidence that it originated in Europe and 
was carried into the Newfoundland population during migration. 
All the haplotype data discussed above is based around a rather large assumption: that all 
the mutations being examined were on a common haplotype. Most of the samples obtained were 
from a single individual in a family and without at least three generations of data, or a large 
number of siblings and parents across at least two generations, constructing a haplotype is 
problematic. The assumption made here was that the mutation is shared on a common haplotype, 
and when markers surrounding CNGB3/CNGA3 were genotyped, they could be arranged to 
produce a similar haplotype. Of course, this is a huge assumption, and parental DNA would be 
required in order to confirm the segregation of these marker genotypes. 
Interestingly, one family (1734) showed one mutation in CNGB3 ( c.1 148delC), but a 
second mutation was unable to be found in any of the four genes. A sequence anomaly was 
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observed surrounding exons 17 and 18 in PDE6C (Figure 3.4) though it was determined through 
a series of cloning experiments and primer tests, that the primers used to amplify these exons 
were not as specific as in silica analysis had suggested, and had amplified a region on Chr8. It is 
also possible that the conditions for amplification were not stringent enough, allowing the 
primers to bind in other locations. A second set of primers was designed to amplify this region, 
and no pathogenic variants were found in the patient sample from Family 1734. It remains 
possible that the second mutation for this individual is in CNGB3, but is unable to be picked up 
by sequencing the coding regions of this gene. The second mutation may be in a regulatory 
domain of CNGB3, such as the promotor, or perhaps in one of the larger intronic regions creating 
a splice variation in a branch site. To evaluate the possibility of a splice mutation somewhere in 
CNGB3, a cell line could be obtained, and the entire CNGB3 eDNA transcript amplified and 
compared to a normal control. Any variation in the size of the eDNA transcript could provide 
hints towards the mechanism of disease in this individual. A second approach to solve this 
individual would be to use whole genome or targeted next generation sequencing to identify the 
second mutation, or potentially another gene entirely. The limitation of this method lies in the 
massive amounts of data that is produced. If mutations are found in a regulatory region, it 
becomes difficult to distinguish which variant is having an effect without functional studies on 
each individual variant found. My suspicion is that the former situation is going to be the most 
likely, where a splice variation of CNGB3 is the second mutation which was missed through the 
initial screening of coding regions in functional candidate genes. 
Even more interesting was family 0094, a large family with achromatopsia and no 
pathogenic mutations in any of the four known achromatopsia genes. Rather than using linkage 
analyses for this project, we decided to use NOS technology and used exome sequencing to solve 
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the etiology of achromatopsia in this family. The results from the exome sequencing were 
intriguing, as after filtering for common variations, a transition, c.1555 C>T, was seen in 
CNNM4, a gene associated with Jalili Syndrome, a disorder with achromatopsia or cone-rod 
dystrophy and defective tooth enamel (amelogenesis imperfecta). The transition mutation caused 
a premature stop at codon 519 (p.R519X) and prompted a review of archived medical records. 
These records revealed that in fact, these patients had teeth like that of Jalili Syndrome patients 
(brown discolouration, soft and weak enamel) which were extracted at a young age. This was not 
recognized at the time of ophthalmological examination in the 1980s as all the family members 
had dentures, a common ' treatment' for dental caries in areas ofNewfoundland where access to 
dental services was scarce. Their ocular phenotype was also progressive, resembling that of 
cone-rod dystrophy, rather than achromatopsia. This portion of the study provided an interesting 
story, as well as highlighted the importance of exome sequencing technologies as a diagnostic 
tool. More interestingly still, if no archived records had been available, we could not have 
confirmed the dental phenotype, and would potentially have made a claim that mutation of 
CNNM4 causes achromatopsia. This highlights the importance of combining these new 
technologies with old, accurate records, which can refine diagnoses and has allowed us to present 
the first cases of Jalili Syndrome in North America. 
Chapter 4 examined, in my opinion, the most interesting of the three diseases, MOW. 
This apparently autosomal recessive condition showed great similarity to that of HSS, with 
microphthalmia, short stature, frontal bossing and hypotrichosis. The interesting thing about the 
presence of the phenotype in these two fami lies is that the younger individuals show very little to 
no resemblance to the facial appearance of HSS described by Cohen in 1991 ,226 though one of 
the affected females from family 0066 who is currently age 60 shows very marked similarities to 
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HSS. This, along with the clinical description of the younger individuals from both families 
suggests that this is a form of HSS which progresses over time. Some cases of HSS are known to 
be caused by mutations in GJAJ, and it would not be surprising if the mutation in this family is 
in a gene in the same pathway or process that GJAJ is involved in. The studies ofHH, and 
linkage showed great promise by using the 61 OK SNP Illumina SNP array by revealing a 
putative locus on Chromosome 16q 12-21 , which was then refined to 16q21 through addition of 
microsatellite markers, and sequencing of positional candidate genes. This now 3 eM region 
contains 71 genes, and a large gene desert of about 1-2 eM in size. 
Surprisingly, exome sequencing of affected patients from both families revealed no 
pathogenic variants after filtering for rare variations within the chromosome 16 critical region. 
This result prompted sequencing of all miRNAs, SNORA, and SNORD genes within the region, 
which would not be covered by exome sequencing. Only two SNORA genes resided in the 
critical region (though a total of 10 from the larger linkage region were sequenced as well) and 
no mutations were found. Some of the genes in the critical region have functions in the immune 
system, skin conditions, retinal and eye conditions etc, which when taken together make sense as 
the causative genes for this condition. However, since no mutations were found in these genes, 
this leads me to believe that the mutation of interest is in fact in this large gene desert telomeric 
to the cluster of71 genes (shown in Figure 4.9). A mutation in the large intergenic region could 
be that of an enhancer or repressor, which is skewing the expression and function of these genes. 
To fully evaluate this hypothesis, however, whole genome technologies would need to be 
employed to gather variant information from this region. Alternatively, a sequence capture of the 
2 eM gene desert could be performed. The issue with this is again, the large amount of data, but 
it is likely that a large number of variants will be discovered in this region, and determining 
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which variant is having an effect is not an easy task. Another interesting assay would be to pick 
some of the genes in this region and to quantitatively check their expression against a normal 
unaffected individual using qPCR based approaches. This may provide some clue as to the 
mechanism of disease in these families. 
Lastly, these projects highlight the usefulness of many types of analysis, and the use of a 
genetic isolate with large family sizes such as Newfoundland to identify many rare conditions. I 
used functional candidate gene, linkage, HH, and NOS approaches to solve a total of eight 
families (one ASD, seven achromatopsia) and determined one putative locus for a rare 
progressive form ofHSS, MDW. These studies contain great importance to the medical 
management of these families , as gene therapy trials are showing great promise for diseases such 
as achromatopsia. By knowing the gene and mutation present in each family, these treatments 
can eventually be implemented, increasing the quality of life of these patients, and leading to a 
new era of medicine. 
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Appendix A: Polymerase Chain Reaction (PCR) setup protocols 
lx Polymerase Chain Reaction (PCR) Protocol w/ 25% Betaine 
Reagent Volume (uL) 
dH20 9.92 
KapaTaq Buffer 2 
25mM Betaine 5 
KapaTaq dNTPs 0.4 
Forward Primer ( 1 OuM) 0.8 
Reverse Primer 0.8 
KapaTaq Taq Pol. 0.08 
l 0 ng/uL DNA Sample 1 
Total Volume 20 
lx Polymerase Chain Reaction (PCR) Protocol w/ 25% Betaine and 5% Dimethylsulfoxide 
(DMSO) 
Reagent 
DMSO 
KapaTaq Buffer 
25mM Betaine 
Kapa Taq dNTPs 
Forward Primer 
Reverse Primer 
KapaTaq Taq Pol. 
Volume CuL) 
8.92 
2 
5 
0.4 
0.8 
0.8 
0.08 
10 ng/uL DNA Sample 
Total Volume 20 
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Appendix B: TouchDown (TD) Thermocycling Program 
94 oc for 5 mins 
5 cycles of: 
94 oc Denaturation for 30s 
64°C Annealing minus 2°C per cycle for 30s 
n oc Extenstion for 30s 
30 cycles of: 
94°C Denaturation for 30s 
54°C Annealing for 30s 
72°C Extenstion for 30s 
72°C Final Extension for 7 mins 
Hold at 4° 
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Appendix C: lx ABI BigDye Terminator (BDT) 3.1 Kit Cocktail for Sanger 
Sequencing 
Reaaent 
BOT 5x Buffer 
BDT Sequencing Mix 
Primer ( 1 OuM) 
Purified PCR Sample 
Total Volume 
Volume (uL) 
15.68 
2 
0.5 
0.32 
20 
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Appendix D: Thermocycling Protocols for Cycle Sequencing (ABI.SEQ) 
94°C for 1 min 
25 cycles of: 
96°C Denaturation for 1 Os 
50°C Annealing for 5s 
60°C Extension for 4 mins 
Hold at 4° 
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Appendix E: Cycle Sequencing DNA Precipitation Protocol 
This step was performed after Cycle sequencing was completed, as a second purification step 
before being placed on the ABI 3130xl of ABI 3730. 
Step 1) DNA precipitation 
• Add 65uL of 95% Ethanol (EtOH) to each well 
• Add 5uL of 125mM Ethylenediaminetetraacetic acid to each well 
• Let precipitate for 15 mins to overnight in dark 
o Can place at -20°C if preferred or if not using plate for a few days. 
Step 2) Ethanol mixture Removal 
• Place plate in centrifuge, spin at 3000 RPM for 30 mins 
• Remove plate from centrifuge and decant ethanol mixture onto a dry paper towel by 
inverting the plate. 
• Leave plate inverted on paper towel and place back in centrifuge. Spin up to 200 RPM, 
and then immediately stop the spinning. 
• Remove and discard paper towel. 
Step 3) Rinse step 
• Add 150uL of 70% EtOH to each well, and place in centrifuge . 
• Spin plate at 3000 RPM for 5 mins . 
• Remove plate from centrifuge and decant EtOH mixture onto a paper towel 
• Leave plate inverted on paper towel and place back in centrifuge. Spin up to 200 RPM, 
and then immediately stop the spinning. 
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• Remove and discard paper towel. Let plate dry in dark and uncovered for 20 mins 
Step 4) Sample Resuspension 
• 
• 
Add 15 uL of Hi-Dye Forrnamide (HDF) to each well 
Place plate in thermocycler on 'denat' program 
o 95°C for 2 mins 
o Hold at 4°C 
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Appendix F: Sequences and Tms for all Primers used for PCR and 
bidirectional sequencing in the Anterior Segment Dysgenesis project. 
PAX6 
Ex on Direction Sequence Tm Size DMSO 
1 Forward ggcgctgctttgcata a a 61 249 No 
Reverse tggtgatggctcaagtgtgt 60.2 
2 Forward ttccctcaccca ca ctcttt 59.5 418 No 
Reverse ctcctgcgtggaaacttctc 60 
3 Forward agtgggatccgaacttgcta 59.7 576 No 
Reverse tgagggtca ctcagctctgc 61.8 
4 Forward gaggttgagtggatcaattcct 59.4 388 No 
Reverse cagtatcgagaagagccaagc 59.2 
5 Forward ttgtcctttatttgatcgatagca 60 466 No 
Reverse gggtccata attagcatcgttta c 60 
6 Forward cactttaagcaaggtcagcaca 60.5 468 No 
Reverse tcgctactctcggtttactacca 60.3 
7 Forward aaagtccaagtgctggacaatc 60.5 399 No 
Reverse aggtaaagaggagagagcattgg 60.3 
8 Forward gagatgggtgactgtgtcttca 60.2 310 No 
Reverse agaggaaatggttgggagagtag 60 
9 Forward aagaaggctgacagttaccttgg 61 392 No 
Reverse caaagggccctggctaaat 61.3 
10 Forward gtgggaaagttcttccaagtacag 60.4 379 No 
Reverse cagagcatttagcagactgaacc 60.4 
11 Forward tttcctagagacagaggtgcttg 60.1 447 No 
Reverse cagatgtgaaggaggaaactgag 60.3 
12 Forward cagtgtctaccaaccaattccac 60.7 405 No 
Reve rse gattgactgtctccgacttgact 59.8 
13 Forward cataggcagctttcttctagctg 59.8 442 No 
Reverse cccataagaccaggagattctgt 60.7 
14 Forward ttccatgtctgtttctcaaagg 59.2 31 0 No 
Reve rse aagtccattccttccccagt 59.8 
PITX2 
Ex on Direction Sequence Tm Size DMSO 
1 Forward gttggcgcagattgcttt 60 734 No 
Reverse aagccacaaatcacctacgg 60 
2 Forward ccgcttcttacagccttcct 60.9 247 No 
Reverse ctggcgatttggttctgatt 60.1 
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3 
4-1 
4-2 
4-3 
PITX3 
Ex on 
1 
2 
3 
4-1 
4-2 
CYPlBl 
Ex on 
1 
2-1 
2-2 
3-1 
3-2 
Forward cagctcttccacggcttct 
Reverse gctgccttcca cattctctc 
Forward gaggccagggtgtgtgag 
Reverse ctgcata ctggcaagcactc 
Forward cagcctgagactgaaagcaa 
Reverse ctcgcaagcga a a a a tecta 
Forward a a caaatgtttga ctggatatga ca 
Reverse aggaggggagaaagaatcca 
Direction Sequence 
Forward tcactccctccgagagtcc 
Reverse tttagggattccaaggtcca 
Forward gggaatttacgaggaaacgc 
Reverse gacctcctaagccactcgc 
Forward agcgagtggcttaggaggtc 
Reverse agtgggagcagaggctgg 
Forward tctcgtttattgaccgcagg 
Reverse cgtg ctgtttgg ctttg a g 
Forward cgtgtcctgcccttatgc 
Reverse cgcctgtagacagtgggg 
Direction Sequence 
Forward ccctccttcta cccagtcct 
Reverse cgtaacggttcctgcaatct 
Forward tctccagagagtcagctccg 
Reverse gggtcgtcgtggctgtag 
Forward atggctttcggccactac 
Reverse tatggagcacacctcacctg 
Forward catgcaaggcctatta cagga 
Reverse gccttttgccca ctga a a a 
Forward gacccagtgaagtggcctaa 
Reverse cacacctcacctgatggaca 
60.7 387 No 
60 
60.3 670 No 
59.6 
59.3 572 No 
60.5 
59.7 489 No 
60 
Tm Size DMSO 
60.3 236 No 
5934 
60.8 327 No 
60 
60.9 466 No 
61.6 
61.2 612 No 
60.6 
60.2 601 No 
60.3 
Tm Size DMSO 
59.6 569 No 
60.1 
60.8 786 No 
60.3 
58.7 359 No 
59.7 
60.1 588 No 
61.1 
60.1 493 No 
60.6 
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3-3 
3-4 
3-5 
3-6 
3-7 
3-8 
3-9 
3-10 
3-11 
3-12 
3-13 
3-14 
3-15 
3-16 
FOXCl 
Ex on 
1-1 
1-2 
1-3 
Forward atga gcctgcga a a a tga at 
Reverse cacacctcacctgatggaca 
Forward cagttcctcttttgtgctgct 
Reverse tcttggattccca ccaa a a a 
Forward cacccaaacacttacaccaaa 
Reverse tgagcaactgactttatgatttatcc 
Forward tgattgaaggtgataagggaaa 
Reverse tgaaatcagtacattatggtcaca 
Forward tttgcttgccaaagtacagaa 
Reverse gaaaccctgcttcatttcca 
Forward ccagccaagcttta a attatgtg 
Reverse tctgccttccacaggaga at 
Forward tgga a atgaagcagggtttc 
Reverse tttcca a a cagcttcca aga 
Forward ggga ca ga a ctcccatta ca a 
Reverse cccacacacacatacacacaa 
Forward tttggtagctgggaaagcat 
Reverse ggcaagcctgctttgtgtag 
Forward tcaaagcatggacatttagaaga 
Reve rse aggcatccagattggttcat 
Forward caggcttgcccagtacattt 
Reverse tccagcctccaa attcagtt 
Forward atgtaggcccagtcgtcatc 
Reverse ggctaagttctggga catga a 
Forward ccggagagagaatgtatttgc 
Reverse tgcactgtagctattatgcacaca 
Forward ctgtgacacaactgtgtgattaaa 
Reverse tttggta atggtgtcccagt 
Direction Sequence 
Forward cccggactcggactcggc 
Reverse aagcggtccatgatgaactgg 
Forwa rd cccaaggacatggtgaagc 
Reverse ctgaagccctggctatggt 
Forward atcaagaccgagaacggtacg 
52.8 426 No 
60.6 
59.7 318 No 
60.3 
58.4 333 No 
59.9 
58.6 362 No 
57.1 
58.6 321 No 
60.1 
60 512 No 
59.8 
60.1 469 No 
58.5 
58.9 345 No 
58.7 
59.7 552 No 
61 
58.9 37 1 No 
59.4 
60.1 372 No 
59.7 
60 420 No 
59.2 
58.8 441 No 
60.7 
57.8 254 No 
57.8 
Tm Size DMSO 
68.8 428 Yes 
64.5 
61.5 710 Yes 
60.2 
61.4 635 Yes 
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1-4 
CRYAA 
Ex on 
1 
2 
3 1 
3 2 
B3GALTL 
Ex on 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Reverse gtgaccggaggcagagagta 
Forward taccactgcaacctgcaagc 
Reverse gggttcgatttagttcggct 
Direction Sequence 
Forward ccttaatgcctccattctgc 
Reverse cagagtccatcgctctccac 
Forward a catggcacgtttggatttc 
Reverse ccctctccca cctctcagt 
Forward gcagcttctctggcatgg 
Reverse TAAGCTCTCCTGGCTGCTCT 
Forward GGCGGGGTGTCTGTCTTC 
Reverse agacagcaccagcagacg 
Direction Sequence 
Forward gtcagacgcctcgaagga 
Reverse ggacccaagaccgaaagg 
Forward cagcaatgcagctgcttaaa 
Reverse aacca agtggatcagcctta a a 
Forward aatcttcctcccatgtgctg 
Reverse gctgggccaaagacagaata 
Forward ttgtctctagaattacatacgaattga 
Reverse tgagtcagaggagttattctcgt 
Forward ggtgcagagtgtagaggttgc 
Reverse agagcgagactctgtctccaa 
Forward cctgaactagtgttgttatggaga 
Reverse tggctcattataagctctgtcc 
Forward ccaccttctattggtcttacatga 
Reverse tta ccacacactgcctctgg 
Forward tgtgttagtcttgcttgacacttc 
Reverse aagcaccta attcgctggag 
Forward tggttcagcctactctctatgg 
Reverse a ccaacttgcacatgaatgc 
Forward agtgtagcaggcaggtccag 
Reverse tcacttcaacatccgaattgtc 
60.4 
62.4 517 Yes 
60.5 
Tm Size DMSO 
59.7 395 No 
61 
60.8 176 No 
59.2 
60.7 437 No 
59.5 
61 .7 486 No 
58.6 
Tm Size DMSO 
60.1 621 No 
60.4 
60.3 406 No 
60 
60.1 289 No 
60.2 
57.7 383 No 
57.2 
59.9 538 No 
59.3 
57.5 537 No 
58.5 
59.4 332 No 
59.7 
58.6 281 No 
59.5 
58.5 357 No 
59.6 
60.5 405 No 
60 
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11 
12 
13 
14 
15 
15.1 
15.2 
15.3 
15.4 
15.5 
15.6 
15.7 
15.8 
15.9 
15.1 
15.11 
CRYAA 
Ex on 
1.1 
1.2 
Forward ggaagcaagcaactcttgga 
Reverse ga a ccaatca gtatctgagaga agg 
Forward ttggcatgtaagctcttagaaca 
Reverse tgttccttaagaggattggttca 
Forward ctgccactctcaccacacaa 
Reverse ccattcacagagtactcacgtacag 
Forward gctactattgcctctcagtctgc 
Reverse tggagcctgtcaacacagtt 
Forward tcctatagccaatgttaggtagtgaa 
Reverse ctgctgtatca cagcttggag 
Forward tgctgtgctcacaacacttg 
Reverse ccattcacaatatccatgtcaa 
Forward ttcctgttctgtctcttcattg 
Reverse gcaatacgaagctctagcagaa 
Forward tgaagtctgtaatcatggtggtt 
Reverse tgatcaccatgctgtccttc 
Forward gaggtcttctgctagagcttcg 
Reverse actgcaacacgtgaggtctg 
Forward ggacagcatggtgatcagg 
Reverse actgca a cacgtgaggtctg 
Forward cagacctcacgtgttgcagt 
Reverse gccagcttcaatcatgtcaa 
Forward gctgcctacaccagtggaa 
Reverse aagacaatatctggtcctggaa 
Forward gctggcatccgtatatgaaga 
Reverse aaga caatatctggtcctggaa 
Forward tggtgtaagcctaaccacaag 
Reverse gaggatatatacaacaagaggtcttca 
Forward tgtgtggaataactggaatgtca 
Reverse catctctgattatgaatggaagaca 
Forward tctagaatgcctaggagcagaa 
Reverse tggatgcctggagaatatca 
Direction Sequence 
Forward gttctggcaacttggaa agg 
Reverse cagccggaacttcttagtgc 
Forward atggaggagaagcgcaaa 
60.5 404 No 
59.7 
59.1 349 No 
60 
60.9 537 No 
60.2 
59.7 385 No 
59.3 
59.5 563 No 
58.7 
59.6 388 No 
58.2 
57.1 353 No 
58.9 
58.5 379 No 
59.6 
59.9 720 No 
59.9 
60.1 427 No 
59.9 
59.9 347 No 
59.8 
59.8 563 No 
57.7 
60.1 469 No 
57.7 
57.8 686 No 
58.3 
60.3 326 No 
59.5 
58.4 307 No 
59 
Tm Size DMSO 
59.7 547 No 
60 
59.5 563 No 
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1_3 
FOXE3 
Ex on 
1-1 
1-2 
1-3 
1-4 
1-5 
1-6 
Reverse gtctccaccatcccaacct 
Forward agaaagccaagggctatcag 
Reverse cagatcatgttggcaccttt 
Direction Sequence 
Forward ttgggaatgatccaaaggag 
Reverse tgagcgcgatgtacgagtag 
Forward gggctgggagaggaaattag 
Reverse aggctgtcgacgctgaac 
Forward ccatctaccgcttcatcacc 
Reverse gcgcaggctcacaggtag 
Forward cgacagcctggtgaacct 
Reverse gctcacaagtggagggagaa 
Forward cctggactcaaactcctgct 
Reverse acctaaaggcccaccaactc 
Forward ctgccctcagcttcttcct 
Reverse aataaagctcacccgtctcc 
59.8 
58.6 599 No 
58.6 
Tm Size DMSO 
59.86 584 Yes 
60.18 
60.03 819 Yes 
60.15 
60.48 682 Yes 
60.73 
59.82 559 Yes 
60.39 
59.45 559 Yes 
60.36 
59.69 300 Yes 
58.27 
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Appendix G: eDNA Synthesis Protocol. 
1. Mix and briefly centrifuge each component before use. 
2. Combine the following in a 0.2- or 0.5-ml tube : 
Component 
RNA (up to Sug) 
SOuM Oligo dT primers 
10 mM dNTP mix 
DEPC-Treated Water 
Amount 
nul 
lul 
lul 
up to 10ul 
3. Incubate at 65°C for 5 min, then place on ice for at least 1 min . 
4. Prepare the following eDNA Synthesis Mix, adding each component in the indicated order: 
Component 1 Rxn 
lOX RT buffer 2 ~I 
25 mM MgCI2 4 ~I 
0.1 M DTT 2 ~I 
RNaseOUT (40 U/~1 ) 1 ~I 
SuperScri pt Ill RT (200 U/~1) 1 ~I 
5. Add 10 ~I of eDNA Synthesis M ix to each RNA/primer m ixture, mix gently, and collect by brief 
centrifugation . Incubate for 50 min at sooc 
6. Terminate the reactions at 85°C for 5 min. Chill on ice. 
7. Collect the reactions by brief centrifugation. Add 1 ~I of RNa se H to 
each tube and incubate for 20 min at 37"C. 
8. eDNA synthesis reaction can be stored at -20°C or used for PCR 
immediately. 
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Appendix H: Sequences and Tms for all Primers used for PCR and 
bidirectional sequencing in the achromatopsia project. 
CNGA3 
Ex on 
1 
2 
3 
4 
5 
6 
7 
8a 
8b 
8c 
8d 
8e 
8f 
8g 
8h 
CNGB3 
Ex on 
Direction 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Direction 
Sequence 
cttccctaagatggcaaa c 
ctgcgtgtggttctctaa ct 
agagacagcagagggtgtgc 
ctgccctctgacctgtgg 
ggtggctttccctgctaag 
tttttcctgagaggtcactacctt 
cagacagagagggagggaga 
gtgctgcatccaaacaggat 
gaggaccctgttgtgga cag 
ggagaaaccgaggcacaata 
agggccattcccatattaca 
atccaccatgctgggtctc 
tcagagtgcatttcctgtag 
caaggtggaccagtagagac 
ctttgaccgca cagagac 
tctcatccaccgtcttctt 
ggagtatctctttgtggtcgtaga 
aggtctgagtagccaatgctg 
ctggggattatatctgcaag 
cctctgtttttgtagcatcc 
aaggaccttgaggagaaagt 
gccta aaaaca ccttgcag 
gtgtgactgcctgagagaac 
aggggatgtctcttctccta 
ggtatcacctcgtgtgttct 
ctgcaatctgtgagctttc 
gagtcagggccctaggtga 
ttttgaggaggaaaagaggaga 
agagga agcctcaagatcc 
cctatcctttctagggaagc 
Sequence 
Tm Size DMSO 
54.9 576 No 
55.6 
60.6 385 No 
60.4 
59.8 300 No 
59.7 
59.5 374 No 
61. 1 
60.6 384 No 
60.1 
59.1 300 No 
60.9 
53.9 577 No 
54.7 
55.1 500 No 
55.6 
58.9 600 No 
59.5 
54.9 558 No 
55 
54.6 552 No 
56.1 
55.8 590 No 
55.4 
55 512 No 
54.5 
60.2 500 No 
59.5 
55.9 500 No 
54.8 
Tm Size DMSO 
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1 Forward tgcctgtagga attaaccag 55.4 382 No 
Reverse tggtgcca ggta a a a eta ct 54.9 
2 Forward gtgg a a a a tggtgtta tgttt 54.1 245 No 
Reverse tttcatcagacagcacattt 54.2 
3 Forward aagcagcatctttgtagctc 55 300 No 
Reverse aaaggggagagtggatattt 54.3 
4 Forward a a ccta a tgtttg a a ttgtg c 54.4 389 No 
Reverse tttgggagatccaa a eta a a 54.9 
5 Forward ggtgtttggtt a a g a a a tt c a 54.4 387 No 
Reverse tgatcctttgcaggttattt 57.9 
6 Forward cctcctatggcaaatta etc 54 399 No 
Reverse tgctgtta ctttttgtagcc 53.4 
7 Forward gaaccaaccaagagaaacag 54.8 280 No 
Reverse gcaga aacttcaggcttatc 54 .3 
8 Forward ttggtcaacttttacagacatc 54.5 300 No 
Reverse ttgggaaaaattaagaatattga 54.9 
9 Forward a a a a agacatatgaatga aatta 50 .6 300 No 
Reverse ccaaagctgaaattatat cct 53 
10 Forward a cagttcacaaatccaaagc 55.3 365 No 
Reverse atagcatttaccagccattg 55.4 
11 Forward tgtttgcca gtg ctgtct 56.2 390 No 
Reverse a a agaagaaccagacagatttt 54 
12 Forward tgaataaaatcaagtaatcagg 51.6 369 No 
Reverse aggatcatttagttgtttttcaa 54.9 
13 Forward ggtatggaggtccaatagaa 54.1 374 No 
Reverse ttgttaaaacataaggcaaaa a 54.6 
14 Forward catagccattggcagttaat 55.4 385 No 
Reverse tgaactctgagagcacgtta 54.6 
15 Forward tgttctttgcttccttcatt 55 .1 400 No 
Reverse ctttggtgaagggatgaata 55.1 
16 Forward cctcacctctagggaatgat 55.7 397 No 
Reverse agttgttcattaagcatatctcac 54.5 
17 Forward a atgtaggtacccattgaaact 54.4 392 No 
Reverse aaatcatcccagtgtctgaa 55.5 
18a Forward gt ctgt cttggtggtg a tct 54.9 596 No 
Reverse ctgcatga a a tea ca ctctc 54.1 
18b Forward gtcaaagaaaaggctaagca 55 593 No 
Reverse gaaagcttcatgatctctgc 55.1 
18c Forward cttctttggcactctaaagc 54.6 560 No 
Reverse ttgtggggatatgtcaatct 55.3 
18d Forward a a ccaacttaaaagaca ccaa 54.1 559 No 
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18e 
18f 
GNAT2 
Ex on 
1 
2 
3 
4 
5 
6 
7 
PDE6C 
Ex on 
1.1 
1.2 
2 
3 
4 
5 
6+7 
8 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Direction 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Direction 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
ttgatttgtacatggtttgc 
gctggtgtcggaagta at a a 
aagcataa attgcaatggtc 
caggatttaagggaatatgg 
gggaagtaacatggtcaaaa 
Sequence 
gtctttaccccttgccata 
agaggagaggaaaaatgacc 
cagtcatccctatgtattctcc 
gcattgga atcagatcctt 
ttgagaaagcagtagcaaca 
agcaggtgggattttagtta 
cttcactggatactgcttcc 
cagatctccccatagcatta 
aggtttga agga a aga atcc 
gggagaagcagaacagtaat 
cctttggtgaagcctaatct 
gagacattgattggtctgct 
g ctgtt ct ctgt cttg cttt 
gtaactgtgcccaaggttc 
Sequence 
gccttctgtcacatcccaag 
ACCTGGGTCAGCTCAGAGAA 
TACCTGGAGGAGAACCCTCA 
ttgccaaactaatgccaca a 
tgtcatcatccctagatctacca 
aaatttcctgagcctccaa c 
TTGCTGTGATCATGGCAGTT 
ggaca cgtgggactga agtt 
tttatttgatgcacctcatgttt 
ggcgatgtgagatgagacaa 
ggtaggtcatggaacagtgtgt 
ttta gca cctga ca ccatgc 
caagttccccaatgaaaaatg 
ggatgcattcttgctttca c 
ctcactcccaatgcgttctt 
gaggagaggcgagagcatc 
54.5 
55.4 564 No 
55.3 
53.8 586 No 
55.1 
Tm Size DMSO 
55.2 542 No 
54.9 
55.3 299 No 
55 
54.8 389 No 
54.1 
54 .9 482 No 
55.3 
54.9 400 No 
53.6 
56.1 400 No 
55.2 
54.9 394 No 
55.6 
Tm Size DMSO 
60.66 363 No 
59.99 
59 .65 547 No 
60.11 
58.54 267 No 
58.24 
60.27 400 No 
60.01 
58.56 278 No 
59.79 
58.85 180 No 
59.72 
59.3 397 No 
58.3 
60.25 214 No 
60.2 
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9 Forward ctgggtg a a gggta c ctg a a 59.96 447 No 
Reverse tgttgcagtttatagaagtcagga 58.15 
10 Forward tcatggtgcatggta ca cttt 58.91 486 No 
Reverse ccctccttccctgtctctc 58.75 
11 Forward atcttcccgcctcttcctc 60.69 391 No 
Reverse accagaggcgacaaagatga 60.8 
12 Forward ctgtgcaaactgcatcatcc 60.27 496 No 
Reverse ggttagaaggtctgtggcaatc 60.00 
13 Forward tgg ct ctg ctt ca ctg a tgt 59.58 462 No 
Reverse accggtgctcaaggatactg 60.13 
14 Forward a aggttcagtcttcacccaca 59.61 425 No 
Reverse ggaagcttgggagggaatag 60.03 
15 Forward tgaggagggagaagagagaca 59.11 371 No 
Reverse gctacttccacttggctgttc 60.30 
16 Forward agaggggtttgcttagtcca 58.79 490 No 
Reverse ggcaggcatctgtcttgaa 59.93 
17+18 Forward tctggccctgtagactttgc 60.40 547 No 
Reverse gggcctaatcaaattgcctac 59.82 
17+18 Forward aaaccctttctgagccaaagt 59.3 400 No 
New Reverse catcatcattgcccttaggaa 59.9 
19 Reverse gga agaaaaagctcccctttc 60.53 411 No 
Reverse ttggtcaggatggtctcgat 60.47 
20 Forward cagtgagccgagattgtgg 60.41 354 No 
Reverse gtgatacccca atggctttc 59.25 
21 Forward acttcataggcccgtggtta 59.45 409 No 
Reverse tctgcaccagtaaagcaggt 58 .52 
22 Forward ccactgcacctaacccagat 59.99 635 No 
Reverse ttggttaagcacccagtctgt 59.65 
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Appendix 1: Setup Protocol for the TOPO TA Cloning kit (Invitrogen) and 
schematic of the PCR 4-TOPO plasmid used for cloning experiments in the 
achromatopsia project. 
Reagent* Volume 
Fresh PCR product 0.5-4 !-!L 
Salt Solution 1 !JL 
Water add to a total volume of 5 !JL 
TOPO®vector 1 !JL 
Final Volume 6 J!L 
*Store all reagents at -zooc when finished. Salt solutions and 
water can be stored at room temperature or 4°C. 
1. Mix the reaction gently and incubate for 5 minutes at room temperature 
(22-23°C). 
Note: For most applications, 5 minutes will yield sufficient colonies for 
ana lysis. Depending on your needs, the length of the TOPO®-cloning reaction 
can be varied from 30 seconds to 30 minutes. For routine subcloning of PCR 
products, 30 seconds may be sufficient. For large PCR products (greater than 
1 kb) or if you are TOPO®-cloning a pool of PCR products, increasing the 
reaction time will yield more colonies. 
2. Place the reaction on ice 
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L..aaa lrMatlon codon 
M13 Revene priming 11te I T3 prtmlng ale 
I I I 
201 CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCA GAATTAACCC TCACTAAAGG 
GTGTGTCCTT TGTCGATACT GGTACTAATG CGGT'l'CGAGT CTTAA'M'GGG AGTGATTTCC 
Spe I Pit I Pme I EooR I EooR I Not I 
281 ~TAGTCCT GCAbGTT~AA ACJAATTCGC CCT~GGGC ~TTCGdGG 
CTGATCAGGA CGTCCAAA'rl' TGCTTAAGCG ~ TCCCG CTTAAGCGCC 
T7 priming alta M13 Fotward (-20) prtmlng alta 
311 CCGCTAAATT CAATTcdCCc TATAGTGAGT CGTATT~CAA TTc1CTGGCC GTCG'rTTTAd 
GGCGATTTAA GTI'AAGCGGG ATATCACTCA GCATAATGTT AAGTGACCGG CAGCAAAATG 
pCR1114-TOPO® 
3956 bp 
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Appendix J: Sequencing results from cloning experiments using 1734.1 
surrounding exons 17-18 ofPDE6C. 
'---- = pCR4.0 EcoRl Site 
- = pCR4.0 Plasmid Sequence 
= Matches PDE6C Sequence (Appears that this is the reverse primer in all cases) 
'---- = Neither Plasmid nor PDE6C Sequence (Seems to be related to Chr8) 
__ =Poor quality sequence 
1F Sequence: 
GAATI GTAGACTTTGCAGGGTACAGCCCCACTCCAAGCTICCTICATAGGAT 
GGCATIGAGTGTCTGTGGCTITICCAGGTGCATGGTGCAAGCTGTCAGTGGATCTACCATICTGGGGTCTGGAGG 
ACAATAAGGCACTCTCAGGCAGACCTGTGTTIGAGGTCTGGAGGACAGGTCTACTAGGGAATGCCCCAGTGGGG 
ACTCTGTGTGGGCTCTCCAAACCCACATTICCCTTCTGCACTGGCCTAGCCAAGGTICTCCATGAGGGCCCTGCCCC 
TGCAGCAAACTTCTGCCTGGACATCCAGGCATTICCATACATCCTCTGAAATCTAGGTGGAGGTICCCAAACTIGA 
ATICTTGACTICTGTGCACCCACAGGCTCAACACAATGTGCAAGCTGTCAGGGCTIGGGACTTGCACCCTCTGAAG 
CCATGGCCTGAGCTGTACCTTGGCCTCTITIAGCCACAGCTAAAAGACACAGGGCACCAAGTCCTGAGACTGCCCA 
AAGCCACAAGGCCCTGGGCCCCACCCATGAAACCAIIIIIICCTCCTAGGTCTCTGGGCCTGTGATGGGAGAAGCT 
GCCATGAAGACCTCTGACATGCCTIGGAAACATITICCCCATIGT GAAT 
TCG AA ,. rr rrrr r / r r r r ~ - - - - - - - -
TATGAGATGTIGATIAAGCCCA 
l R Sequence: 
. :'" '. '(~' . ..!....!....!.~~\.JAA TI CAATGGGGAAAATGTTICCAAGG 
• ' .. ~· ' r:. ..... 
CATGTCAGAGGTCTICATGGCAGCTTCTCCCATCACAGGCCCAGAGACCTAGGAGGAAAAAATGGTTICATGGGT 
GGGGCCCAGGGCCTIGTGGCTTIGGGCAGTCTCAGGACTIGGTGCCCTGTGTCTITIAGCTGTGGCTAAAAGAGG 
CCAAGGTACAGCTCAGGCCATGGCTTCAGAGGGTGCAAGTCCCAAGCCCTGACAGCTIGCACATIGTGTIGAGCC 
TGTGGGTGCACAGAAGTCAAGAATICAAGTTIGGGAACCTCCACCTAGATTICAGAGGATGTATGGAAATGCCTG 
GATGTCCAGGCAGAAGTTIGCTGCAGGGGCAGGGCCCTCATGGAGAACCTIGGCTAGGCCAGTGCAGAAGGGAA 
ATGTGGGTTIGGAGAGCCCACACAGAGTCCCCACTGGGGCATICCCTAGTAGACCTGTCCTCCAGACCTCAAACAC 
AGGTCTGCCTGAGAGTGCCTTATIGTCCTCCAGACCCCAGAATGGTAGATCCACTGACAGCTTGCACCATGCACCT 
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2F Sequence: 
uuc:.:cc GT AGACmG 
CAGGGTAAGAAGGTAAGAGCTTCCTTCATAGGATGGCATTGAGTGTCTGAGGAAATTACCAGGTGCATGGTGCAA 
GCTGTCAGTGGATCTACCATTCTGGGGTCTGGAGGACAATAAGGCACTCTCAGGCAGACCTGTGmGAGGTCTG 
GAGGACAGGTCTACTAGGGAATGCCCCAGTGGGGACTCTGTGTGGGCTCTCCAAACCCACAmCCCTTCTGCACT 
GGCCTAGCCAAGGTTCTCCATGAGGGCCCTGCCCCTGCAGCAAACTTCTGCCTGGACATCCAGGCAmCCATACA 
TCCTCTGAAATCTAGGTGGAGGTTCCCAAACTTGAATTCTTGACTTCTGTGCACCCACAGGCTCAACACAATGTGCA 
GCTGTCAGGGCTTGGGACTTGCACCCTCTGAAGCCATGGCCTGAGCTGTACCTTGGCCTCTTTTAGCCACAGCTA 
AAAGACACAGGGCACCAAGTCCTGAGACTGCCCAAAGCCACAAGGCCCTGGGCCCCACCCATGAAACCAII I IIIC 
CTCCTAGGTCTCTGGGCCTGTGATGGGAGAAGCTGCCATGAAGACCTCTGACATGCCTTGGAAACATTTTCCCCAT 
2R Sequence: 
~GAATT CCCTTGCCTAGACAATGGGGAAAATGmCCAAGGC 
ATGTCAGAGGTCTTCATGGCAGCTTCTCCCATCACAGGCCCAGAGACCTAGGAGGAAAAAATGGmCTTGGGTG 
GGGCCCAGGGCCTTGTGGCmGGGCAGTCTCAGGACTTGGGGCCTGTG I I I I I I AACTGTGGTAAAAAAAAGGC 
AAGGGTACCCCTAAGGCCGGGTTTTCAAAGGGGGAAGTCCCAACCC 
3F Sequence: 
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3R Sequence: 
.... ~ • ~ - .. ,., - ' • ~. :1'. 
. ~. ( 
' . \' 
SF Sequence: 
CCCCCAAAAAAGGGGGCGAAATGAATTTAGCGGCCGCGAATT 
SR Sequence: 
TTIAA GAATT 
r. f r r _ ' r GAAGAGGACCA TGTTCCAAAAAAT~GTTGATGCCTGTGAAC.L\AATGCAAACGGAAG~A.§!l__ 
• 1 l • •• • ........ i 1 
- - - • - r - • _' - ._-·'. GCAATGAT.GATG 
CGGCATGTGACTTGTCTGCTATTACCAAGCCCTGGGAGGTGCAAAGTCAG , - -. . ' . ' , ·c. • ;:_:~ 
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Appendix K: All cutoff values for the Homozygosity Haplotyping study 
carried out in collaboration with the Genome Center of McGill University. 
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Figure 2. Identification of candidate regions for two Microphthalmia dwarfism pedigrees using 
the HH approach for a cutoff of 1 eM for 5 affected individual 
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Figure 3. Identification of candidate regions for 5 affected individuals and 24 controls for two 
Microphthalmia dwarfism pedigrees using HH approach for a cutoff of 1 eM. 
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Cutoff of 1.5 eM 
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Figure 4. Identification of candidate regions for two Microphthalmia dwarfism pedigrees using 
the HH approach for a cutoff of 1.5 eM for 5 affected individuals 
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Figure 5. Identification of candidate regions for 5 affected individuals and 24 controls for two 
Microphthalmia dwarfism pedigrees using HH approach for a cutoff of 1.5 eM. 
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Cutoff of 2 eM 
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Figure 6. Identification of candidate regions for two Microphthalmia dwarfism pedigrees using 
the HH approach for a cutoff of 2 eM for 5 affected individuals 
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Figure 7. Identification of candidate regions for 5 affected individuals and 24 controls for two 
Microphthalmia dwarfism pedigrees using HH approach for a cutoff of 2 eM. 
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Cutoff of 3 eM 
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Figure 8. Identification of candidate regions for two Microphthalmia dwarfism pedigrees using 
the HH approach for a cutoff of 3 eM for 5 affected individuals 
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Figure 9. Identification of candidate regions for 5 affected individuals and 24 controls for two 
Microphthalmia dwarfism pedigrees using HH approach for a cutoff of 3 eM. 
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Cutoff of 4 eM 
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Figure 10. Identification of candidate regions for two Microphthalmia dwarfism pedigrees using 
the HH approach for a cutoff of 4 eM for 5 affected individuals 
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Figure 11. Identification of candidate regions for 5 affected individuals and 24 controls for 
two Microphthalmia dwarfism pedigrees using HH approach for a cutoff of 4 eM. 
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Cutoff of 5 eM 
26 
25 
24 
23 
22 ·- 2llZ 2 1 
20 
19 
18 
17 
16 
15 
14 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
3 
2 
I 
• 
-
-
-
Figure 12. Identification of candidate regions for two Microphthalmia dwarfism pedigrees using 
the HH approach for a cutoff of 5 eM for 5 affected individuals 
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Figure 13. Identification of candidate regions for 5 affected individuals and 24 controls for 
two Microphthalmia dwarfism pedigrees using HH approach for a cutoff of 5 eM. 
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Cutoff of 1 eM 
There are 96 RCHH, found on all chromosomes except chromosomes 13, 24, and 26, which may 
include false positives RCHH (see table 1 ). 60 of them, on all chromosomes except 13, 23, 24, 
and 26, are longer than or equal to 1 eM (see table 2). When we included controls, there are 59 
RCHH found on chromosomes 1, 4, 6, 7, 9, 10, 11 , 12, 13 , 15, 16, 17, 18, and 22 with a-
log10(p_value) higher than or equal to 3 (see table 3). Only 7 ofthem are longer than or equal to 
1 eM and we find them on chromosomes 9, 10, 11 , 17, and 18 (see table 4 ). 
Cutoff of 1.5 eM 
There are 12 RCHH, found on chromosomes 3, 12, 14, 15, 16, 17, 18, and 21 which may include 
false positives RCHH (see table 5). 10 ofthem, on chromosomes 3, 12, 14, 15 16, 17, 18, and 21 , 
are longer than or equal to 1.5 eM (see table 6). When we included controls, there are 19 RCHH 
found on chromosomes 1, 4, 7, 12, 15, 16, and 18 with a -loglO(p_value) higher than or equal to 
3 (see table 7). Only 2 of them are longer than or equal to 1.5 eM and we find them on 
chromosomes 1, and 7 (see table 8). 
Cutoff of 2 eM 
There are 6 RCHH, found on chromosomes 3, 14, 15, 16, 17, and 21 (see table 9). 5 ofthem, on 
chromosomes 3, 14, 16, 17, and 21, are longer than or equal to 2 eM (see table 1 0). When we 
included controls, there are 10 RCHH found on chromosomes 4, 15, 16, and 18 with a-
log 1 O(p _value) higher than or equal to 3 (see table 11 ). Only 2 of them are longer than or equal 
to 2 eM and we find them on chromosomes 15, and 18 (see table 12). 
Cutoff of 3 eM 
There are only 2 RCHH, found on chromosomes 3 and 16 (see table 13). 1 of them, on 
chromosome 16, is longer than or equal to 3 eM (see table 14). When we included controls, there 
are 5 RCHH found on chromosomes 16, and 18 with a -log10(p_value) higher than or equal to 3 
(see table 15). Only 1 of them is longer than or equal to 3 eM and we find it on chromosome 18 
(see table 16). 
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Cutoff of 4 eM 
There is only 1 RCHH, found on chromosome 16 (see table 17) and it is longer than 4 eM (see 
table 18). When we included controls, there are 3 RCHH found on chromosomes 15, and 16 with 
a -log 1 O(p _value) higher than or equal to 3 (see table 19), but they are smaller than 1 eM. 
Cutoff of 5 eM 
There is only 1 RCHH, found on chromosome 16 (see table 21) and it is longer than 4 eM (see 
table 22) . When we included controls, there are 2 RCHH found on chromosome 16, with a -
loglO(p_value) higher than or equal to 3 (see table 23), but they are smaller than 1 eM. 
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Appendix L: List of primer sequences and melting temperatures (Tm) for 
genes sequenced in the critical region on chromosome 16 in the MDW project, 
namely ARL2BP, BBS2, C160RF57, MMP15, and HERPUDJ. 
ARL2BP 
Exon 1 Sequence Tm Size 
Forward gtggccatggtgacaggag 62.62 599 
Reverse tgctgacagctgagggttg 61.2 
Exon 2 Sequence Tm Size 
Forward tgaagatgggtgatgggaag 60.86 300 
Reverse aattgcaggcagcttgatgt 60.81 
Exon 3 Sequence Tm Size 
Forward ccttccagagactgatcattgag 60.25 392 
Reverse caaaggctgtgcagaggaa 60.12 
Exon 4 Sequence Tm Size 
Forward ttggtatccttggcactcag 58.72 400 
Reverse gagccaatgcctgatcttt 57 .82 
Exon 5 Sequence Tm Size 
Forward tgacagagcaagacccagtc 58.97 397 
Reverse ccagccacaacagaatagca 59.86 
Exon 6 Sequence Tm Size 
Forward tagggcaggccagtattgag 60.23 440 
Reverse AGGTCCAGGAGGGTTAGGTC 59.42 
BBS2 
Exon 1 Sequence Tm Size 
Forward GTTCAACCCGCAGGAGTAAA 60.1 674 
Reverse TGCCTGATGACAAGAAAACG 59.8 
Exon 2 Sequence Tm Size 
Forward cca ctg gatttccg tg attt 60.86 566 
Reverse gcaaaatctccatgttgtttacc 60.81 
Exon 3 Sequence Tm Size 
Forward gggccagttaatgtgtgagg 60.4 485 
Reverse atgccatcgtttctccattt 59.4 
Exon 4 Sequence Tm Size 
Forward tctttttggtacccttaagcattt 59.5 500 
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Reverse caccatggctttgatctttg 59.1 
Exon 5 Sequence Tm Size 
Forward agagggagcatttctgagca 60.1 480 
Reverse tgcctttatgtattcaactatatgcaa 60.2 
Exon 6+7 Sequence Tm Size 
Forward ttccccactaatggattgga 60.1 599 
Reverse tgtgcagctcttgacaatgat 59.5 
Exon 8 Sequence Tm Size 
Forward ttgaaaactgctagactaaatgacct 59 374 
Reverse tccccaactttggtgaattt 59.3 
Exon 9 Sequence Tm Size 
Forward tcaccaaagttggggagaac 59.9 368 
Reverse ttctgacaatggcaaaaagg 58.7 
Exon 10 Sequence Tm Size 
Forward gctggaggctctgtcttttg 60.1 387 
Reverse acaggagaatggcatgaacc 59.9 
Exon 11 Sequence Tm Size 
Forward accacgcccagctaattttt 60.8 494 
Reverse tttttacaggtttcaaactgagga 59.2 
Exon 12 Sequence Tm Size 
Forward gatgacccagaagtggcttt 59.1 369 
Reverse aagccacccccaagttagag 60.5 
Exon 13 Sequence Tm Size 
Forward ccttcatatctagaggcacattaaaa 59.2 300 
Reverse aatctatgcccctctcattcc 59.4 
Exon 14 Sequence Tm Size 
Forward agctgctggaaataatgcag 58.1 432 
Reverse tgcaaaaattcttgaaaacatca 59.6 
Exon 15 Sequence Tm Size 
Forward taagcgaacaggggaaagaa 59.8 396 
Reverse ttgctgggtcatagaggaca 59.2 
Exon 16 Sequence Tm Size 
Forward caaagcaaactagcagttactcg 58.5 400 
Reve rse gctactttcagccccaatatg 58.7 
Exon 17 Sequence Tm Size 
Forward tttttcaataattccctcaccaa 59.7 740 
Reverse ccagcccacatttttgtttt 59.8 
C160RF57 
I Exon 1 I Sequence lrm I Size 
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Forward gggctgaatcttcaccactg 60.66 695 
Reverse gccactctggagctttgtct 59.6 
Exon 2 Sequence Tm Size 
Forward cccaatgagacaatactggaga 59.05 590 
Reverse tcctcgtgaacagggagaat 59.65 
Exon 3 Sequence Tm Size 
Forward agacataggctgctgtccaag 59.51 484 
Reverse aaggtcacggaggatgagaa 59.65 
Exon 4 Sequence Tm Size 
Forward gttactcgggctgggtgat 59.94 384 
Reverse gctgcctttatagtcatagagttgg 59.75 
Exon 5 Sequence Tm Size 
Forward agagttggctcatggagcag 60.55 400 
Reverse cagaaggctggcattcagag 61 .08 
Exon 6 Sequence Tm Size 
Forward cagtccatagcaaggaccag 58.31 500 
Reverse gggcaaagatctgtgttgtt 57.64 
HERPUDl 
Exon 1 Sequence Tm Size 
Forward ctgctaggataccccactcc 58.62 695 
Reverse gaggaggccacaggacag 59.31 
Exon 2+3 Sequence Tm Size 
Forward aaagtgttttcccgtgatgc 59.98 572 
Reverse agcactaacggaacaatctgc 59.4 
Exon 4 Sequence Tm Size 
Forwa rd ttttgtcacgttcagaggtg 57.28 451 
Reverse tttgtgtgtactaaaaggctgtg 57.16 
Exon 5 Sequence Tm Size 
Forward catgggtgcgtcatacagtc 59.99 376 
Reverse cactcatccctccattctga 58.59 
Exon 6 Sequence Tm Size 
Forward tcaaaggcatatctacctacttgaaa 59.63 376 
Reverse cagagcgagactccatctca 59.23 
Exon 7 Sequence Tm Size 
Forward cagggtgctgctgtgattag 59.47 300 
Reverse aaatggtaaaccgcaagctg 60.13 
Exon 8 Sequence Tm Size 
Forward ctatccagcctagggcatca 60.19 500 
Reverse TGTATCACGGCTTCACGTTT 59.2 
Page 255 of 257 
MMPlS 
Exon 1 Sequence Tm Size 
Forward CTCGGGCTTGGGAATTTG 61.52 472 
Reverse ccaagtccgcttgcttcc 61.89 
Exon 2 Sequence Tm Size 
Forward gaggtgatgacggctcagat 60.23 397 
Reverse ccaaaccatttggcatctct 59.93 
Exon 3 Sequence Tm Size 
Forward ctcctgggcactcagtcttc 59.99 457 
Reverse gtgtgtggctggtctcatca 60.76 
Exon 4 Sequence Tm Size 
Forward gataatgacgggcttgttgg 60.33 578 
Reverse tggtgggacaacagactgaa 60.13 
Exon 5 Sequence Tm Size 
Forward agcaagggcaggctctct 60.25 399 
Reverse tgtgggcaagtcactaatcct 59.61 
Exon 6 Sequence Tm Size 
Forward tctgctgtagatggacaggattt 60.14 486 
Reverse tctagagctgagggcttaatgg 60 
Exon 7 Sequence Tm Size 
Forward ccactgcctgcctcagtatc 60.82 379 
Reverse gaccagacatgcaatgcaac 60.13 
Exon 8+9 Sequence Tm Size 
Forward gggcccagaagagcattc 60.71 596 
Reverse atcacagtgccgggtgac 60.56 
Exon 10 Sequence Tm Size 
Forward cagtctggctcctgcaagtt 60.59 658 
Reverse AGCCATCTCAGAACCACAGG 60.26 
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Appendix M: Primer sequences and Tms for all non-coding genes (miR, 
SNORA, and SNORD) genes. 
Gene Direction Sequence Tm GC% Size 
miR3935 Forward gccctgacgttccatttg 60.05 55.56 461 
Reverse gggccatgttttgacagaga 61.05 50 
m1Rl38-2 Forward gggacccagattccaccata 61.88 55 390 
Reverse ttgaaagctgccaggtgatt 60.78 45 
miR328 Forward acccaccttgtcgaagtcct 60.94 55 394 
Reverse gactccttgccccattctct 60.6 55 
SNORDlll Forward ggtgccttttaggaatcagg 58.65 50 232 
Reverse aaccccacagctcaaaattc 59.03 45 
SNORDlllB Forward tggaaatgggtgtttttcaa 58.84 35 226 
Reverse tcattagccttattctctgaaatagat 57.47 29.63 
miR1972 Forward ttgagatggggtcttgctatg 60.08 47.62 224 
Reverse ggtctcgaactcctgacctc 58.82 60 
miR140 Forward ctcctctccaggctctgct 59.83 63.1 6 239 
Reverse taaaccagcaaggggatgtc 59.93 50 
miR1538 Forward tccgtttcgtgtttctcctc 60.23 50 395 
Reverse gcttctctcggctctgtctc 59.43 60 
SNORA70D Forward aaaagctgtggagataacatttca 59.23 33.33 246 
Reverse cagagacatgaacatccatctga 60.13 43.48 
SNORD71 Forward ggcacagataagctaggcaaa 59.51 47.62 224 
Reverse tgctacctgctgcctaacag 59.24 55 
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